AHA Scientific Statement

Diagnosis and Management of Cerebral Venous Thrombosis

A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.

The American Association of Neurological Surgeons and Congress of Neurological Surgeons have reviewed this document and affirm its educational content.

The Ibero-American Stroke Society (Sociedad Iberoamericana de Enfermedad Cerebrovascular) endorses the recommendations contained in this report.

Endorsed by the Society of NeuroInterventional Surgery

Gustavo Saposnik, MD, MSc, FAHA, Chair; Fernando Barinagarrementeria, MD, FAHA, FAAN; Robert D. Brown, Jr, MD, MPH, FAHA, FAAN; Cheryl D. Bushnell, MD, MHS, FAHA; Brett Cucchiara, MD, FAHA; Mary Cushman, MD, MSc, FAHA; Gabrielle deVeber, MD; Jose M. Ferro, MD, PhD; Fong Y. Tsai, MD; on behalf of the American Heart Association Stroke Council and the Council on Epidemiology and Prevention

Background—The purpose of this statement is to provide an overview of cerebral venous sinus thrombosis and to provide recommendations for its diagnosis, management, and treatment. The intended audience is physicians and other healthcare providers who are responsible for the diagnosis and management of patients with cerebral venous sinus thrombosis.

Methods and Results—Members of the panel were appointed by the American Heart Association Stroke Council’s Scientific Statement Oversight Committee and represent different areas of expertise. The panel reviewed the relevant literature with an emphasis on reports published since 1966 and used the American Heart Association levels-of-evidence grading algorithm to rate the evidence and to make recommendations. After approval of the statement by the panel, it underwent peer review and approval by the American Heart Association Science Advisory and Coordinating Committee.

Conclusions—Evidence-based recommendations are provided for the diagnosis, management, and prevention of recurrence of cerebral venous thrombosis. Recommendations on the evaluation and management of cerebral venous thrombosis during pregnancy and in the pediatric population are provided. Considerations for the management of clinical complications (seizures, hydrocephalus, intracranial hypertension, and neurological deterioration) are also summarized. An algorithm for diagnosis and management of patients with cerebral venous sinus thrombosis is described. (Stroke. 2011;42:00-00.)

Key Words: AHA Scientific Statements ▪ venous thrombosis ▪ sinus thrombosis, intracranial ▪ brain infarction, venous ▪ stroke ▪ disease management ▪ prognosis ▪ outcome assessment ▪ anticoagulants ▪ pregnancy ▪ children

Author order is alphabetical after the writing group chair. All authors have contributed equally to the present work.

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on October 26, 2010. A copy of the statement is available at http://www.americanheart.org/presenter.jhtml?identifier=3003999 by selecting either the “topic list” link or the “chronological list” link (No. KB-0186). To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.


Permission of the American Heart Association is required for all other uses.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the “Permission Request Form” appears on the right side of the page.

© 2011 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STR.0b013e31820a8364
Thrombosis of the dural sinus and/or cerebral veins (CVT) is an uncommon form of stroke, usually affecting young individuals.\(^1\) Despite advances in the recognition of CVT in recent years, diagnosis and management can be difficult because of the diversity of underlying risk factors and the absence of a uniform treatment approach. CVT represents \(\sim 0.5\%\) to 1\% of all strokes.\(^2\) Multiple factors have been associated with CVT, but only some of them are reversible. Prior medical conditions (eg, thrombophilias, inflammatory bowel disease), transient situations (eg, pregnancy, dehydration, infection), selected medications (eg, oral contraceptives, substance abuse), and unpredictable events (eg, head trauma) are some predisposing conditions.\(^3,4\)

Given the diversity of causes and presenting scenarios, CVT may commonly be encountered not only by neurologists and neurosurgeons but also by emergency physicians, internists, oncologists, hematologists, obstetricians, pediatricians, and family practitioners. Our purpose in the present scientific statement is to review the literature on CVT and to provide recommendations for its diagnosis and management. Writing group members were appointed by the American Heart Association (AHA) Stroke Council’s Scientific Statement Oversight Committee and the Council on Epidemiology and Prevention. The panel included members with several different areas of expertise. The panel reviewed relevant articles on CVT in adults and children using computerized searches of the medical literature through July 2010. These articles were supplemented by other articles known to the authors. The evidence is organized within the context of the AHA framework and is classified according to the joint AHA/American College of Cardiology Foundation and supplementary AHA Stroke Council methods of classifying the level of certainty and the class and level of evidence (Tables 1 and 2).\(^5\) After review by the panel members, the manuscript was reviewed by expert peer reviewers and members of the Stroke Council Leadership Committee and was subsequently approved by the AHA’s Science Advisory and Coordinating Committee.

Although information about the cause and clinical manifestations of CVT is included for the convenience of readers who may be unfamiliar with these topics, the group’s recommendations emphasize issues regarding diagnosis, management, and treatment. The recommendations are based on the current available evidence and were approved by all members of the writing group. Despite major progress in the evaluation and management of this rare condition in recent years, much of the literature remains descriptive. In some areas, evidence is lacking to guide decision making; however, the writing group made an effort to highlight those areas and provide suggestions, with the understanding that some physicians may need more guidance, particularly in making decisions when extensive evidence is not available. Continued research is essential to better understand issues related to the diagnosis and treatment of CVT. Identification of subgroups at higher risk would allow a more careful selection of patients who may benefit from selective interventions or therapies.

**Epidemiology and Risk Factors for CVT**

CVT is an uncommon and frequently unrecognized type of stroke that affects approximately 5 people per million annually and accounts for 0.5\% to 1\% of all strokes.\(^1\) CVT is more commonly seen in young individuals. According to the largest cohort study (the International Study on Cerebral Venous and Dural Sinuses Thrombosis [ISCVT]), 487 (78\%) of 624 cases occurred in patients <50 years of age (Figure 1).\(^1,6\) Clinical features are diverse, and for this reason, cases should be sought among diverse clinical index conditions. A prior pathological study found a prevalence of CVT of 9.3\% among 182 consecutive autopsies.\(^7\) No population studies have reported the incidence of CVT. Very few stroke registries included cases with CVT. This may result in an overestimation of risk associated with the various conditions owing to referral and ascertainment biases. In the Registro Nacional Mexicano de Enfermedad Vascular Cerebral (RENAMEVASC), a multihospital prospective Mexican stroke registry, 3\% of all stroke cases were CVT.\(^8\) A clinic-based registry in Iran reported an annual CVT incidence of 12.3 per million.\(^9\) In a series of intracerebral hemorrhage (ICH) cases in young people, CVT explained 5\% of all cases.\(^9\)

**Cause and Pathogenesis: Underlying Risk Factors for CVT**

Predisposing causes of CVT are multiple. The risk factors for venous thrombosis in general are linked classically to the Virchow triad of stasis of the blood, changes in the vessel wall, and changes in the composition of the blood. Risk factors are usually divided into acquired risks (eg, surgery, trauma, pregnancy, puerperium, antiphospholipid syndrome, cancer, exogenous hormones) and genetic risks (inherited thrombophilia). Table 3 summarizes the evidence for a cause-and-effect relationship\(^10,11\) between prothrombotic factors and CVT.\(^12–55\)

Evidence for the strength and consistency of association, biological plausibility, and temporality is summarized. These criteria are most closely met for deficiency of antithrombin III, protein C, and protein S; factor V Leiden positivity; use of oral contraceptives; and hyperhomocysteinemia, among others.

**Prothrombotic Conditions**

The most widely studied risk factors for CVT include prothrombotic conditions. The largest study, the ISCVT, is a multinational, multicenter, prospective observational study with 624 patients. Thirty-four percent of these patients had an inherited or acquired prothrombotic condition.\(^10\) The prevalence of different prothrombotic conditions is summarized in Table 3. Recently, another group in the United States reported that 21\% of 182 CVT case subjects in 10 hospitals had a prothrombotic condition.\(^11\)

**Antithrombin III, Protein C, and Protein S Deficiency**

Two studies have analyzed the role of natural anticoagulant protein deficiencies (antithrombin III, protein C, and protein S) as risk factors for CVT. One study compared 121 patients with a first CVT with 242 healthy control subjects.\(^40\) The other study compared 51 patients with CVT with 120 healthy control subjects.\(^12\) Only 1 patient (2\%) had antithrombin III deficiency. The combined odds ratio (OR) of CVT when these 2 studies were combined was 11.1 for protein C deficiency (95\% confi-
dence interval [CI] 1.87 to 66.05; $P=0.009$) and 12.5 for protein S deficiency (95% CI 1.45 to 107.29; $P=0.03$).

Antiphospholipid and Anticardiolipin Antibodies
The first study mentioned above found a higher prevalence of antiphospholipid antibodies in patients with CVT (9 of 121) than in control subjects (0 of 242). In another study from India with 31 CVT patients, anticardiolipin antibodies were detected in 22.6% of CVT patients compared with 3.2% of normal control subjects. Similar findings (5.9%) were observed in the ISCVT study.

Factor V Leiden Gene Mutation and Resistance to Activated Protein C
Resistance to activated protein C is mainly caused by the presence of the factor V Leiden gene mutation, which is a common inherited thrombophilic disorder. A recent meta-analysis of 13 studies, including 469 CVT cases and 3023 control subjects, reported a pooled OR of CVT of 3.38 (95% CI 2.27 to 5.05) for factor V Leiden, which is similar to its association with venous thromboembolism (VTE) in general.

Hyperhomocysteinemia
Hyperhomocysteinemia is a risk factor for deep vein thrombosis (DVT) and stroke but has not been clearly associated with an increased risk of CVT. Five case-control studies evaluated...
hyperhomocysteinemia in patients with CVT.\textsuperscript{11,16,17,29,30} Researchers from Milan\textsuperscript{13} reported on 121 patients with a first CVT and 242 control subjects, finding hyperhomocysteinemia in 33 patients (27\%) and 20 control subjects (8\%; OR 4.2, 95\% CI 2.3 to 7.6). Low levels of serum folate and the 677TT methylenetetrahydrofolate reductase genotype were not associated with CVT risk, independent of homocysteine level.\textsuperscript{13} The prevalence of prothrombin or methylenetetrahydrofolate reductase mutation. No factor V Leiden mutation was found. A small Italian study of 26 consecutive patients with CVT and 100 healthy control subjects reported that 38.5\% of case subjects and 13\% of control subjects had hyperhomocysteinemia (OR 4.2, 95\% CI 1.6 to 11.2).\textsuperscript{16} No significant differences were found in the prevalence of prothrombin or methylenetetrahydrofolate reductase mutation. No factor V Leiden mutation was found. Another Italian group\textsuperscript{17} found a strong and significant association of the prothrombin G20210A mutation (30\% versus 2.5\% in patients versus control subjects, respectively, \textit{P}=0.001; OR 16.2, \textit{P}=0.002) and hyperhomocysteinemia (43.3\% versus 10\%, \textit{P}=0.002; OR 6.9, \textit{P}=0.002).

A study of 45 patients with CVT and 90 control subjects in Mexico reported an adjusted OR of CVT of 4.6 (95\% CI 1.6 to 12.8) associated with high fasting homocysteine and an OR of 3.5 (95\% CI 1.2 to 10.0) associated with low folate.\textsuperscript{29} A small Italian study of 26 consecutive patients with CVT and 100 healthy control subjects reported that 38.5\% of case subjects and 13\% of control subjects had hyperhomocysteinemia (OR 4.2, 95\% CI 1.6 to 11.2).\textsuperscript{16} No significant differences were found in the prevalence of prothrombin or methylenetetrahydrofolate reductase mutation. No factor V Leiden mutation was found. Another Italian group\textsuperscript{17} found a strong and significant association of the prothrombin G20210A mutation (30\% versus 2.5\% in patients versus control subjects, respectively, \textit{P}=0.001; OR 16.2, \textit{P}=0.002) and hyperhomocysteinemia (43.3\% versus 10\%, \textit{P}=0.002; OR 6.9, \textit{P}=0.002).

A study of 60 case subjects and 64 control subjects.\textsuperscript{30} In a study from Mexico, \textasciitilde{}50\% of CVT occurred during pregnancy or puerperium.\textsuperscript{32} Most pregnancy-related CVT occurs in the third trimester or puerperium. Seven of 8 CVTs among 50 700 admissions for delivery in Canada occurred postpartum.\textsuperscript{33} During pregnancy and for 6 to 8 weeks after birth, women are at increased risk of venous thromboembolic events.\textsuperscript{34} Pregnancy induces several prothrombotic changes in the coagulation system that persist at least during early puerperium. Hypercoagulability worsens after delivery as a result of volume depletion and trauma. During the puerperium, additional risk factors include infection and instrumental delivery or cesarean section. One study reported that the risk of postpartum CVT increased with increasing maternal age, increasing hospital size, and cesarean delivery, as well as in the presence of hypertension, infections, and excessive vomiting in pregnancy.\textsuperscript{35} Recently, it was reported that in pregnant women, hyperhomocysteinemia was associated with increased risk of puerperal CVT (OR 10.8, 95\% CI 4.0 to 29.4) in a study of 60 case subjects and 64 control subjects.\textsuperscript{30}

**Table 2. Definition of Classes and Levels of Evidence Used in AHA Stroke Council Recommendations**

<table>
<thead>
<tr>
<th>Class I</th>
<th>Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and effective.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class II</td>
<td>Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment.</td>
</tr>
<tr>
<td>Class IIa</td>
<td>The weight of evidence or opinion is in favor of the procedure or treatment.</td>
</tr>
<tr>
<td>Class IIb</td>
<td>Usefulness/efficacy is less well established by evidence or opinion.</td>
</tr>
<tr>
<td>Class III</td>
<td>Conditions for which there is evidence and/or general agreement that the procedure or treatment is not useful/effective and in some cases may be harmful.</td>
</tr>
</tbody>
</table>

**Therapeutic recommendations**

- **Level of Evidence A**: Data derived from multiple randomized clinical trials or meta-analyses.
- **Level of Evidence B**: Data derived from a single randomized trial or nonrandomized studies.
- **Level of Evidence C**: Consensus opinion of experts, case studies, or standard of care.

**Diagnostic recommendations**

- **Level of Evidence A**: Data derived from multiple prospective cohort studies using a reference standard applied by a masked evaluator.
- **Level of Evidence B**: Data derived from a single grade A study, or \geq1 case-control studies, or studies using a reference standard applied by an unmasked evaluator.
- **Level of Evidence C**: Consensus opinion of experts.

**Pregnancy and Puerperium**

Pregnancy and the puerperium are common causes of transient prothrombotic states.\textsuperscript{57} Approximately 2\% of pregnancy-associated strokes are attributable to CVT.\textsuperscript{31} The frequency of CVT in the puerperium is estimated at 12 cases per 100 000 deliveries, only slightly lower than puerperal arterial stroke.\textsuperscript{58}

In a study from Mexico, \textasciitilde{}50\% of CVT occurred during pregnancy or puerperium.\textsuperscript{32} Most pregnancy-related CVT occurs in the third trimester or puerperium. Seven of 8 CVTs among 50 700 admissions for delivery in Canada occurred postpartum.\textsuperscript{33} During pregnancy and for 6 to 8 weeks after birth, women are at increased risk of venous thromboembolic events.\textsuperscript{34} Pregnancy induces several prothrombotic changes in the coagulation system that persist at least during early puerperium. Hypercoagulability worsens after delivery as a result of volume depletion and trauma. During the puerperium, additional risk factors include infection and instrumental delivery or cesarean section. One study reported that the risk of puerperal CVT increased with increasing maternal age, increasing hospital size, and cesarean delivery, as well as in the presence of hypertension, infections, and excessive vomiting in pregnancy.\textsuperscript{35} Recently, it was reported that in pregnant women, hyperhomocysteinemia was associated with increased risk of puerperal CVT (OR 10.8, 95\% CI 4.0 to 29.4) in a study of 60 case subjects and 64 control subjects.\textsuperscript{30}

**Oral Contraceptives**

A 1998 study compared the prevalence of several risk factors, including use of oral contraceptives, among 40 female patients with CVT, 80 female patients with DVT of the lower extremities, and 120 female control subjects.\textsuperscript{36} Nearly all CVT case subjects were using oral contraceptives (96\%), which conferred 22.1-fold increased odds of CVT (95\% CI 5.9 to 84.2). The OR for women with the prothrombin G20210A mutation who used oral contraceptives was 149.3 (95\% CI 31.0 to 711.0) compared with those with neither characteristic. Stratification for the presence of factor V Leiden or prothrombin mutation and the use...
Table 3. Predisposing Conditions for CVT and Principles in Favor of a Cause-and-Effect Relationship

<table>
<thead>
<tr>
<th>Condition</th>
<th>Prevalence, %*</th>
<th>Consistency†</th>
<th>Strength of Association‡</th>
<th>Biological Plausibility§</th>
<th>Temporality¶</th>
<th>Biological Gradient¶</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prothrombotic conditions</td>
<td>34.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antithrombin III deficiency</td>
<td>Yes2,12</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>Protein C deficiency</td>
<td>Yes2,13</td>
<td>11.1 (1.9–66.0)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>Protein S deficiency</td>
<td>Yes2,13</td>
<td>12.5 (1.5 to 107.3)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>Antiphospholipid and anticardiolipin antibodies</td>
<td>5.9</td>
<td>Yes12,14,15*</td>
<td>8.8 (1.3–57.4)*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes‡</td>
</tr>
<tr>
<td>Resistance to activated protein C and factor V Leiden</td>
<td>Yes16–27</td>
<td>3.4 (2.3 to 5.1)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>Mutation G20210A of factor II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperhomocysteinemia</td>
<td>4.5</td>
<td>Yes13,17,18,25,37,39–41</td>
<td>4.6 (1.6–12.0)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes‡</td>
</tr>
<tr>
<td>Pregnancy and puerperium</td>
<td>21</td>
<td>Yes31–35</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Oral contraceptives</td>
<td>54.3</td>
<td>Yes13,17,18,23,27,32,36–38</td>
<td>5.6 (4.0–7.9)*</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Androgen, danazol, lithium, vitamin A, IV immunoglobulin, ecstasy</td>
<td>7.5</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Cancer related</td>
<td>7.4</td>
<td>Yes36–41</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Local compression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercoagulable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antineoplastic drugs (tamoxifen, L-asparaginase)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>12.3</td>
<td></td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Parameningeal infections (ear, sinus, mouth, face, and neck)</td>
<td></td>
<td>Yes42–44</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical precipitants</td>
<td>4.5</td>
<td>Yes45–47</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Complication of epidural blood patch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spontaneous intracranial hypotension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumbar puncture</td>
<td>1.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other hematologic disorders</td>
<td>12</td>
<td>Yes48–51</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Paroxysmal nocturnal hemoglobinuria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron deficiency anemia</td>
<td></td>
<td>Yes</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Nephrotic syndrome</td>
<td>0.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polycythemia, thrombocythemia</td>
<td>2.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic diseases</td>
<td>7.2</td>
<td>Yes2,46</td>
<td>NA</td>
<td>Yes</td>
<td>Yes</td>
<td>NA</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behçet disease</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>1.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>0.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>1.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None identified</td>
<td>12.5</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

CVT indicates cerebral venous thrombosis; OR, odds ratio; CI, confidence interval; NA, nonapplicable/nonavailable; and IV, intravenous.

*Prevalence as per Ferro et al.10 Percentages for CVT associated with oral contraceptives or pregnancy/puerperium are reported among 381 women 50 years of age.

†Cause-and-effect relationship determined as follows: (1) Consistency of association: Has the association been repeatedly observed by different investigators (yes/no)? (2) Strength of association: How strong is the effect (relative risk or OR)? (3) Biological plausibility: Does the association make sense, and can it be explained pathophysiologically (yes/no)? (4) Temporality: Does exposure precede adverse outcome (yes/no)? (5) Biological gradient: Does a dose-response relationship exist (yes/no)? Evidence of a strong and consistent association, evidence of biological plausibility, a notable risk of recurrent events, and detection of a biological gradient are suggestive of causation rather than association by chance alone. Modified from Grimes and Schulz54 with permission of the publisher. Copyright © 2002, Elsevier.

‡Evidence for the biological gradient is not specific for CVT but for VTE: Anticardiolipins and CVT—based on a case-matched control study (Christopher et al)55; oral contraceptives—from Dentali et al55; cancer—results among 7029 patients with cancer, 20 of whom (0.3%) developed CVT, combined with results from Ferro et al (OR 27.9, 95% CI 16.5 to 47.2)56; hyperhomocysteinemia and CVT—Martini et al.19 For patients with the prothrombin 20210 mutation, having a heterozygous mutation increases the risk of developing a first venous thrombotic event by approximately 2 to 3 times the background risk (or 2 to 3 in 1000 people each year). Having homozygous prothrombin mutations increases the risk further, but it is not yet well established how much the risk is increased (Varga et al).55
of oral contraceptives showed similar point estimates for the coagulation abnormalities alone and the use of oral contraceptives alone, whereas the presence of both risk factors gave an OR of 30.0 (95% CI 3.4 to 263.0) for factor V Leiden and 79.3 (95% CI 10.0 to 629.4) for the prothrombin mutation. A study in the Netherlands found that of 40 female CVT patients, 85% used oral contraceptives, with an adjusted OR of 13 (95% CI 5 to 37). The combination of oral contraceptives with a prothrombotic condition also dramatically increased the risk of CVT. A study from Brazil showed similar results. In a meta-analysis that included 16 studies, the authors reported an increased risk of CVT in oral contraceptive users (relative risk 15.9, 95% CI 6.98 to 36.2). In another meta-analysis of 17 studies, an increased risk of CVT was found in patients who used oral contraceptives (OR 5.59, 95% CI 3.95 to 7.91; P<0.001). It is clear that the use of oral contraceptives is associated with an increased risk of CVT, that the great majority of younger nonpregnant women with CVT are oral contraceptive users, and that the risk of CVT with oral contraceptive use in women is greater among those with a hereditary prothrombotic factor.

Cancer
In the ISCVT, 7.4% of cases of CVT were associated with cancer. It has been speculated that CVT could be more frequent in cancer patients, particularly in patients with hematologic malignancies; however, there are no studies with a control group. Potential mechanisms for an association of cancer with CVT include direct tumor compression, tumor invasion of cerebral sinuses, or the hypercoagulable state associated with cancer. Chemotherapeutic and hormonal agents used for cancer treatment may also play a role.

Other Uncommon Causes
New neuroimaging procedures have increased the ability to detect CVT in recent years and have also helped to identify other potential causes, including infections, mainly in parameningeal locations (ear, sinus, mouth, face, and neck). These causes only explained 8.2% of all cases in the ISCVT series. In contrast, CVT caused by infection is more common in children. In a recent series of 70 children with CVT in the United States, 40% had infection-related CVT. Conversely, a French study of 62 adults with isolated lateral sinus thrombosis found that only 3 cases were related to parameningeal infections.

Other conditions have been associated with CVT in case reports or small series, including paroxysmal nocturnal hemoglobinuria, iron deficiency anemia, thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, nephrotic syndrome, inflammatory bowel disease, systemic lupus erythematosus, Behçet disease, mechanical precipitants, epidural blood patch, spontaneous intracranial hypotension, and lumbar puncture.

Clinical Diagnosis of CVT
Principal Clinical Findings
The diagnosis of CVT is typically based on clinical suspicion and imaging confirmation. Clinical findings in CVT usually fall into 2 major categories, depending on the mechanism of neurological dysfunction: (1) Those that are related to increased intracranial pressure attributable to impaired venous drainage and (2) those related to focal brain injury from venous ischemia/infarction or hemorrhage. In practice, many patients have clinical findings due to both mechanisms, either at presentation or with progression of the underlying disease. Headache, generally indicative of an increase in intracranial pressure, is the most common symptom in CVT and was present in nearly 90% of patients in the ISCVT. Similar headache frequency has been reported in other populations studied. The headache of CVT is typically described as diffuse and often progresses in severity over days to weeks. A minority of patients may present with thunderclap headache, suggestive of subarachnoid hemorrhage, and a migrainous type of headache has been described. Isolated headache without focal neurological findings or papilledema occurs in up to 25% of patients with CVT and presents a significant diagnostic challenge. CVT is an important diagnostic consideration in patients with headache and papilledema or diplopia (caused by sixth nerve palsy) even without other neurological focal signs suggestive of idiopathic intracranial hypertension. When focal brain injury occurs because of venous ischemia or hemorrhage, neurological signs and symptoms referable to the affected region are often present; most common are hemiparesis and aphasia, but other cortical signs and sensory symptoms may occur. Psychosis, in conjunction with focal neurological signs, has also been reported.

Clinical manifestations of CVT may also depend on the location of the thrombosis (Figure 2). The superior sagittal sinus is most commonly involved, which may lead to headache, increased intracranial pressure, and papilledema. A motor deficit, sometimes with seizures, can also occur. Scalp edema and dilated scalp veins may be seen on examination. For lateral sinus thromboses, symptoms related to an underlying condition (middle ear infection) may be noted, including constitutional symptoms, fever, and ear discharge. Pain in the ear or mastoid region and headache are typical. On examination, increased intracranial pressure and distention of the scalp veins may be noted. Hemianopia, contralateral weakness, and aphasia may sometimes be seen owing to cortical involvement. Approximately 16% of patients with CVT have thrombosis of the deep cerebral venous system (internal cerebral vein, vein of Galen, and straight sinus), which can lead to thalamic or basal ganglial infarction. Most patients present with rapid neurological deterioration. CVT may be confused with other medical conditions. Cortical vein thrombosis is also uncommon, and specific clinical syndromes related to the larger cortical veins are rarely seen (eg, temporal lobe hemorrhage associated with vein of Labbé thrombosis).

Several important clinical features distinguish CVT from other mechanisms of cerebrovascular disease. First, focal or generalized seizures are frequent, occurring in ~40% of patients. Second, an important clinical correlate to the anatomy of cerebral venous drainage is that bilateral brain involvement is not infrequent. This is particularly notable in cases that involve the deep venous drainage system, when bilateral thalamic involvement may occur, causing alterations in level of consciousness without focal neurological findings. Bilateral motor signs, including paraparesis, may also be present due to sagittal sinus thrombosis and bitemporal injury. Finally, patients with...
CVT often present with slowly progressive symptoms. Delays in diagnosis of CVT are common and significant. In the ISCVT, symptom onset was acute (>48 hours) in 37% of patients, subacute (48 hours to 30 days) in 56% of patients, and chronic (>30 days) in 7% of patients. The median delay from onset of symptoms to hospital admission was 4 days, and from symptom onset to diagnosis, it was 7 days.10

Other Clinical and Laboratory Findings

Routine Blood Work
A complete blood count, chemistry panel, sedimentation rate, and measures of the prothrombin time and activated partial thromboplastin time are indicated for patients with suspected CVT. These studies may demonstrate abnormalities suggestive of an underlying hypercoagulable state, an infectious process, or an inflammatory state, all of which may contribute to the development of CVT.

Recommendations

1. In patients with suspected CVT, routine blood studies consisting of a complete blood count, chemistry panel, prothrombin time, and activated partial thromboplastin time should be performed (Class I; Level of Evidence C).

2. Screening for potential prothrombotic conditions that may predispose a person to CVT (eg, use of contraceptives, underlying inflammatory disease, infectious process) is recommended in the initial clinical assessment (specific recommendations for testing for thrombophilia are found in the long-term management section of this document) (Class I; Level of Evidence C).

Lumbar Puncture
Unless there is clinical suspicion of meningitis, examination of the cerebrospinal fluid (CSF) is typically not helpful in cases with focal neurological abnormalities and radiographic confirmation of the diagnosis of CVT. Elevated opening pressure is a frequent finding in CVT and is present in >80% of patients.10 An elevated opening pressure may be a clue for diagnosing CVT in patients who present at the emergency department with headaches. Elevated cell counts (found in ~50% of patients) and protein levels (found in ~35%) are often present, but their absence should not discourage consideration of the diagnosis of CVT.10 There are no specific CSF abnormalities in CVT. Therapeutic considerations are described in “Management and Prevention of Early Complications (Hydrocephalus, Intracranial Hypertension, Seizures).”

D-Dimer
Measurement of D-dimer, a product of fibrin degradation, has a diagnostic role in exclusion of DVT or pulmonary embolus when used with pretest probability assessment. A number of small studies, all with methodological limitations, demonstrated high sensitivity for the identification of patients with CVT and a potential role for exclusion of the diagnosis, although this finding was not universal.77–81 As is the case with its use in DVT and pulmonary embolism (PE), the specificity of D-dimer was poor, because there are many causes of elevated D-dimer. In a well-designed prospective, multicenter study of 343 patients presenting to the emergency department with symptoms that suggested CVT, a positive D-dimer level (defined as a level >500 µg/L) was found in 34 of 35 patients with confirmed CVT and 27 of 308 patients without CVT.82 This yielded a sensitivity of 97.1%, a specificity of 91.2%, a negative predictive value of 99.6%, and a positive predictive value of 55.7%, which supports a clinically useful role of D-dimer in excluding CVT. A normal D-dimer level according to a sensitive immunoassay or rapid ELISA may help identify patients with a low probability of CVT.82,83 A subsequent study of 73 patients with confirmed CVT found normal D-dimer levels in 7 patients (10%).83 Five of the 7 patients with confirmed CVT and negative D-dimer presented with isolated headache, which suggests that this subgroup might be particularly at risk of false-negative results of D-dimer testing. In contrast, of the 57 patients with confirmed CVT who presented with isolated intracranial hypertension or encephalitis signs, only 2 (3.5%) had negative D-dimer testing.

Several factors may account for some of the discrepant findings noted above. First, D-dimer levels decline with time from onset of symptoms, which suggests that patients who...
present with subacute or chronic symptoms are more likely to have negative D-dimer levels. Second, the anatomic extent of thrombosed sinuses may correlate with D-dimer levels, which suggests that patients with lesser clot burden may have false-negative D-dimer testing results. Finally, a number of different D-dimer assays are available with variable test performance characteristics.

**Recommendation**

1. A normal D-dimer level according to a sensitive immunoassay or rapid enzyme-linked immunosorbent assay (ELISA) may be considered to help identify patients with low probability of CVT (Class IIb; Level of Evidence B). If there is a strong clinical suspicion of CVT, a normal D-dimer level should not preclude further evaluation.

**Common Pitfalls in the Diagnosis of CVT**

There are several clinical scenarios in which misdiagnosis, or delay in diagnosis, of CVT frequently occurs.

**Intracranial Hemorrhage**

Approximately 30% to 40% of patients with CVT present with ICH. Identification of these patients is critical given that the pathophysiology underlying hemorrhage in such cases is distinct from other causes of ICH, and this has important treatment implications. Features suggestive of CVT as a cause of ICH include prodromal headache (which is highly unusual with other causes of ICH), bilateral parenchymal abnormalities, and clinical evidence of a hypercoagulable state. These features may not be present, however, and a high index of clinical suspicion is necessary. Isolated subarachnoid hemorrhage may also occur due to CVT, although this is rare (0.8% of patients in ISCVT). Hemorrhage location is an important consideration in estimating the likelihood of CVT and is discussed elsewhere in this statement (see “Imaging in the Diagnosis of CVT” for further details).

**Recommendation**

1. In patients with lobar ICH of otherwise unclear origin or with cerebral infarction that crosses typical arterial boundaries, imaging of the cerebral venous system should be performed (Class I; Level of Evidence C).

**Isolated Headache/Idiopathic Intracranial Hypertension**

In 1 series, 25% of patients with CVT presented with isolated headache, and another 25% presented with headache in conjunction with papilledema or sixth nerve palsies suggestive of idiopathic intracranial hypertension. In a series of 131 patients who presented with papilledema and clinically suspected idiopathic intracranial hypertension, 10% had CVT when magnetic resonance imaging (MRI)/magnetic resonance venography (MRV) was performed. Imaging of the cerebral venous system has been recommended for all patients with the clinical picture of idiopathic intracranial hypertension, because the distinction between CVT and idiopathic intracranial hypertension has important prognostic and treatment implications, and the yield of imaging is significant. For patients with isolated headache, the proper strategy for identification of CVT is much less clear. Headache is an extremely common symptom, and the vast majority of patients with isolated headache will not have CVT. The cost-effectiveness and yield of routine imaging are highly uncertain. Factors that may suggest the diagnosis, and thus prompt imaging evaluation, include a new, atypical headache; headache that progresses steadily over days to weeks despite conservative treatment; and thunderclap headache. In addition, a greater level of clinical suspicion for CVT should be maintained in patients with a hypercoagulable state.

**Recommendations**

1. In patients with the clinical features of idiopathic intracranial hypertension, imaging of the cerebral venous system is recommended to exclude CVT (Class I; Level of Evidence C).

2. In patients with headache associated with atypical features, imaging of the cerebral venous system is reasonable to exclude CVT (Class IIa; Level of Evidence C).

**Isolated Mental Status Changes**

Occasionally, patients with CVT will present with somnolence or a confusional state in the absence of obvious focal neurological abnormalities. Such clinical presentations are more common in the elderly and with thrombosis of the deep venous system. Although a number of mechanisms may underlie this clinical presentation, an important cause is bilateral thalamic lesions due to involvement of the deep venous system. Computed tomography (CT) scanning, especially if performed early in the clinical course, may be unremarkable; MRI will usually demonstrate abnormalities in such cases.

**Imaging in the Diagnosis of CVT**

Over the past 2 decades, diagnostic imaging has played an increasing role in the diagnosis and management of CVT. Diagnostic imaging of CVT may be divided into 2 categories, which will be reviewed in more detail below: Noninvasive modalities and invasive modalities. The goal is to determine vascular and parenchymal changes associated with this medical condition. In some cases, the diagnosis is made only with cerebral digital subtraction angiography.

**Noninvasive Diagnostic Modalities: CT, MRI, and Ultrasound**

**Computed Tomography**

CT is widely used as the initial neuroimaging test in patients who present with new-onset neurological symptoms such as headache, seizure, mental alteration, or focal neurological signs. CT without contrast is often normal but may demonstrate findings that suggest CVT. Anatomic variability of the venous sinuses makes CT diagnosis of CVT insensitive, with results on a plain CT being abnormal only in ~30% of CVT cases. The primary sign of acute CVT on a noncontrast CT is hyperdensity of a cortical vein or dural sinus. Acutely thrombosed cortical veins and dural sinuses appear as a homogenous hyperdensity that fills the vein or sinus and are most clearly visualized when CT slices are perpendicular to the dural sinus or vein (Figure 3). However, only approximately one third of CVT demonstrates direct signs of hyperdense dural sinus. Thrombosis of the posterior portion of the superior sagittal sinus may appear as
a dense triangle, the dense or filled delta sign. An ischemic infarction, sometimes with a hemorrhagic component, may be seen. An ischemic lesion that crosses usual arterial boundaries (particularly with a hemorrhagic component) or in close proximity to a venous sinus is suggestive of CVT. Subarachnoid hemorrhage and ICH are infrequent. Subarachnoid hemorrhage was found in only 0.5% to 0.8% of patients with CVT, and when present, it was localized in the convexity as opposed to the area of the circle of Willis usually observed in patients with aneurysmal rupture.

Contrast-enhanced CT may show enhancement of the dural lining of the sinus with a filling defect within the vein or sinus. Contrast-enhanced CT may show the classic “empty delta” sign, in which a central hypointensity due to very slow or absent flow within the sinus is surrounded by contrast enhancement in the surrounding triangular shape in the posterior aspect of the superior sagittal sinus. This finding may not appear for several days after onset of symptoms but does persist for several weeks.

Because symptoms of CVT may be overlooked or associated with delays in seeking medical attention, CVT may be seen only during the subacute or chronic stage. Compared with the density of adjacent brain tissue, thrombus may be isodense, hypodense, or of mixed density. In this situation, contrast CT or CT venography (CTV) may assist the imaging diagnosis.

### Table 4. Comparison of the Advantages and Disadvantages of CT and MRI in the Diagnosis of CVT

<table>
<thead>
<tr>
<th>CT + CTV</th>
<th>MRI + MRV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages</strong></td>
<td><strong>Disadvantages</strong></td>
</tr>
<tr>
<td>Good visualization of major venous sinuses</td>
<td>Exposure to ionizing radiation</td>
</tr>
<tr>
<td>Quick (5–10 min)</td>
<td>Risk of contrast reactions</td>
</tr>
<tr>
<td>Readily available</td>
<td>Risk of iodinated contrast nephropathy (eg, in patients with diabetes, renal failure)</td>
</tr>
<tr>
<td>Fewer motion artifacts</td>
<td>Low resolution for small parenchymal abnormalities</td>
</tr>
<tr>
<td>Can be used in patients with a pacemaker, defibrillator, or claustrophobia</td>
<td>Poor detection of cortical and deep venous thrombosis</td>
</tr>
<tr>
<td><strong>Sensitivity/specificity</strong></td>
<td><strong>Practical application</strong></td>
</tr>
<tr>
<td>Small studies comparing multiplanar CT/CTV vs DSA showed 95% sensitivity and 91% specificity</td>
<td>Acute onset of symptoms</td>
</tr>
<tr>
<td>Overall accuracy 90% to 100%, depending on vein or sinus</td>
<td>Acute or subacute onset of symptoms</td>
</tr>
<tr>
<td><strong>Practical application</strong></td>
<td>Emergency setting</td>
</tr>
<tr>
<td>Multidetector CTV can be used as the initial test when MRI is not readily available</td>
<td>Patients with suspected CVT and normal CT/CTV</td>
</tr>
</tbody>
</table>

CT indicates computed tomography; MRI, magnetic resonance imaging; CVT, cerebral venous thrombosis; CTV, CT venography; MRV, magnetic resonance venography; and DSA, digital subtraction angiography. *Wetzel et al.*
detection of thrombus in a venous sinus. Findings are variable but may include a “hyperintense vein sign.” Isolated cortical venous thrombosis is identified much less frequently than sinus thrombosis. The magnetic resonance signal intensity of venous thrombus varies according to the time of imaging from the onset of thrombus formation. Acute thrombus may be of low intensity. In the first week, venous thrombus frequently appears as isointense to brain tissue on T1-weighted images and hypointense on T2-weighted images owing to increased deoxyhemoglobin. By the second week, thrombus contains methemoglobin, which results in hyperintensity on T1- and T2-weighted images (Figure 5). With evolution of the thrombus, the paramagnetic products of deoxyhemoglobin and methemoglobin are present in the sinus. A thrombosed dural sinus or vein may then demonstrate low signal on gradient-echo and susceptibility-weighted images of magnetic resonance images. The principal early signs of CVT on non–contrast-enhanced MRI are the combination of absence of a flow void with alteration of signal intensity in the dural sinus. MRI of the brain is suggestive of CVT by the absence of a fluid void signal in the sinus, T2 hypointensity suggestive of a thrombus, or a central isodense lesion in a venous sinus with surrounding enhancement. This appearance is the MRI equivalent of the CT empty delta sign. An acute venous thrombus may have hypointense signal that mimics a normal flow void. The nature of the thrombus then evolves through a subacute and chronic phase.

Figure 4. Proposed Algorithm for the Management of CVT. The CVT Writing group recognize the challenges facing primary care, emergency physicians and general neurologists in the diagnosis and management of CVT. The aim of this algorithm is to provide guidance to physicians in the initial management of CVT. Anticoagulation remains the principal therapy and is aimed at preventing thrombus propagation and increasing recanalization. This algorithm is not comprehensive, nor applicable to all clinical scenarios and patient management must be individualized. Limited evidence is available on the benefits of decompressive hemicraniectomy and endovascular therapy for the management of CVT as reflected by the low grade and level of recommendations. Anticipated future advances in imaging techniques, new pharmacological agents and endovascular procedures may provide other therapeutic alternatives to be considered in patients with CVT, and in the future these guidelines will be periodically updated to reflect the changing evidence. CVST indicates cerebral venous and sinus thrombosis; LMWH, low molecular weight heparin; Tx, therapy; ICH, intracerebral hemorrhage; CTV, CT venogram; MRV, MR venogram.

†Intracranial hemorrhage that occurred as the consequence of CVST is not a contraindication for anticoagulation. ‡Endovascular therapy may be considered in patients with absolute contraindications for anticoagulation therapy or failure of initial therapeutic doses of anticoagulant therapy.
Thus, contrast-enhanced MRI and either CTV or MRV may be necessary to establish a definite diagnosis.

The secondary signs of MRI may show similar patterns to CT, including cerebral swelling, edema, and/or hemorrhage. Occasionally, diffusion-weighted imaging (DWI) and perfusion-weighted MRI may assist in making the diagnosis. DWI may show high signal intensity as restricted diffusion- and perfusion-weighted MRI with prolonged transit time.

Brain parenchymal lesions of CVT are better visualized and depicted on MRI than at CT (Figure 6). Focal edema without hemorrhage is visualized on CT in ~8% of cases and on MRI in 25% of cases. Focal parenchymal changes with edema and hemorrhage may be identified in up to 40% of patients. The discrepancy in frequency of detection may be due in part to varying timing of imaging after thrombosis. Petechial or confluent hemorrhage may also represent an underlying hemorrhagic venous infarction. This may include DWI abnormalities consistent with acute infarction, but the degree of DWI findings may be reduced in venous infarction compared with arterial infarction (Figure 7).

An altered enhancement pattern suggestive of collateral flow or of venous congestion may be seen. There are some characteristic patterns of brain parenchymal changes that distinguish CVT from other entities. Also, to some extent, lesions related to specific sinuses are regionally distributed. Brain parenchymal changes in frontal, parietal, and occipital lobes usually correspond to superior sagittal sinus thrombosis (Figure 8). Temporal lobe parenchymal changes correspond to lateral (transverse) and sigmoid sinus thrombosis. Deep parenchymal abnormalities, including thalamic hemorrhage, edema, or intraventricular hemorrhage, correspond to thrombosis of the vein of Galen or straight sinus. MRI signal can also predict radiographic outcome to some extent, because DWI abnormality within veins or sinus predicts poor recanalization.

CT Venography
CTV can provide a rapid and reliable modality for detecting CVT (Figure 9). CTV is much more useful in subacute or chronic situations because of the varied density in thrombosed veins.
sinus (Figure 10). Because of the dense cortical bone adjacent to dural sinus, bone artifact may interfere with the visualization of enhanced dural sinus. CTV is at least equivalent to MRV in the diagnosis of CVT. However, drawbacks to CTV include concerns about radiation exposure, potential for iodine contrast material allergy, and issues related to use of contrast in the setting of poor renal function.

In some settings, MRV is preferable to CTV because of these concerns (Table 4).

**Magnetic Resonance Venography**

The most commonly used MRV techniques are time-of-flight (TOF) MRV (Figures 11 and 12) and contrast-enhanced magnetic resonance. Phase-contrast MRI is used less frequently, because defining the velocity of the encoding parameter is both difficult and operator-dependent.
The 2-dimensional TOF technique is the most commonly used method currently for the diagnosis of CVT, because 2-dimensional TOF has excellent sensitivity to slow flow compared with 3-dimensional TOF. It does have several potential pitfalls in imaging interpretation (see “Potential Pitfalls in the Radiological Diagnosis of CVT: Anatomic Variants, Thrombus Signal Variability, and Imaging Artifacts” below). Despite the challenges, other sequences such as gradient echo, susceptibility-weighted imaging, and contrast MRI/MRV may assist in these situations. Nonthrombosed hypoplastic sinus will not have abnormal low signal in the sinus on gradient echo or susceptibility-weighted images. The chronic thrombosed hypoplastic sinus will have marked enhanced sinus and no flow on 2-dimensional TOF venography. Contrast-enhanced MRI offers improved visualization of cerebral venous structures.

In patients with persistent or progressive symptoms despite medical treatment, repeated neuroimaging (including a CTV or MRV) may help identify the development of a new ischemic lesion, ICH, edema, propagation of the thrombus, or other brain parenchymal lesions.

Deep CVT

The deep venous system is readily seen on CT and MRI and may be less impacted by artifact because of the separation from bony structures (Figure 13). A potential pitfall at the junction of the straight sinus and vein of Galen on TOF MRI is the appearance of absence of flow if image acquisition is in an axial plane to the skull. This pitfall may be overcome with contrast-enhanced MRI and DWI. Table 4 compares the advantages and disadvantages of CT/CTV and MRI/MRV.

Invasive Diagnostic Angiographic Procedures

Cerebral Angiography and Direct Cerebral Venography

Invasive cerebral angiographic procedures are less commonly needed to establish the diagnosis of CVT given the availability of MRV and CTV. These techniques are reserved for situations in which the MRV or CTV results are inconclusive or if an endovascular procedure is being considered.

Cerebral Angiography

Arteriographic findings include the failure of sinus appearance due to the occlusion; venous congestion with dilated cortical, scalp, or facial veins; enlargement of typically diminutive veins from collateral drainage; and reversal of venous flow. The venous phase of cerebral angiography will show a filling defect in the thrombosed cerebral vein/sinus (Figure 14). Because of the highly variable cerebral venous structures and inadequate resolution, CT or MRI may not provide adequate visualization of selected veins, especially cortical veins and in some situations the deep venous structures. Hypoplasia or atresia of cerebral veins or dural sinuses may lead to inconclusive results on MRV or CTV and can be
clarified on the venous phase of cerebral angiography. Acute dural sinus and cortical vein thrombosis typically causes a delay in cerebral venous circulation, and cerebral angiography will demonstrate delayed and slow visualization of cerebral venous structures. Normally, the early veins begin to opacify at 4 to 5 seconds after injection of contrast material into the carotid artery, and the complete cerebral venous system is opacified in 7 to 8 seconds.74,91,124,152 If cerebral veins or dural sinuses are not visualized in the normal sequences of cerebral angiography, the possibility of acute thrombosis is suspected. This finding accounts for the observed delayed cerebral perfusion seen with perfusion-weighted MRI with prolonged transit time.74,91,104,124,130,132,153

**Direct Cerebral Venography**
Direct cerebral venography is performed by direct injection of contrast material into a dural sinus or cerebral vein from microcatheter insertion via the internal jugular vein. Direct cerebral venography is usually performed during endovascular therapeutic procedures.74,91 In direct cerebral venography, intraluminal thrombus is seen either as a filling defect within the lumen in the setting of nonocclusive thrombosis or as complete nonfilling in occlusive thrombosis. Complete thrombosis may also demonstrate a “cupping appearance” within the sinus. Venous pressure measurements may be performed during direct cerebral venography to identify venous hypertension. Normal venous sinus pressure is <10 mm H\textsubscript{2}O. The extent of parenchymal change correlates with increased venous pressure and with the stage of thrombosis, with changes being maximal in acute thrombosis.

**Other Diagnostic Modalities**
Transfontanellar ultrasound may be used to evaluate pediatric patients, including newborn or young infants with open anterior or posterior fontanels. Ultrasound, along with transcranial Doppler, may be useful to support the diagnosis of CVT and for ongoing monitoring of thrombus and parenchymal changes.152,154,155

**Perfusion Imaging Methods**
Anecdotal evidence using positron emission tomography showed a reduction of the cerebral blood flow after ligation of the superior sagittal sinus with a concomitant venous infarction.156 An increased regional cerebral blood volume was also observed in a young adult with sagittal sinus thrombosis.157 A prolonged mean transit time and increased cerebral blood volume have been suggested as venous congestion, contrary to the pattern observed in patients with an ischemic arterial stroke (prolonged mean transit time with reduction in cerebral blood volume).111,124

**Potential Pitfalls in the Radiological Diagnosis of CVT:**

Anatomic Variants, Thrombus Signal Variability, and Imaging Artifacts

The positive findings of intraluminal thrombus are the key to a confident diagnosis of CVT by CT or MRI. Unfortunately, these findings are not always evident, and the diagnosis rests on nonfilling of a venous sinus or cortical vein (Figure 15). Given the variation in venous anatomy, it is sometimes impossible to exclude CVT on noninvasive imaging studies. Anatomic variants of normal venous anatomy may mimic sinus thrombosis, including sinus atresia/hypoplasia, asymmetrical sinus drainage, and normal sinus filling defects related to prominent arachnoid granulations or intrasinus septa.2,71,72,95,97,106,108,109,125,142–150,158 Angiographic examination of 100 patients with no venous pathology159 showed a high prevalence of asymmetrical lateral
(transverse) sinuses (49%) and partial or complete absence of 1 lateral sinus (20%).

Flow gaps are commonly seen on TOF MRV images, which sometimes affects their interpretation. The hypoplastic dural sinus may have a more tapering appearance than an abrupt defect in contrast-enhanced images of the sinus. The lack of identification of a thrombus within the venous sinus on MRI or contrast-enhanced MRV or CTV is helpful to clarify the diagnosis.160

As mentioned, sinus signal-intensity variations may also affect the interpretation of imaging in the diagnosis of CVT.70 Direct cerebral venography may be difficult to interpret owing to retrograde flow of contrast from the point of injection, and the venous pressure may not be accurate because of relative compartmentalization within the system.70

Recommendations

1. Although a plain CT or MRI is useful in the initial evaluation of patients with suspected CVT, a negative plain CT or MRI does not rule out CVT. A venographic study (either CTV or MRV) should be performed in suspected CVT if the plain CT or MRI is negative or to define the extent of CVT if the plain CT or MRI suggests CVT (Class I; Level of Evidence C).

2. An early follow-up CTV or MRV is recommended in CVT patients with persistent or evolving symptoms despite medical treatment or with symptoms suggestive of propagation of thrombus (Class I; Level of Evidence C).

3. In patients with previous CVT who present with recurrent symptoms suggestive of CVT, repeat CTV or MRV is recommended (Class I; Level of Evidence C).

4. Gradient echo T2 susceptibility-weighted images combined with magnetic resonance can be useful to improve the accuracy of CVT diagnosis.70,129,151 (Class IIa; Level of Evidence B).

5. Catheter cerebral angiography can be useful in patients with inconclusive CTV or MRV in whom a clinical suspicion for CVT remains high (Class IIa; Level of Evidence C).

6. A follow-up CTV or MRV at 3 to 6 months after diagnosis is reasonable to assess for recanalization of the occluded cortical vein/sinuses in stable patients (Class IIa; Level of Evidence C).

Management and Treatment

Acute Management and Treatment of CVT
To address treatment of CVT in adults, we reviewed systematic reviews and guideline statements of the Cochrane Collaboration,161 the American College of Chest Physicians,162,163 and the European Federation of Neurological Sciences,164 in addition to performing a literature review using search terms in PubMed: (“cerebral vein thrombosis” OR “cerebral venous thrombosis” OR “sinus thrombosis”) AND randomized trial; (“cerebral vein thrombosis” OR “cerebral venous thrombus” OR “sinus thrombosis”) AND treatment guideline. Secondary sources of data included reference lists of articles reviewed and cohort studies that related treatment to outcomes. A summary algorithm for the diagnosis and management of patients with CVT is provided (Figure 4).

Setting
Organized care has been defined as collaborative, high-quality, standardized, effective and cost-effective care given by an interdisciplinary team using protocols based on best practices.165 According to the Stroke Unit Trialists’ Collaboration, the most important components of organized stroke care are assessment by a stroke neurologist, admission to a stroke unit with stroke-directed nursing care, physiotherapy, and occupational therapy.166–169 Organized care is one of the most effective interventions to reduce mortality and morbidity after acute stroke.166,167 For example, stroke unit care was associated with a 14% reduction in the odds of death at 1 year (OR 0.86, 95% CI 0.76 to 0.98; P=0.02), death or institutionalization (OR 0.82, 95% CI 0.73 to 0.92; P<0.001), and death or dependency (OR 0.82, 95% CI 0.73 to 0.92; P=0.001). These benefits were independent of age, sex, stroke severity, and stroke subtype.167,169,170

CVT is an uncommon but potentially serious and life-threatening cause of stroke. On the basis of findings for stroke unit care in general, management of CVT in a stroke unit is reasonable for the initial management of CVT to optimize care and minimize complications. Additional specialist input as needed to provide therapeutic anticoagulation is appropriate.

Initial Anticoagulation
There are several rationales for anticoagulation therapy in CVT: To prevent thrombus growth, to facilitate recanalization, and to prevent DVT or PE. Controversy has ensued because cerebral infarction with hemorrhagic transformation or ICH is commonly present at the time of diagnosis of CVT, and it may also complicate treatment. A summary table is provided with data from observational studies and randomized clinical trials.10,84,136,171–181 (Table 5) of CVT.

There are 2 available randomized controlled trials comparing anticoagulant therapy with placebo or open control in patients with CVT confirmed by contrast imaging. Taken together, these trials included only 79 patients. One trial of 20 patients assessed intravenous unfractionated heparin (UFH) using dose adjustment to achieve an activated partial thromboplastin time twice the pretreatment value compared with placebo.171 This study used a heparin bolus of 3000 U followed by continuous intravenous infusion. The primary outcome was a CVT severity scale at 3 months, which evaluated headache, focal signs, seizures, and level of consciousness. The secondary outcome was ICH. The trial was stopped early after 20 of the planned 60 patients were enrolled because there was a benefit of treatment. Among 10 patients in the heparin group, 8 recovered completely and 2 had mild deficits at 3 months. Among 10 patients in the placebo group, 1 recovered completely, 6 had minor deficits, and 3 died by 3 months. Two patients treated with placebo and none treated with heparin developed ICH. One patient in the placebo group had unconfirmed pulmonary embolus.

The other trial of 59 patients compared subcutaneous nadroparin dosed on the basis of body weight (180 anti-factor Xa units per kilogram daily in 2 divided doses) with placebo for 3 weeks followed by 3 months of oral anticoagulation (without placebo control) in those randomized to nadroparin.172 The study was blinded during the first 3 weeks and...
open label thereafter. Primary outcomes were scores for activities of daily living, the Oxford Stroke Handicap Scale, and death. Secondary end points were symptomatic ICH and other major bleeding. At 3 months, 13% of patients in the nadroparin group had a poor outcome compared with 21% given placebo (treatment difference in favor of nadroparin 7%; 95% CI 26% to 12%). There was no symptomatic ICH in either group (1 nonfatal hemorrhage with nadroparin and 1 fatal unconfirmed pulmonary embolus with placebo).

Six patients on active treatment (12%) and 8 control subjects (28%) had full recovery over 3 months.

Meta-analysis of these 2 trials revealed a nonstatistically significant relative risk of death or dependency with anticoagulation (relative risk 0.46, 95% CI 0.16 to 1.31), with a risk difference in favor of anticoagulation of –13% (95% CI –30% to 3%). The relative risk of death was 0.33 (95% CI 0.08 to 1.21), with a risk difference of –13% (95% CI –27% to 1%).

Table 5. Data From Observational Studies and Clinical Trials of CVT That Addressed Anticoagulation Therapy

<table>
<thead>
<tr>
<th>First Author</th>
<th>N</th>
<th>Years Recruited</th>
<th>Regimen</th>
<th>F/U Duration</th>
<th>Died, n</th>
<th>Fully Recovered, n*</th>
<th>Disabled, n</th>
<th>ICH</th>
<th>Other Hemorrhage</th>
<th>VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Einhaupl171</td>
<td>20</td>
<td>1982–4</td>
<td>RCT:</td>
<td>3 mo</td>
<td>0-UFH</td>
<td>8-UFH</td>
<td>2-UFH</td>
<td>0</td>
<td>NR</td>
<td>0-UFH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>10-UFH</td>
<td>2×PTT</td>
<td>10-Placebo</td>
<td>3-Placebo</td>
<td>1-Placebo</td>
<td>6-Placebo</td>
<td>2</td>
<td>1-Placebo</td>
</tr>
<tr>
<td>De Bruijn172</td>
<td>60</td>
<td>1992–6</td>
<td>RCT:</td>
<td>3 mo</td>
<td>30-Nadroparin</td>
<td>2-UFH</td>
<td>20-UFH</td>
<td>8-UFH</td>
<td>0</td>
<td>1-UFH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>29-Placebo</td>
<td>4-Placebo</td>
<td>4-Placebo</td>
<td>21-Placebo</td>
<td>0</td>
<td>0-Placebo</td>
<td>1-Placebo</td>
<td></td>
</tr>
<tr>
<td>De Bruijn173</td>
<td>47</td>
<td>1992–6</td>
<td>RCT as above</td>
<td>18.5 mo</td>
<td>0</td>
<td>16</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferro14</td>
<td>142</td>
<td>1980–98</td>
<td>112-UFH or AVK‡</td>
<td>Hospital stay</td>
<td>0</td>
<td>16</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daif14</td>
<td>40</td>
<td>1985–94</td>
<td>4-UFH</td>
<td>1-UFH</td>
<td>1-UFH</td>
<td>2-UFH</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>De Bruijn172</td>
<td>60</td>
<td>1992–6</td>
<td>30-Nadroparin</td>
<td>2-UFH</td>
<td>20-UFH</td>
<td>8-UFH</td>
<td>0</td>
<td>1-UFH</td>
<td>0-UFH</td>
<td></td>
</tr>
<tr>
<td>De Bruijn173</td>
<td>47</td>
<td>1992–6</td>
<td>RCT as above</td>
<td>18.5 mo</td>
<td>0</td>
<td>16</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fero14 and Girot84</td>
<td>624</td>
<td>1998–2001</td>
<td>UFH/LMWH or AVK‡</td>
<td>Hospital stay</td>
<td>0</td>
<td>16</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preter175</td>
<td>77</td>
<td>1975–90</td>
<td>30-UFH</td>
<td>3.5 y</td>
<td>3 (6.6%)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Maqueda176</td>
<td>54</td>
<td>1985–2002</td>
<td>48-AVK or 3 mo</td>
<td>Not included</td>
<td>11</td>
<td>0</td>
<td>11 (14%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breteau177</td>
<td>55</td>
<td>1995–8</td>
<td>UFH+AVK: 6 mo in 56%, entire F/U in 31%</td>
<td>36 mo</td>
<td>7</td>
<td>15 (31%)</td>
<td>23</td>
<td>NR</td>
<td>NR</td>
<td>3</td>
</tr>
<tr>
<td>Cakmak178</td>
<td>16</td>
<td>1996–2000</td>
<td>UFH/LMWH or AVK‡</td>
<td>3 mo</td>
<td>0</td>
<td>14</td>
<td>2</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Stolz179</td>
<td>79</td>
<td>1985–2001</td>
<td>63-UFH or AVK‡</td>
<td>3 mo</td>
<td>0</td>
<td>14</td>
<td>2</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Mak180</td>
<td>13</td>
<td>1995–1998</td>
<td>12 (Heparin)</td>
<td>5–36 mo</td>
<td>1</td>
<td>11</td>
<td>0</td>
<td>NR</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Brucker177</td>
<td>42</td>
<td>1995–2002</td>
<td>42 Heparin or OAC</td>
<td>5–36 mo</td>
<td>1</td>
<td>40</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

CVT indicates cerebral venous thrombosis; F/U, follow-up; ICH, new intracerebral hemorrhage during follow-up; VTE, venous thromboembolism; RCT, randomized controlled trial; UFH, unfractionated heparin; PTT, partial thromboplastin time; NR, not reported; AVK, anti-vitamin K; ACO, anticoagulation; LMWH, low-molecular-weight heparin; LDUFH, low-dose unfractionated heparin; and OAC, oral anticoagulation.

*Definitions for disability vary among studies.
†Recovered completely.
‡Thirty-one of 49 patients with ICH received anticoagulation; 81 of 93 without ICH received anticoagulation.
¶One patient was asymptomatic.
§Anticoagulation was associated with a 3.8-fold (95% CI, 1.5–9.6) increased odds of full recovery; not associated with death risk.
||No comparisons made by treatment status. Nine patients developed recurrent CVT (11.7%), all while not taking anticoagulation therapy.
#Seven had a predisposing condition; it is unknown whether they had stopped anticoagulation therapy.
**A total of 12.7% died or were dependent with early anticoagulation vs 18.3% without early anticoagulation (P>0.05).
A third trial randomized 57 women with puerperal CVT confirmed only by CT imaging and excluded those with hemorrhage on CT. Treatment was with subcutaneous heparin 5000 IU every 6 hours, dose adjusted to an activated partial thromboplastin time 1.5 times baseline for at least 30 days after delivery. Outcome assessment was not blinded. Three patients in the control group either died or had residual paresis compared with none in the heparin group.

In the special situation of CVT with cerebral hemorrhage on presentation, even in the absence of anticoagulation, hemorrhage is associated with adverse outcomes. Highlighting this, in 1 trial of nadroparin, all 6 deaths in the trial occurred in the group of 29 patients with hemorrhage on their pretreatment CT scan. None of the deaths were attributed to new or enlarged hemorrhage. These 29 patients were equally divided between treatment groups. Thus, cerebral hemorrhage was strongly associated with mortality but not with cerebral bleeding on treatment. Other studies suggested low rates of cerebral hemorrhage after anticoagulation for CVT.

In the special situation of a patient with a major contraindication for anticoagulation (such as recent major hemorrhage), the clinician must balance the risks and benefits of anticoagulation, depending on the clinical situation. In these settings, as for venous thrombosis in general, consultation with an expert in anticoagulation management may be appropriate, and low-intensity anticoagulation may be considered if possible in favor of no anticoagulation until such time as it might be safe to use full-intensity anticoagulation.

Data From Observational Studies
A number of observational studies, both prospective and retrospective, are available, primarily from single centers. Not all studies reported specifically on outcomes of anticoagulation treatment, because the majority of patients in most studies were treated with intravenous UFH or low-molecular-weight heparin (LMWH) at the time of diagnosis, with eventual use of vitamin K antagonists. Data are summarized in Table 5. Mortality rates were low, typically <10%, often due to the underlying disease (eg, cancer) rather than CVT and rarely due to ICH. The majority of patients fully recovered neurological function, and few became disabled.

In a retrospective study of 102 patients with CVT, 43 had an ICH. Among 27 (63%) who were treated with dose-adjusted intravenous heparin after the ICH, 4 died (15%), and 14 patients (52%) recovered completely. Of the 13 patients who did not receive heparin, mortality was higher (69%) with lower improvement in functional outcomes (only 3 patients completely recovered). The largest study by far was the ISCVT, which included 624 patients at 89 centers in 21 countries. Nearly all patients were treated with anticoagulation initially, and mortality was 8.3% over 16 months; 79% had complete recovery (modified Rankin scale [mRS] score of 0 to 1), 10.4% had mild to moderate disability (mRS score 2 to 3), and 2.2% remained severely disabled (mRS score 4 to 5). Few studies had sufficient numbers of patients not treated with anticoagulation to adequately address the role of anticoagulation in relation to outcome. Data from observational studies suggest a range of risks for ICH after anticoagulation for CVT from zero to 5.4%. In conclusion, limited data from randomized controlled clinical trials in combination with observational data on outcomes and bleeding complications of anticoagulation support a role for anticoagulation in treatment of CVT, regardless of the presence of pretreatment ICH. On the basis of the available data, it is unlikely that researchers will have equipoise on this question, so a new randomized trial may not be feasible. Anticoagulation appears safe and effective. There was consensus in the writing group to support anticoagulation therapy in the management of patients with CVT. If anticoagulation is given, there are no data supporting differences in outcome with the use of UFH in adjusted doses or LMWH in CVT patients. However, in the setting of DVT or PE, a recent systematic review and meta-analysis of 22 studies showed a lower risk of major hemorrhage (1.2% versus 2.1%), thrombotic complications (3.6% versus 5.4%), and death (4.5% versus 6.0%) with LMWH.

Other Treatments
Fibrinolytic Therapy
Although patients with CVT may recover with anticoagulation therapy, 9% to 13% have poor outcomes despite anticoagulation. Anticoagulation alone may not dissolve a large and extensive thrombus, and the clinical condition may worsen even during heparin treatment. Incomplete recanalization or persistent thrombosis may explain this phenomenon. Partial or complete recanalization rates for CVT ranged from 47% to 100% with anticoagulation alone.

Unfortunately, most studies reporting partial or complete recanalization at 3 to 6 months have a small sample size. When 4 studies that included 114 CVT patients were combined, partial or complete recanalization at 3 to 6 months was observed in 94 (82.5%). Recanalization rates may be higher for patients who receive thrombolytic therapy. In general, thrombolytic therapy is used if clinical deterioration continues despite anticoagulation or if a patient has elevated intracranial pressure that evolves despite other management approaches.

Many invasive therapeutic procedures have been reported to treat CVT. These include direct catheter chemical thrombolysis and direct mechanical thrombectomy with or without thrombolysis. There are no randomized controlled trials to support these interventions compared with anticoagulation or with each other. Most evidence is based on small case series or anecdotal reports. Here, we review the studied interventions.

Direct Catheter Thrombolysis
In direct catheter thrombolysis, a standard microcatheter and microguidewire are delivered to the thrombosed dural sinus through a sheath or guiding catheter from the jugular bulb. Mechanical manipulation of the thrombus with the guidewire increases the amount of clot that might be impacted by the thrombolytic agent, potentially reducing the amount of fibrinolytic agent used.
In a retrospective multicenter study of CVT in the United States, 27 (15%) of 182 patients received endovascular thrombolysis. Ten patients were receiving concomitant anticoagulation therapy. Recanalization was achieved in 26 patients (96%), 4 developed an intracranial hemorrhage, and 1 patient (4%) died.

A systematic review that included 169 patients with CVT treated with local thrombolysis showed a possible benefit for those with severe CVT, which indicates that fibrinolytics may reduce case fatality in critically ill patients. ICH occurred in 17% of patients after thrombolysis and was associated with clinical worsening in 5%.206

**Mechanical Thrombectomy/Thrombolysis**

**Balloon-Assisted Thrombectomy and Thrombolysis**

Despite systemic thrombolysis or mechanical manipulation of the clot with direct fibrinolytic agent delivery, the sinus thrombosis may persist. Balloon-assisted thrombolysis may be more efficient because the inflated balloon may reduce washout of fibrinolytic agents, potentially lessening the dose of fibrinolytic agents required, the occurrence of hemorrhage,24,207,208 and procedure time. The balloon may be used to perform partial thrombectomy before thrombolysis.112,209

**Catheter Thrombectomy**

For patients with extensive thrombus that persists despite local administration of a fibrinolytic agent, rheolytic catheter thrombectomy may be considered. One such device is the AngioJet (MEDRAD, Inc, Warrendale, PA), which uses hydrodynamic thrombolytic action occurring at the tip of the catheter via the Venturi effect from high-velocity saline jets. Thrombus is disrupted and directed down the second lumen of the device. Perforation of the venous sinus wall may occur rarely, at a rate that is unknown but reported in the existing small series. It may be avoided by removal of the AngioJet after partial recanalization of the thrombosis and follow-up with additional microcatheter thrombolysis.187,189,191,198,199,201,202,210,211

The Merci retrieval device (Concentric Medical, Mountain View, CA) has also been used to remove thrombus in the cerebral venous system. This technique also requires direct catheter access to the venous sinus. The small corkscrew-shaped device is dispensed via the tip of the catheter, advanced into the thrombus, and then slowly pulled back into the catheter with the adherent thrombus. Here again, the device may be used to perform partial recanalization, followed by thrombolysis to avoid damaging the wall or trabeculae of the dural sinus.195 As mentioned above, the evidence available at the present time is anecdotal.

The Penumbra System (Penumbra, Inc, Alameda, CA) is a new-generation neuroembolectomy device that acts to debulk and aspirate acute clots. It uses a reperfusion catheter that aspirates thrombus while passing a wire-based separator within the catheter to break up the clot and facilitate aspiration. Only anecdotal evidence for its efficacy is available.212 The risks associated with use of the Penumbra System for cerebral venous thrombosis are likely similar to those seen with the Merci and AngioJet systems.

**Surgical Considerations**

As endovascular options for management of venous thrombosis have evolved, surgery has played an increasingly limited role. Surgical thrombectomy is needed uncommonly but may be considered if severe neurological or visual deterioration occurs despite maximal medical therapy.213,214

In a recent review, among 13 patients with severe CVT who underwent decompressive craniectomy, 11 (84.6%) achieved a favorable outcome (mRS score ≤3).215 Decompressive craniotomy may be needed as a life-saving measure if a large venous infarction leads to a significant increase in intracranial pressure. Likewise, large hematomas rarely may need to be considered for surgical evacuation if associated with a progressive and severe neurological deficit.

**Summary**

The use of these direct intrasinus thrombolytic techniques and mechanical therapies is only supported by case reports and small case series. If clinical deterioration occurs despite use of anticoagulation, or if the patient develops mass effect from a venous infarction or ICH that causes intracranial hypertension resistant to standard therapies, then these interventional techniques may be considered.

**Aspirin**

There are no controlled trials or observational studies that directly assess the role of aspirin in management of CVT.

**Steroids**

Steroids may have a role in CVT by decreasing vasogenic edema, but steroids may enhance hypercoagulability. In a matched case-control study among the 624 patients in the ISCVT,216 150 patients treated with steroids at the discretion of their healthcare provider were compared with 150 patients not so treated, matched to those treated on the basis of prognostic factors for poor outcome of CVT. Those treated with steroids thus had similar characteristics as control subjects, except they were more likely to have vasculitis. At 6 months, there was a trend toward a higher risk of death or dependence with steroid treatment (OR 1.7, 95% CI 0.9 to 3.3), and this did not differ after the exclusion of those with vasculitis, malignancy, inflammatory disease, and infection. Among those with parenchymal brain lesions on CT/MRI, results were striking, with 4.8-fold increased odds of death or dependence with steroid treatment (95% CI 1.2 to 19.8). Sensitivity analyses that used different analytic approaches yielded similar findings.

**Antibiotics**

Local (eg, otitis, mastoiditis) and systemic (meningitis, sepsis) infections can be complicated by thrombosis of the adjacent or distant venous sinuses. The management of patients with a suspected infection and CVT should include administration of the appropriate antibiotics and the surgical drainage of infectious sources (ie, subdural empymemas or purulent collections within the paranasal sinuses).

**Management and Prevention of Early Complications (Hydrocephalus, Intracranial Hypertension, Seizures)**

**Seizures**

Seizures are present in 37% of adults, 48% of children, and 71% of newborns who present with CVT.102,183 No clinical trials have studied either the optimal timing or medication...
choice for anticonvulsants in CVT. Whether to initiate anticonvulsants in all cases of CVT or await initial seizures before treatment is controversial. Because seizures increase the risk of anoxic damage, anticonvulvant treatment after even a single seizure is reasonable.\textsuperscript{217} In the absence of seizures, the prophylactic use of antiepileptic drugs may be harmful (the risk of side effects may outweigh its benefits).\textsuperscript{196,197,209}

A few studies have reported the occurrence and characteristics of patients with seizures accompanying CVT. Among 91 patients, 1 study\textsuperscript{218} reported that 32\% presented with seizures and 2\% developed them during hospitalization; only 9.5\% developed late seizures, and seizures were not a predictor of prognosis at 1 year. Early seizures were 3.7-fold more likely (95\% CI 1.4 to 9.4) in those with parenchymal lesions on CT/MRI at diagnosis and 7.8-fold more likely (95\% CI 0.8 to 74.8) in those with sensory defects. A more recent report from the ISCVT\textsuperscript{197} showed 245 (39\%) of 624 patients presented with seizures and 43 (6.9\%) experienced early seizure within 2 weeks after diagnosis. Besides seizures on presentation, only a supratentorial parenchymal lesion on CT/MRI at diagnosis (present in 58\%) was associated with occurrence of early seizures (OR 3.1, 95\% CI 1.6 to 9.6). Furthermore, among those with a supratentorial lesion and no presenting seizure, use of antiepileptic drugs was associated with a 70\% lower risk of seizures within 2 weeks, although this was not statistically significant (OR 0.3, 95\% CI 0.04 to 2.6). On the basis of these findings, the authors suggested the prescription of antiepileptic agents in acute CVT patients with supratentorial lesions who present with seizures.\textsuperscript{197}

**Hydrocephalus**

The superior sagittal and lateral dural sinuses are the principal sites for CSF absorption by the arachnoid granulations, highly vascular structures that protrude across the walls of the sinuses into the subarachnoid space and drain into the venous system. In CVT, the function of the arachnoid granulations may be impaired, potentially resulting in failure of CSF absorption and communicating hydrocephalus (6.6\%).\textsuperscript{14,198}

Obstructive hydrocephalus is a less common complication of CVT and results from hemorrhage into the ventricular system. This is typically associated with thrombosis that involves the internal cerebral veins and may be associated with thalamic hemorrhage. This syndrome is well described in term neonates but occurs at all ages.\textsuperscript{201,205} Neurosurgical evacuation of CSF with ventriculostomy, or in persistent cases, ventriculoperitoneal shunt, is necessary. The brain is under increased venous pressure, and tissue perfusion is at increased risk compared with other situations with obstructive hydrocephalus. Therefore, close monitoring and neurosurgical consultation are important, because intervention may be required at lesser severities of ventricular enlargement.

**Intracranial Hypertension**

Up to 40\% of patients with CVT present with isolated intracranial hypertension.\textsuperscript{183} This is characterized by diffuse brain edema, sometimes seen as slit ventricles on CT scanning. Clinical features include progressive headache, papilledema, and third or sixth nerve palsies. Intracranial hypertension is primarily caused by venous outflow obstruction and tissue congestion compounded by CSF malabsorption. No randomized trials are available to clarify the optimal treatment; however, rational management of intracranial hypertension includes a combination of treatment approaches. First, measures to reduce the thrombotic occlusion of venous outflow, such as anticoagulation and possibly thrombolytic treatment, may result in resolution of intracranial hypertension. Second, reduction of increased intracranial pressure can be accomplished immediately by lumbar puncture with removal of CSF until a normal closing pressure is achieved. Unfortunately, lumbar puncture requires temporary cessation of anticoagulants, with an attendant risk of thrombus propagation. Despite the lack of randomized clinical trials, acetazolamide is a commonly used therapeutic alternative for the treatment of intracranial hypertension with CVT.\textsuperscript{139} It may have a limited role in the acute management of intracranial hypertension for patients with CVT. Acetazolamide, a carbonic anhydrase inhibitor, is a weak diuretic and decreases hyperglycemia and high lactate, which are deleterious to an ischemic brain. Serial lumbar punctures may be necessary when hypertension is persistent. In refractory cases, a lumbopteritoneal shunt may be required.\textsuperscript{195} Because prolonged pressure on the optic nerves can result in permanent blindness, it is of paramount importance to closely monitor visual fields and the severity of papilledema during the period of increased pressure. Ophthalmologic consultation is helpful for this. Although rarely required, optic nerve fenestration is a treatment option to halt progressive visual loss.

Decompressive craniectomy has been used in patients with malignant arterial stroke to treat elevated intracranial pressure unresponsive to conventional treatment. In a pooled analysis of randomized trials, surgical decompression within 48 hours of stroke onset reduced case fatality and improved functional outcome.\textsuperscript{204} Limited evidence is available on the role of decompressive craniectomy in CVT with either brain edema, venous infarction, neurological deterioration, or impending cerebral herniation.\textsuperscript{200,202,203} A disadvantage of craniectomy is that it precludes anticoagulation for the immediate postoperative period.

**Recommendations**

1. Patients with CVT and a suspected bacterial infection should receive appropriate antibiotics and surgical drainage of purulent collections of infectious sources associated with CVT when appropriate (Class I; Level of Evidence C).
2. In patients with CVT and increased intracranial pressure, monitoring for progressive visual loss is recommended, and when this is observed, increased intracranial pressure should be treated urgently (Class I; Level of Evidence C).
3. In patients with CVT and a single seizure with parenchymal lesions, early initiation of antiepileptic drugs for a defined duration is recommended to prevent further seizures (Class I; Level of Evidence B).
4. In patients with CVT and a single seizure without parenchymal lesions, early initiation of antiepileptic drugs for a defined duration is probably recommended to prevent further seizures (Class IIa; Level of Evidence C).

5. In the absence of seizures, the routine use of antiepileptic drugs in patients with CVT is not recommended (Class III; Level of Evidence C).

6. For patients with CVT, initial anticoagulation with adjusted-dose UFH or weight-based LMWH in full anticoagulant doses is reasonable, followed by vitamin K antagonists, regardless of the presence of ICH (Class IIa; Level of Evidence B). (For further details, refer to “Acute Management and Treatment of CVT: Initial Anticoagulation.”)

7. Admission to a stroke unit is reasonable for treatment and for prevention of clinical complications of patients with CVT (Class IIa; Level of Evidence C).

8. In patients with CVT and increased intracranial pressure, it is reasonable to initiate treatment with acetazolamide. Other therapies (lumbar puncture, optic nerve decompression, or shunts) can be effective if there is progressive visual loss. (Class IIa; Level of Evidence C).

9. Endovascular intervention may be considered if deterioration occurs despite intensive anticoagulation treatment (Class IIIb; Level of Evidence C).

10. In patients with neurological deterioration due to severe mass effect or intracranial hemorrhage causing intractable intracranial hypertension, decompressive hemicraniectomy may be considered (Class IIIb; Level of Evidence C).

11. For patients with CVT, steroid medications are not recommended, even in the presence of parenchymal brain lesions on CT/MRI, unless needed for another underlying disease (Class III; Level of Evidence B).

Long-Term Management and Recurrence of CVT

Risk of Recurrence With and Without Anticoagulation

Prevention strategies focus on preventing recurrence of CVT or other VTE in those CVT patients at high risk of these outcomes. There are no available risk stratification schemes in CVT, but patients with certain thrombophilic conditions or medical conditions, such as cancer, might be considered high risk. There are no randomized clinical trials of long-term prevention of first or recurrent CVT. Overall, there is approximately a 6.5% annual risk of any type of recurrent thrombosis.

Because there are no secondary prevention trials of anticoagulation in adults with CVT, evaluation of prevention strategies can only be performed with observational studies that evaluate recurrence of CVT or VTE with or without ongoing anticoagulation. In a cohort of 154 patients treated at Mayo Clinic between 1978 and 2001, 56 patients initially received both heparin and warfarin, 12 received heparin only, and 21 received warfarin only. Seventy-seven (50%) were treated with warfarin for an average of 9 months, with 25 committed to lifelong therapy. During 36 months of follow-up (464 patient-years), there were 23 recurrent VTEs in 20 patients (13%), the majority in the first year. Ten patients had recurrent CVT (2.2 per 100 patient-years), and 11 had DVT or PE (2.8 per 100 patient-years). Nine of the recurrent events occurred while the patients were taking warfarin. After 8 years of follow-up, there was no impact of warfarin on survival or recurrence-free survival.

In a cohort of 54 CVT patients treated consecutively at University Hospital Gasthuisberg, Leuven, Belgium, 8 (14.8%) had a recurrence of VTE (7 with DVT or PE, 1 with CVT and mesenteric vein thrombosis) over a median of 2.5 years of follow-up (4.5 per 100 patient-years). Median time to recurrence was 2.5 months (range 2 weeks to 4 years). Only 2 of these 8 patients were taking anticoagulants at the time of recurrence, 1 with an international normalized ratio (INR) of 1.6 and the other with an INR of 2.1. Among the 6 patients with recurrent VTE who were not taking anticoagulants, recurrence occurred between 2 weeks and 10 months after the index event. Those with recurrence more often had a thrombophilic disorder, had a history of DVT, and had not received oral anticoagulation because of perceived contraindications.

In the ISCVT study, among 624 patients with CVT, there were 14 (2.2%) recurrent CVTs and 27 (4.3%) other thrombotic events (16 DVT, 3 PE, 2 ischemic stroke, 2 transient ischemic attack, and 4 acute limb ischemia) over a mean follow-up of 16 months. Seventeen (41.5%) of the 41 patients with recurrent or other thrombotic events were receiving anticoagulants, but the type of anticoagulation and the number who were receiving therapeutic doses of anticoagulation were unknown. It was not reported whether anticoagulation was given long-term and whether recurrent events differed based on its use.

The Cerebral Venous Thrombosis Portuguese Collaborative Study Group (VENOPORT) evaluated outcomes for 142 CVT patients, of whom 51 were retrospectively enrolled and 91 were prospectively enrolled. There were 2 (2%) recurrent CVTs and 10 (8%) other arterial or venous thrombotic events (maximum 16 years of follow-up for the retrospective cases and 12 months of follow-up for prospective cases). For the prospectively followed cases, the incidence of a thrombotic event was 4% per year (5 thrombotic events in 4 patients: 2 DVTs, 1 PE, 1 ischemic stroke, and 1 acute limb ischemia). Three of these events occurred with anticoagulation use, although the INR levels were unknown at the time of the event. In addition, all of these events occurred within 12 months of the index CVT.

A cohort of 77 CVT patients diagnosed in France between 1975 and 1990 was followed up for 63 months. Nine (11.7%) had a recurrence of CVT, 8 during the first 12 months, and none were receiving anticoagulation at the time of recurrence. Eleven patients (14.3%) had other thrombotic events, including retinal vein thrombosis, PE, and arterial thromboses. Use of anticoagulation at the time of recurrent thromboses that were not CVTs was not reported.

More recently, 145 patients with a first CVT were followed up for a median of 6 years after discontinuation of anticoagulation therapy. CVT recurred in 5 patients (3%), and other manifestations of VTE (defined as DVT of the lower limbs or PE) were seen in 10 additional patients (7%). The recurrence rate accounted for 3.4% of all VTEs in the first 16 months (or 2.03 per 100 person-years; 95% CI 1.16 to 3.14) and 1.3% of CVTs in the first 16 months (or 0.53 per 100 person-years; 95% CI 0.16 to 1.10). Approximately half of the recurrences occurred...
within the first year after discontinuation of anticoagulant therapy. Mild thrombophilia abnormalities were not associated with recurrent CVT, but severe thrombophilia showed an increased risk of DVT or PE. In summary, the prevalence of CVT recurrence was similar in the Italian and ISCVT studies (1.3% and 2.2%, respectively) at the 16-month follow-up.

The overall risk of recurrence of any thrombotic event (CVT or systemic) after a CVT is ~6.5%. The risk of other manifestations of VTE after CVT ranges from 3.4% to 4.3% on the basis of the largest studies of this medical condition. Patients with severe thrombophilia have an increased risk of VTE.

**Secondary Prevention of CVT and Other VTE Events**

DVT/PE and CVT share some similarities. The chronic and transient risk factors appear to be similar, although women are more likely to have CVT, and selected thrombophilia subtypes may differ between CVT and DVT/PE. In the ISCVT cohort, the overall rate of recurrent CVT or other VTE recurrence was 4.1 per 100 person-years, with male sex and polycythemia/thrombocythemia being the only independent predictors found. The same study reported a steady increase in the cumulative risk of thrombotic recurrences not influenced by the duration of anticoagulation, which emphasizes the need for a clinical trial to assess the efficacy and safety of short versus extended anticoagulant therapy.

Given that systemic VTE after CVT is more common than recurrent CVT, one may reasonably adopt the VTE guidelines for prevention of both new VTE and recurrent CVT. However, each individual patient should undergo risk assessment (see “Thrombophilias and Risk Stratification for Long-Term Management” below), and the patient’s risk level and preferences regarding long-term anticoagulation treatment, the risk of bleeding, and the risk of thrombosis without anticoagulation should then be considered.

**Thrombophilias and Risk Stratification for Long-Term Management**

Thrombophilias may be hereditary or acquired, and hereditary thrombophilias have been stratified as mild or severe on the basis of the risk of recurrence in very large family cohorts. Among VTE patients, the hereditary thrombophilias with the highest cumulative recurrence rates for VTE in the absence of ongoing anticoagulation have been deficiencies of antithrombin, protein C, and protein S, with a 19% recurrence at 2 years, 40% at 5 years, and 55% at 10 years. Homozygous prothrombin G20210A; homozygous factor V Leiden; deficiencies of protein C, protein S, or antithrombin; combined thrombophilia defects; and antiphospholipid syndrome are categorized as severe.

Interestingly, the more common hereditary thrombophilias, such as heterozygous factor V Leiden and prothrombin G20210A or elevated factor VIII, have a much lower risk of recurrence (7% at 2 years, 11% at 5 years, and 25% at 10 years) and could be categorized as mild. Hyperhomocysteinemia, a common hereditary or acquired risk factor for VTE, was not significantly associated with a high risk of recurrence in addition, the annual incidence and the risk of recurrence increased markedly in those with combined thrombophilic defects, described as double heterozygous/homozygous.

There are several important points regarding the hereditary thrombophilia data described above. First, the familial nature of these deficiencies of protein C, S, or antithrombin was clearly established, which distinguishes these patients from those with sporadic or acquired abnormalities. Second, testing for deficiencies of protein C, S, and antithrombin must be performed at least 6 weeks after a thrombotic event and then confirmed with repeat testing and family studies. In addition, protein C and S functional activity and antithrombin levels are difficult to interpret during treatment with warfarin. Therefore, testing for these conditions is generally indicated 2 to 4 weeks after completion of anticoagulation. Lastly, clearly established deficiencies of proteins C, S, and antithrombin are relatively uncommon.

Antiphospholipid antibody syndrome is an acquired thrombophilia associated with specific laboratory criteria (lupus anticoagulant, anticardiolipin antibody, and anti-β2-glycoprotein I) and a history of a venous or arterial event or fetal loss. Caution must be taken when the results of antiphospholipid antibody testing are interpreted. A normal result may occur at the time of the clinical presentation, which rules out antiphospholipid antibody syndrome. On the other hand, abnormal tests may occur transiently due to the disease process, infection, certain medications (antibiotics, cocaine, hydralazine, procainamide, quinine, and others), or unknown causes. Approximately 5% of the general population at any given time has evidence of abnormal tests, and these mainly have no clinical consequence.

A diagnosis of antiphospholipid syndrome requires abnormal laboratory testing on 2 or more occasions at least 12 weeks apart. Patients diagnosed with antiphospholipid syndrome have an increased risk of recurrent thrombotic events; however, test results cannot predict the likelihood of complications, their type, or their severity in a particular patient.

Although there are no prospective studies that report recurrence rates for CVT specifically, the high risk of recurrent VTE with this disorder meets the definition of severe thrombophilia. The Duration of Anticoagulation Study Group reported a 29% recurrence of VTE in patients with anticardiolipin antibodies versus 14% in those without them ($P=0.001$) over a 4-year period, and the risk increased with the titer of the antibodies. In a randomized controlled trial of warfarin for 3 months versus extended treatment for 24 months after first-ever idiopathic DVT or PE, the presence of antiphospholipid antibodies was associated with a 4-fold increased risk of recurrence (hazard ratio [HR] 4.0, 95% CI 1.2 to 13), and the presence of a lupus anticoagulant was associated with a 7-fold increased risk (HR 6.8, 95% CI 1.5 to 31) in the placebo group. The current recommendations for VTE patients call for indefinite anticoagulation (adjusted-dose warfarin INR 2.0 to 3.0 or heparin) for patients with antiphospholipid syndrome.

**Other Tests That Might Define Risk of Recurrent CVT or VTE After CVT**

In patients with DVT or PE, increasing evidence suggests there is clinical utility to D-dimer measurement when used to define risk of recurrent VTE. For example, in a randomized controlled trial, patients with an abnormal D-dimer level 1 month after the discontinuation of...
anticoagulation had a significant incidence of recurrent VTE (15% versus 2.9%), which was reduced by the resumption of anticoagulation (compared with those not receiving vitamin K antagonists, \( P=0.02 \)).

During 1.4 years of follow-up, 120 subjects with an abnormal D-dimer level were randomized to no anticoagulation, and 18 (15%) in this group developed a recurrent VTE. Of the 103 patients with abnormal D-dimer randomized to no anticoagulation, only 3 (2.9%) had a recurrent VTE. Although the study was randomized, it was unblinded, and D-dimer levels were only obtained once. In addition, there were no subjects with CVT and no similar studies in CVT patients. Although the clinical utility of D-dimer for longer-term anticoagulation for VTE secondary prevention appears promising, the lack of standardization of D-dimer assays may limit their clinical applicability and reliability.

**Recommendations**

1. Testing for prothrombotic conditions, including protein C, protein S, antithrombin deficiency, antiphospholipid syndrome, prothrombin G20210A mutation, and factor V Leiden, can be beneficial for the management of patients with CVT. Testing for protein C, protein S, and antithrombin deficiency is generally indicated 2 to 4 weeks after completion of anticoagulation. There is a very limited value of testing in the acute setting or in patients taking warfarin.

2. In patients with provoked CVT (associated with a transient risk factor), vitamin K antagonists may be continued for 3 to 6 months, with a target INR of 2.0 to 3.0 (Class IIb; Level of Evidence C).

3. In patients with unprovoked CVT, vitamin K antagonists may be continued for 6 to 12 months, with a target INR of 2.0 to 3.0 (Class IIb; Level of Evidence C).

4. For patients with recurrent CVT, VTE after CVT, or first CVT with severe thrombophilia (ie, homozygous prothrombin G20210A; homozygous factor V Leiden; deficiencies of protein C, protein S, or antithrombin; combined thrombophilia defects; or antiphospholipid syndrome), indefinite anticoagulation may be considered, with a target INR of 2.0 to 3.0 (Class IIb; Level of Evidence C).

5. Consultation with a physician with expertise in thrombosis may be considered to assist in the prothrombotic testing and care of patients with CVT (Class IIb; Level of Evidence C).

**Management of Late Complications (Other Than Recurrent VTE)**

**Headache**

Headache is a common complaint during the follow-up of CVT patients, occurring in \( \approx 50\% \) of patients. In general, headaches are primary and not related to CVT. In the Lille study, 53% of patients had residual headache, 29% fulfilled criteria for migraine, and 27% had headache of the tension type. In VENOPORT, 55% of patients reported headaches during the follow-up, and these were mild to moderate in 45%. In a series of 17 patients presenting with headache as the only neurological sign of CVT, several patients had headaches at 3 months, which comprised migraine attacks similar to those that occurred previously (4), tension type (2), and new onset of migraine with aura (2).

At follow-up, severe headaches that required bed rest or hospital admission were reported in 14% of patients in the ISCVT and 11% in VENOPORT. In patients with persistent or severe headaches, appropriate investigations should be completed to rule out recurrent CVT. Occasionally, MRV may show stenosis of a previously occluded sinus, but the clinical significance of this is unclear. Headache during follow-up is more common among patients who present acutely as having isolated intracranial hypertension. In these patients, if headache persists and MRI is normal, lumbar puncture may be needed to exclude elevated intracranial pressure.

**Seizures**

Focal or generalized post-CVT seizures can be divided into early or remote (occurring >2 weeks after diagnosis) seizures. On the basis of case series, remote seizures affect 5% to 32% of patients. Most of these seizures occur in the first year of follow-up. In ISCVT, 11% of the patients experienced remote seizures (36 patients by 6 months, 55 by 1 year, and 66 by 2 years). Risk factors for remote seizures were hemorrhagic lesion on admission CT/MRI (HR 2.42, 95% CI 1.38 to 4.22), early seizure (HR 2.22, 95% CI 1.33 to 3.69). Five percent of the patients had post-CVT epilepsy (>1 remote seizure). Post-CVT epilepsy was also associated with hemorrhagic lesion on admission CT/MRI (OR 6.76, 95% CI 2.26 to 20.41), early seizure (OR 3.99, 95% CI 1.16 to 11.0), and paresis (OR 2.75, 95% CI 1.33 to 6.54). Initiation of antiepileptic drugs for a defined duration is recommended to prevent further seizures in patients with CVT and parenchymal lesions who present with a single seizure. Recommendations covering different scenarios are provided in the section on the “Management and Prevention of Early Complications.”

**Visual Loss**

Severe visual loss due to CVT rarely occurs (2% to 4%). Papilledema can cause transient visual impairment, and if prolonged, optic atrophy and blindness may ensue. Visual loss is often insidious, with progressive constriction of the visual fields and relative sparing of central visual acuity. Visual deficits are more common in patients with papilledema and those who present with increased intracranial pressure. Delayed diagnosis is associated with an increased risk of later visual deficit. Patients with papilledema or visual complaints should have a complete neuro-ophthalmological study, including visual acuity and formal visual field testing.

**Dural Arteriovenous Fistula**

Thrombosis of the cavernous, lateral, or sagittal sinus can later induce a dural arteriovenous fistula. A pial fistula can also follow a cortical vein thrombosis. The relationship between the 2 entities is rather complex, because (1) dural fistulas can be a late complication of persistent dural sinus occlusion with increased venous pressure, (2) the fistula can close and cure if the sinus recanalizes, and (3) a preexisting fistula can be the underlying cause of CVT. The exact frequency of dural fistula after CVT is not known because there are no cohort studies with
long-term angiographic investigation. The incidence of dural arteriovenous fistula was low in cohort studies without systematic angiographic follow-up (1% to 3%).\textsuperscript{35,04,201,205,237} A cerebral angiogram may help identify the presence of a dural arteriovenous fistula.

**Recommendation**

1. In patients with a history of CVT who complain of new, persisting, or severe headache, evaluation for CVT recurrence and intracranial hypertension should be considered (Class I; Level of Evidence C).

**CVT in Special Populations**

**CVT During Pregnancy**

Pregnancy induces changes in the coagulation system that persist into the puerperium and result in a hypercoagulable state, which increases the risk of CVT. Incidence estimates for CVT during pregnancy and the puerperium range from 1 in 2500 deliveries to 1 in 10,000 deliveries in Western countries, and ORs range from 1.3 to 13.\textsuperscript{238–240} The greatest risk periods for CVT include the third trimester and the first 4 postpartum weeks.\textsuperscript{240} Up to 73% of CVT in women occurs during the puerperium.\textsuperscript{241} Cesarean delivery appears to be associated with a higher risk of CVT after adjustment for age, vascular risk factors, presence of infections, hospital type, and location (OR 3.10, 95% CI 2.26 to 4.24).\textsuperscript{35}

Vitamin K antagonists, including warfarin, are associated with fetal embryopathy and bleeding in the fetus and neonate and thus are generally believed to be contraindicated in pregnancy. Therefore, anticoagulation for CVT during pregnancy and early in the puerperium consists of LMWH in the majority of women.\textsuperscript{220}

In contrast to UFH, LMWH is not associated with teratogenicity or increased risk of fetal bleeding. The American College of Chest Physicians guidelines for antithrombotic address prevention and treatment of DVT and pulmonary embolus in pregnancy and the puerperium, recommending LMWH over UFH (recommendation 4.2.1).\textsuperscript{241} They recommend that treatment be continued throughout pregnancy and for at least 6 weeks postpartum (for a total minimum duration of treatment of 6 months). Although these recommendations are directed to systemic venous thrombosis, it is logical to apply them to CVT for several reasons. First, safety in terms of teratogenicity and fetal/newborn/maternal bleeding complications should be similar, and second, the recommendations are concordant with treatment of non–pregnancy-associated CVT. In a retrospective cohort study of 37 high-risk pregnancies, once-daily tinzaparin was studied for the prevention of initial or recurrent cerebral thrombosis. During treatment, no systemic venous thrombosis occurred; however, 1 parietal infarct and 1 postpartum CVT were documented.\textsuperscript{242}

As in nonpregnant women, fibrinolytic therapy is reserved for patients with deterioration despite systemic anticoagulation, and its use has been reported during pregnancy.\textsuperscript{243}

**Future Preganacies and Recurrence**

Patients with previous VTE are at increased risk of further venous thrombotic events compared with healthy individuals.\textsuperscript{244,245} Similarly, women with a history of VTE appear to have an increased risk of thrombotic events (ie, DVT, PE) in future pregnancies.\textsuperscript{57} Pregnancy, and in particular puerperium, are known risk factors for CVT. Six studies investigated the outcome and complications of pregnancy in women who had CVT,\textsuperscript{10,117,175,246–248} with a total of 855 women under observation, of whom 83 became pregnant (101 pregnancies) after their CVT.

These studies found that the risk of complications during future pregnancies was low. In fact, 88% of the pregnancies ended in a normal birth, the remainder being terminated prematurely by voluntary or spontaneous abortion. There was only 1 case of recurrent CVT and 2 cases of DVT; however, a high proportion of spontaneous abortion was noted.

On the basis of the available evidence, CVT is not a contraindication for future pregnancies. Considering the additional risk that pregnancy confers to women with a history of CVT, prophylaxis with LMWH during future pregnancies and the postpartum period can be beneficial.

**Recommendations**

1. For women with CVT during pregnancy, LMWH in full anticoagulant doses should be continued throughout pregnancy, and LMWH or vitamin K antagonist with a target INR of 2.0 to 3.0 should be continued for at least 6 weeks postpartum (for a total minimum duration of therapy of 6 months) (Class I; Level of Evidence C).
2. It is reasonable to advise women with a history of CVT that future pregnancy is not contraindicated. Further investigations regarding the underlying cause and a formal consultation with a hematologist and/or maternal fetal medicine specialist are reasonable.\textsuperscript{10,117,175,246–248} (Class IIa; Level of Evidence B).
3. It is reasonable to treat acute CVT during pregnancy with full-dose LMWH rather than UFH (Class IIa; Level of Evidence C).
4. For women with a history of CVT, prophylaxis with LMWH during future pregnancies and the postpartum period is probably recommended (Class IIa; Level of Evidence C).

**CVT in the Pediatric Population**

The incidence of pediatric CVT is 0.67 per 100,000 children per year.\textsuperscript{91} When neonates are excluded, the reported incidence is 0.34 per 100,000 children per year.\textsuperscript{249} Neonates present with seizures or lethargy, whereas older infants and children (similar to adults) usually present with seizures, altered levels of consciousness, increasing headache with papilledema, isolated intracranial hypertension, or focal neurological deficits.

**Risk Factors**

Risk factors for pediatric CVT are age related. Neonates constitute 43% of pediatric patients with CVT.\textsuperscript{91} There are several likely reasons for their increased risk. First, considerable mechanical forces are exerted on the infant’s head during birth that result in molding of the skull bones along the suture lines. This results in mechanical distortion of and damage to the underlying dural venous sinuses and thrombosis. The neonate also has an increased thrombotic tendency.\textsuperscript{250} First, there is a transplacental transfer of circulating maternal antiphospholipids to the fetus, which can persist into the newborn.
period.251 Second, neonates have reduced levels of circulating anticoagulant proteins, including proteins C and S and antithrombin, and higher hematocrit relative to adults. Furthermore, hemoconcentration occurs with the normal fluid loss and relative dehydration of the neonate during the first week of postnatal life. Multiple risk factors are present in more than half of neonates with CVT.252 Additional complications of gestation and labor and delivery increase the risk of CVT. Maternal preeclampsia/eclampsia is a reported risk factor for neonatal CVT.253 Neonatal diseases including head and neck infections, meningitis, dehydration secondary to feeding difficulties or gastroenteritis, and congenital heart disease also cause CVT.91

A recent meta-analysis of observational studies estimated the impact of thrombophilia on the incident risk of arterial ischemic stroke and CVT. The reported magnitude of association was as follows: Antithrombin deficiency, OR 7.1 (95% CI 2.4 to 22.4); protein C deficiency, OR 8.8 (95% CI 4.5 to 17.0); protein S deficiency, OR 3.2 (95% CI 1.2 to 8.4); factor V G1691A, OR 3.3 (95% CI 2.6 to 4.1); factor II G20210A, OR 2.4 (95% CI 1.7 to 3.5); methylene tetrahydrofolate reductase C677T (arterial ischemic stroke), OR 1.58 (95% CI 1.2 to 2.1); antiphospholipid antibodies (arterial ischemic stroke), OR 7.0 (95% CI 3.7 to 13.1); elevated lipoprotein(a), OR 6.3 (95% CI 4.5 to 8.7); and combined thrombophilias, OR 11.9 (95% CI 5.9 to 23.7). The authors also concluded that further studies are needed to determine the impact of thrombophilias on outcome and recurrence risk.250

In older children and adolescents, systemic lupus erythematosus, nephrotic syndrome, leukemia or lymphoma with L-asparaginase treatment, and trauma are reported causes of CVT.102,245 Iron deficiency anemia is an established risk factor for CVT.254 Prothrombotic disorders ranged from 33% to 66% of neonatal and pediatric CVTs and are frequently present when there are other risk factors for CVT.102

Radiographic Diagnosis

As in adults, a high index of suspicion for CVT and specific venous imaging are required make a diagnosis. This is especially true for neonates, who have nonspecific presentations that consist solely of seizures in the majority. The neuroimaging findings of CVT are similar in children and adults. In neonates, 2-dimensional TOF MRV has several pitfalls, including a focal area of absent flow where the occipital bone compresses the posterior superior sagittal sinus in the supine position. This is present in up to 14% of neonates without CVT.255,256 Therefore, CTV is frequently required to confirm the presence of CVT suggested by MRV. In neonates, transfontanellar Doppler ultrasound can suggest CVT by demonstrating an absence of flow from an occlusive thrombus; however, in partially occlusive thrombosis, this technique may not be as reliable.257

Parenchymal lesions are more likely hemorrhagic in neonates than in children.102 Intracranial hemorrhage in neonates frequently includes subependymal subdural hemorrhage. Term neonates with intraventricular hemorrhage have CVT as the cause in 34% of cases, frequently in association with thalamic hemorrhage.205

Outcome

CVT is associated with a significant frequency of adverse outcomes in neonates and older infants and children. In neonates, long-term follow-up is required to ascertain the outcomes, because deficits may only become evident with brain maturation over many years. Among neonates with CVT, neurological deficits are observed in 28% to 83%,102,245,253,259 Differences among studies may relate to treatment protocols: In 1 study of 39 neonates with CVT, neurological deficits were reported in 83%, and only 10% of neonates received anticoagulation. In contrast, in a Canadian Registry that included 160 children with CVT, venous infarction occurred in 42%, and 8% died. Additional outcomes included seizures in 20% and symptomatic recurrent thrombosis in 19 children (13%; CVT in 12 and extracerebral thrombosis in the remaining 7 children). Among the 63 neonates with CVT, neurological deficits were seen in only 34%, anticoagulation was used in 36%, and mortality among neonates was 7%.102 In CVT occurring beyond the newborn period, neurological deficits are reported in 17% to 46% of cases.43,175,185,260,261

One study showed that 18% of children with CVT had residual visual impairment on long-term follow-up. Other studies reported similar findings in children and adults with CVT.237,235,262

Management of CVT in the Pediatric Population

Consideration of endovascular treatment for neonates and children with CVT is driven by the high rates of adverse outcomes. No randomized clinical trials have been conducted in pediatric CVT. Therefore, treatment practices have been extrapolated primarily from adult studies.

In children, and increasingly in neonates, the mainstay of CVT treatment is anticoagulation, including LMWH, UFH, and warfarin. Individual and regional practices vary widely in pediatric CVT and particularly in neonatal CVT. Seizures were observed in >50% of the pediatric population with CVT.102 Given the higher frequency of epileptic seizures in children, continuous electroencephalography monitoring may be considered for unconscious or mechanically ventilated children.

Primary Evidence

Despite the absence of randomized trials, increasing evidence from case series and large observational studies supports the efficacy of anticoagulation in children or neonates with CVTconst.72,179,201,236,263 In the Canadian Pediatric Ischemic Stroke Registry, 85 of 160 children with CVT at 16 Canadian children’s hospitals received anticoagulation (25 neonates and 60 non-neonates). There were no fatal or severe complications reported; however, follow-up was not systematic.102

In a European multicenter study among 396 pediatric patients (75 neonates) with CVT, 250 (63%) received acute anticoagulation. Twenty-two (6%) had recurrent VTE (13 cerebral; 3%) after a median of 6 months of follow-up. In the multivariable survival analysis, nonadministration of an anticoagulant before relapse (HR 11.2, 95% CI 3.4 to 37.0; P=0.0001), persistent occlusion on repeat venous imaging (HR 4.1, 95% CI 1.1 to 14.8; P=0.032), and heterozygosity for the prothrombin G20210A mutation (HR 4.3, 95% CI 1.1 to 16.2; P=0.034) were independently associated with recurrent VTE. Of note, there was no significant difference in recurrence based on medical conditions such as cancers (acute lymphoblastic leukemia, lymphoma, or brain tumor), type 1 diabetes mellitus, nephrotic syndrome, infectious diseases, or heparin-induced thrombocytopenia. The number
of CVT cases needed to screen to detect at least 1 prothrombin G20210A heterozygote was 16. The number needed to treat for 1 year with anticoagulation to prevent 1 recurrent VTE was 32 for the entire group. The number needed to treat was 3 for those with prothrombin G20210A who were older than 2 years of age at diagnosis of CVT.245

A recently published case series from the Netherlands studied anticoagulation use in neonates with CVT, intraventricular hemorrhage, or thalamic hemorrhage.201 Among the 10 neonates, 1 infant died before therapy could be initiated, and 2 were born before typical use of LMWH therapy. The remaining 7 neonates received 3 months of LMWH (dalteparin) with a target anti-Xa level of 0.5 to 1.0 U/mL. There were no increased or new hemorrhages during treatment. Another pediatric CVT study that included 42 children reported safety and improved outcomes with anticoagulation even in the presence of ICH.187

Finally, in a prospective single-center study of protocol-based anticoagulation therapy among 162 pediatric patients, approximately half received anticoagulation at diagnosis, including 35% of neonates and 71% of children. Hemorrhagic complications were rare (6%); all were nonfatal and were associated with a favorable clinical outcome in the majority. Propagation of CVT thrombus was observed in more than one quarter of neonates and more than one third of children not treated with anticoagulation.264 Further studies on optimal dosing of anticoagulation with stratification by cerebral hemorrhage at the time of the diagnosis are in the planning stage through the International Pediatric Stroke Study.265,266

Published Pediatric Stroke Guidelines

In the past 5 years, 3 sets of guidelines addressing treatment of pediatric CVT were published.367–369 All 3 guidelines recommended use of anticoagulation with LMWH, UFH, and/or warfarin for 3 to 6 months in children beyond the newborn period, even in the presence of intracranial hemorrhage.

By contrast, recommendations regarding anticoagulation for neonatal CVT have been discordant. Of the 3 published guidelines, 1 did not address neonatal CVT.260 1 recommended acute anticoagulation,260 and the other recommended no acute anticoagulation.261 Specifically, the American College of Chest Physicians recommended initial anticoagulation except in the presence of significant hemorrhage, in which case monitoring for propagation was suggested, with initiation of anticoagulation if propagation should occur. Anticoagulation was recommended for a minimum of 6 weeks and no longer than 3 months. It was suggested that a venous imaging study be performed at 6 weeks, and if full recanalization is seen, anticoagulation can be discontinued. The AHA guidelines make no recommendations regarding initial anticoagulation. Anticoagulation is considered reasonable in neonates with thrombus propagation or thrombophilia (which cannot always be diagnosed during acute illness). The reluctance to treat neonatal CVT with anticoagulation was based on several concerns. First, there was an absence of safety data for neonates, and second, there was concern regarding increased susceptibility of the neonatal brain to hemorrhage. Before the current outcome literature, another reason not to treat neonates was the erroneous perception that neonates have a good outcome from CVT and treatment is therefore unnecessary. As noted in previous sections, these assumptions have been refuted in part by studies published in the past few years. However, in the absence of clinical trial evidence, practice variability is understandable.251

Recommendations

1. Supportive measures for children with CVT should include appropriate hydration, control of epileptic seizures, and treatment of elevated intracranial pressure (Class I; Level of Evidence C).

2. Given the potential for visual loss owing to severe or long-standing increased intracranial pressure in children with CVT, periodic assessments of the visual fields and visual acuity should be performed, and appropriate measures to control elevated intracranial pressure and its complications should be instituted (Class I; Level of Evidence C).

3. In all pediatric patients, if initial anticoagulation treatment is withheld, repeat neuroimaging including venous imaging in the first week after diagnosis is recommended to monitor for propagation of the initial thrombus or new infarcts or hemorrhage (Class I; Level of Evidence C).

4. In children with acute CVT diagnosed beyond the first 28 days of life, it is reasonable to treat with full-dose LMWH even in the presence of intracranial hemorrhage (Class IIa; Level of Evidence C).

5. In children with acute CVT diagnosed beyond the first 28 days of life, it is reasonable to continue LMWH or oral vitamin K antagonists for 3 to 6 months (Class IIa; Level of Evidence C).

6. In all pediatric patients with acute CVT, if initial anticoagulation is started, it is reasonable to perform a head CT or MRI scan in the initial week after treatment to monitor for additional hemorrhage (Class IIa; Level of Evidence C).

7. Children with CVT may benefit from thrombophilia testing to identify underlying coagulation defects, some of which could affect the risk of subsequent rethromboses and influence therapeutic decisions250–252 (Class IIb; Level of Evidence B).

8. Children with CVT may benefit from investigation for underlying infections with blood cultures and sinus radiographs272,273,274 (Class IIb; Level of Evidence B).

9. In neonates with acute CVT, treatment with LMWH or UFH may be considered272,179,201,236,263 (Class IIb; Level of Evidence B).

10. Given the frequency of epileptic seizures in children with an acute CVT, continuous electroencephalography monitoring may be considered for individuals who are unconscious or mechanically ventilated (Class IIb; Level of Evidence C).

11. In neonates with acute CVT, continuation of LMWH for 6 weeks to 3 months may be considered (Class IIb; Level of Evidence C).

12. The usefulness and safety of endovascular intervention are uncertain in pediatric patients, and its use may only be considered in carefully selected patients with progressive neurological deterioration despite intensive and therapeutic levels of anticoagulant treatment (Class IIb; Level of Evidence C).

Clinical Outcomes: Prognosis

There are several studies and reviews on the outcome and prognosis of CVT.181,256,257 The majority of such studies are retrospective (totally or in part).14,63,66,90,136,175,179,190,194,233,270–274 Of the few
prospective studies, some did not analyze prognostic factors, or performed only a bivariate analysis of such predictors or analyzed specific subgroups of patients. There are only 5 cohort studies that analyzed prognostic factors for the short-term and the long-term outcome of CVT patients (Table 6).

### Neurological Worsening After Diagnosis

Neurological worsening may occur in 25% of patients, even several days after diagnosis. Neurological worsening can feature depressed consciousness, mental status disturbance, new seizure, worsening of or a new focal deficit, increase in headache intensity, or visual loss. Approximately one third of patients with neurological deterioration will have new parenchymal lesions when neuroimaging is repeated. Patients with depressed consciousness on admission are more likely to deteriorate.

### Early Death

Approximately 3% to 15% of patients die in the acute phase of the disorder. Most early deaths are a consequence of CVT. In the ISCVT, 21 (3.4%) of 624 patients died within 30 days from symptom onset; however, in a recent retrospective/prospective multicenter study from the United States, higher mortality (13%) was reported. Case series from developing countries also have higher figures for early deaths, with 6% reported in a large Pakistan-Middle East registry and 15% in a single-center case series from Iran.

In the largest study, the ISCVT, risk factors for 30-day mortality were depressed consciousness, altered mental status, and thrombosis of the deep venous system, right hemispheric hemorrhage, and posterior fossa lesions. The main cause of acute death with CVT is transtentorial herniation secondary to a large hemorrhagic lesion, followed by herniation due to multiple lesions or to diffuse brain edema. Status epilepticus, medical complications, and PE are among other causes of early death.

### Late Deaths

Deaths after the acute phase are predominantly related to the underlying conditions, in particular malignancies.

### Long-Term Outcome

In the ISCVT study, complete recovery at last follow-up (median 16 months) was observed in 79% of the patients; however, there was an 8.3% overall death rate and a 5.1% dependency rate (mRS score ≥3) at the end of follow-up (12.6% if we consider patients who survived with an mRS score ≥2). In a systematic review that included both retrospective and prospective studies, overall mortality was 9.4%, and the proportion of dependency (mRS score ≥3 or Glasgow Outcome Scale score ≥3) was 9.7%. Two retrospective/prospective studies were reported after this review. In the Pakistan-Middle East registry, the dependency rate (mRS score ≥3) was higher (11%), whereas in the US multicenter registry, 28% of patients were dependent at 12 months. Of note, some studies include patients transferred to tertiary care centers, whose strokes are usually more severe, with the potential for a referral bias. Among the 7 cohort studies (including the prospective part of retrospective/prospective studies in which information can be analyzed separately), the overall death and dependency rate was 15% (95% CI 13% to 18%).

### Neuropsychological and Neuropsychiatric Sequelae

There is little information on the long-term neuropsychological and neuropsychiatric outcome in CVT survivors. Despite the apparent general good recovery in most patients with CVT, approximately one half of survivors feel depressed or anxious, and minor cognitive or language deficits may preclude them from resuming their previous jobs.

Abulia, executive deficits, and amnesia may result from thrombosis of the deep venous system, with bilateral pantoilamic infarcts. Memory deficits, behavioral problems, or executive deficits may persist. Aphasia, in general of the fluent type, results from left lateral sinus thrombosis with temporal infarct or hemorrhage. Recovery is usually favorable, but minor troubles in spontaneous speech and naming might persist.

### Risk Factors for Long-Term Poor Outcomes

Risk factors for poor long-term prognosis in the ISCVT cohort were central nervous system infection, any malignancy, thrombosis of the deep venous system, intracranial hemorrhage on admission CT/MRI, Glasgow Coma Scale score <9, mental status disturbance, age >37 years, and male sex. Brain herniation leading to early death was more frequent in young patients, whereas late deaths due to malignancies and less favorable functional outcome were more frequent in elderly patients. Table 6 summarizes demographic, imaging, and clinical variables associated with poor prognosis. A Glasgow Coma Scale score of 14 to 15 on admission, a complete or partial intracranial hypertension syndrome (including isolated headache) as the only

---

**Table 6. Variables Associated With Poor Prognosis in Cohort Studies**

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Clinical</th>
<th>Neuroimaging</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;37 y</td>
<td>Coma</td>
<td>Intracerebral hemorrhage</td>
<td>Cancer</td>
</tr>
<tr>
<td>Male sex</td>
<td>Neurological deficit and severity (NIHSS)</td>
<td>Involvement of the straight sinus</td>
<td>CNS infection</td>
</tr>
<tr>
<td></td>
<td>Encephalopathy</td>
<td>Thrombosis of the deep venous system</td>
<td>Underlying coagulopathy hereditary thrombophilia</td>
</tr>
<tr>
<td></td>
<td>Decreased level of consciousness</td>
<td>Venous infarction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemiparesis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seizure</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NIHSS indicates National Institutes of Health Stroke Scale; CNS, central nervous system.
manifestation of CVT, and absence of aphasia were variables associated with a favorable outcome.\textsuperscript{117,177}

**Risk Score Models**

Despite the overall favorable outcome, \(~\approx 15\)% of CVT patients die or become dependent after CVT.\textsuperscript{10,283} Risk stratification scores might improve the ability to inform CVT patients of their individual prognosis and to select those who might benefit most from intensive monitoring and invasive treatments. One study created and validated a risk score model to predict a poor outcome. The risk score model range from 0 (lowest risk) to 9 (highest risk), and a cutoff of \(\geq 3\) points indicated a higher risk of death or dependency at 6 months. Two points were assigned for the presence of malignancy, coma, or thrombosis of the deep venous system and 1 point for male sex, presence of decreased level of consciousness, or ICH. The predictive ability (c-statistics) in the derivation cohort was 85.4\%, 84.4\%, and 90.1\% in the validation samples. Sensitivity and specificity in the combined samples were 96.1\% and 13.6\%, respectively.

Another study\textsuperscript{284} incorporated age >37 years and central nervous system infection into this model and assigned a weighted index to each variable. The study validated the score in 90 CVT patients and obtained an area under the receiver operator characteristic curve of 0.81 to predict mortality. With a cutoff score of \(\geq 14\), sensitivity was 88\% and specificity was 70\%. The predictive value for good outcome, defined as an mRS score \(<2\), was 95\%, and for bad outcome, it was 39\%.

**Recanalization**

In a systematic review of 5 small studies,\textsuperscript{28} recanalization rates of CVT at 3 months and 1 year of follow-up were 84\% and 85\%, respectively. The highest rates of recanalization are observed in deep cerebral veins and cavernous sinus thrombosis and the lowest rates in lateral sinus thrombosis.\textsuperscript{193} In adults, recanalization of the occluded sinus is not related to outcome after CVT.\textsuperscript{41,194}

**Summary/Future Considerations**

This statement provides an extensive and critical review of the literature related to the diagnosis and management of CVT and its most common complications.

A dural sinus or cerebral venous thrombosis (CVT) accounts for 0.5\% to 1\% of all strokes, mostly affecting young individuals and women of childbearing age.\textsuperscript{1,4,6} Patients with CVT commonly present with headache, although some develop a focal neurological deficit, decreased level of consciousness, seizures, or intracranial hypertension without focal neurological signs.\textsuperscript{1,4,6} Uncommonly, an insidious onset may create a diagnostic challenge. A prothrombotic factor or a direct cause is identified in approximately two thirds of patients with sinus thrombosis. The diagnosis is usually made by venographic studies with CT (CTV) or MRI (MRV) to demonstrate obstruction of the venous sinuses or cerebral veins by thrombus.\textsuperscript{70,96} Management of CVT includes treatment of the underlying condition; symptomatic treatment; the prevention or treatment of complications of increased intracranial pressure, ICH, or venous infarction; and typically, anticoagulation therapy (see algorithm in Figure 4).

Diagnostic and therapeutic techniques in stroke are in continuous evolution. Important advances have been made in the understanding of the pathophysiology of cerebral sinus thrombosis. Yet promising techniques (endovascular procedures, hemicraniectomy for the management of cerebral sinus thrombosis hypertension in the context of refractory intracranial hypertension in the context of mass effect or ICH, etc) need to be evaluated rigorously before they are widely adopted.

Despite substantial progress in the study of CVT in recent years, much of the literature remains descriptive. The CVT writing group made an effort to highlight areas that require further study (eg, larger randomized clinical trials to determine the benefit of therapeutic interventions) and provided suggestions that reflect the current standard practice. A randomized clinical trial aimed at comparing the benefit of anticoagulation therapy versus endovascular thrombolysis (TO-ACT Trial; Thrombolysis Or Anticoagulation for Cerebral Venous Thrombosis) is under way. The results of TO-ACT may contribute to improving the acute management of patients with CVT.

Management dilemmas in CVT can be complex. Healthcare providers managing these patients may require assistance from appropriate subspecialists given that there is no strong literature evidence to guide some of these challenging clinical decisions. The present statement is unlikely to end the debate about the management of CVT. Rather, the content of the present statement should be seen as a compilation of the best available evidence at the present time. Through a process of innovative research and systematic evaluation, diagnosis, management, and therapeutic alternatives will continue to evolve and consequently lead to better outcomes for patients with CVT.

**Search Strategy**

To address the diagnosis and management of CVT, we systematically searched in PubMed on the following terms: “cerebral vein thrombosis” OR “cerebral venous thrombosis” OR “sinus thrombosis.” Then, we refined our search by combining these with "epidemiology," "management," "diagnosis," "imaging," "MRI, "randomized trial," "prognosis," and “outcome.” These terms were searched with regard to adults, pregnant women, children, and neonates. Our last search was undertaken on July 7, 2010. No language restriction was placed on the searches. Because the intention was to guide readers on the management of CVT based on a comprehensive review of the literature, including sometimes specific and/or uncommon clinical situations, no formal restrictions or further quality assessment was undertaken.

For the treatment section, we reviewed systematic reviews and guideline statements of the Cochrane Collaboration,\textsuperscript{161} the AHA/American Stroke Association,\textsuperscript{285} the American College of Chest Physicians,\textsuperscript{162,163} and the European Federation of Neurological Sciences,\textsuperscript{164} in addition to literature reviews and treatment guidelines. For specific therapeutic alternatives, we combined (“cerebral vein thrombosis” OR “cerebral venous thrombosis” OR “sinus thrombosis”) with “hemicraniectomy,” “thrombolysis,” or “endovascular.” Secondary sources of data included reference lists of articles reviewed and cohort studies that related treatment to outcomes.

Authors assigned to each section were responsible for checking for additional references for their specific topic.
For the section on “CVT in the Pediatric Population,” we also reviewed the guideline statements of the AHA267 and the “American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)” on antithrombotic therapy in neonates and children.269 For the section on “CVT During Pregnancy,” we also reviewed the guideline statements from the American College of Chest Physicians.241a

Disclosures

Writing Group Disclosures

<table>
<thead>
<tr>
<th>Writing Group Member</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/ Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gustavo Saposnik</td>
<td>University of Toronto</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Fernando Barinagarrenergieria</td>
<td>Universidad del Valle de Mexico</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert D. Brown, Jr</td>
<td>Mayo Clinic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Cheryl D. Bushnell</td>
<td>Wake Forest University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Brett Cucchiara</td>
<td>University of Pennsylvania</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mary Cushman</td>
<td>University of Vermont</td>
<td>NIH†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Gabrielle deVeber</td>
<td>Hospital for Sick Children, Toronto</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jose M. Ferro</td>
<td>University of Lisbon, Portugal</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Fong Y. Tsai</td>
<td>University of California at Irvine</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “Significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “Modest” if it is less than “Significant” under the preceding definition.

*Modest.
†Significant.

Reviewer Disclosures

<table>
<thead>
<tr>
<th>Reviewer</th>
<th>Employment</th>
<th>Research Grant</th>
<th>Other Research Support</th>
<th>Speakers’ Bureau/ Honoraria</th>
<th>Expert Witness</th>
<th>Ownership Interest</th>
<th>Consultant/Advisory Board</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth A. Bauer</td>
<td>Beth Israel Deaconess Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Guilherme Dabus</td>
<td>Baptist Cardiac and Vascular Institute</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Adnan I. Qureshi</td>
<td>University of Minnesota</td>
<td>Protein Design Labs*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Brian Silver</td>
<td>Henry Ford Medical Center</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Greg Zipfel</td>
<td>Washington University</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “Significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “Modest” if it is less than “Significant” under the preceding definition.

*Modest.
References


286. Reference deleted in proof.
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Gustavo Saposnik, Fernando Barinagarrementeria, Robert D. Brown, Jr, Cheryl D. Bushnell, Brett Cucchiara, Mary Cushman, Gabrielle deVeber, Jose M. Ferro and Fong Y. Tsai

Stroke. published online February 3, 2011;
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2011/02/03/STR.0b013e31820a8364

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2012/03/12/STR.0b013e31820a8364.DC1
http://stroke.ahajournals.org/content/suppl/2012/02/28/STR.0b013e31820a8364.DC2
http://stroke.ahajournals.org/content/suppl/2012/02/03/STR.0b013e31820a8364.DC3

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
Diagnóstico y tratamiento de la trombosis venosa cerebral. Comunicado de la American Heart Association/American Stroke Association para los profesionales de la salud

El Stroke Council on Epidemiology and Prevention de la American Heart Association aborda por primera vez la realización de unas guías de práctica clínica para el diagnóstico y tratamiento de la trombosis venosa cerebral. Aunque se trata de un tipo poco frecuente de ictus (representando sólo el 0,5-1% del total), presenta unas características diferenciales importantes al afectar predominantemente a pacientes jóvenes y ser múltiples los factores de riesgo asociados a esta enfermedad. Se establecen recomendaciones basadas en la evidencia que abordan tanto los métodos diagnósticos de laboratorio y neuroimagen; las diferentes opciones terapéuticas, desde el tratamiento anticoagulante (con el uso de heparina en fase aguda) hasta nuevas alternativas en desarrollo como el tratamiento endovascular (trombectomía/trombolisis); y el manejo de las posibles complicaciones asociadas a la trombosis venosa cerebral, tanto las precoces (hidrocefalia, hipertensión intracraneal, crisis) como las tardías (recurrencias de trombosis venosa cerebral, cefalea, crisis, pérdida visual, fistula arteriovenosa). Por último, se analiza la evidencia disponible sobre el manejo de esta enfermedad en dos grupos poblacionales especialmente susceptibles: mujeres gestantes y niños. 

AHA/ASA Scientific Statement

脳静脈洞血栓症の診断と管理
Diagnosis and Management of Cerebral Venous Thrombosis

The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.


脳静脈洞血栓症の疫学と危険因子
CVT は若年者に発症し、発症率は 5 人 /100,000/ 年と推定され、全脳卒中の 0.5 ~ 1.0%を占める。CVT には遺伝性または後天性の凝固亢進状態が存在する。遺伝性因子（血栓性素因）には抗凝固蛋白欠乏症（アンチトロンビン III、プロテイン C、プロテイン S）、第 5 凝固因子 Leiden 変異、プロトロンビン G20210A 変異が含まれている。高ホモステイニン血症と CVT の関連についてはまだ結論が得られていない。後天性因子には手術、外傷、妊娠、産褥、抗リン脂質症候群、悪性腫瘍、ホルモン療法などが、静脈変異 G20210A 変異が第 5 凝固因子子 Leiden 変異の保有者ではOC によりリスクが極めて高くなる。幼児は感染症が CVT の原因であることが多い。

脳静脈洞血栓症の臨床診断
CVT の臨床所見は頭著に血管地を脳実質の虚血 / 出血によるが、多くの場合両者が併存する。頭痛は 90% の症例にみられ、頭痛に乳頭浮腫が複発（外転神経麻痺）があれば CVT を考慮すべきである。局所徴候としては片麻痺、失語が多い。局所または全身性けいれん発作は約 40% にみられ、脳深部静脈系では視床の損傷により、局所症状なしに意識障害を発症する可能性がある。管理的 CVT を疑った場合、血液検査ではプロトロンビン時間（PT-INR）と活性化部分トロンボプラスチン時間（aPTT）を測定し、凝固亢進状態を起こし得る疾患と薬物を検索する必要がある（表 1: 推奨クラス I、エビデンス・レベル C）。脳骨液検査は脳膜炎の疑いがあるとき以外ではあまり有用でないが、脳液圧の亢進は 80% にみられる。D-マイトレインは静脈血栓症（DVT）や肺塞栓（PE）の除外には有用だが、D-マイトレイン値が正常である場合、CVT の可能性は低いかかもしれないが（表 1: 推奨クラス IIb、エビデンス・レベル B）除外はできない。

脳静脈洞血栓症の画像診断（表 2）
頭部 CT は頭痛やけいれん発作がある症例の検査の第一步であるが、造影なしでは診断感度は低い。上矢状静脈洞後方部に血栓が形成されると高シグナル（high density: HD）三角形がみられることがある（デルタサイアン）。造影 CT では静脈静脈洞内血栓が造影欠損として認められ、静脈洞に沿った硬膜の造影が増強される。MRI では静脈洞内の血栓が認められるため、血栓形成後の時期により性状が異なる。CT 静脈造影（CTV）は迅速かつ確実に CVT を描出するが、頭部をより見にくい

---

Stroke 2011; 42: 1158-1192
脳静脈洞血栓症の管理と治療（表3〜5）

1）急性期の管理と内科的治療（表3）：脳卒中集中治療室（SU）での徹底した管理により合併症が予防できると考えられる。急性期の抗凝固療法につき議論が続く理由は、CVTの診断がつく頃には出血性梗塞か脳内出血（ICH）が起こっていることが多く、安全性が問題のためである。無作為比較試験としては2件が造影画像で確認されたCVTで施行されているが、そのうち1件は(Lancet 1991; 338: 597-600, Lancet 1991; 338: 958 [correction])であった。

20例で未分画ヘパリン（UFH）と偽薬のポーラス（3000U）の持続点滴により活性化部分トロンボプラスチン時間（aPTT）を治療前の2倍に延長させた。もう1件では(Stroke 1999; 30: 484-488)、59例において低分子ヘパリン（LMWH）nadroparin（180 anti-Factor Xa units/kg/day 分2皮下注）と偽薬が3週間投与され、その後経口抗凝固薬としてnadroparinを用いた試験で29例中6例が死亡したが、死亡は新規の出血やICHの増加によるものではなかった。大規模観察研究であるISCVT研究（Stroke 2004; 35: 664-670）では、624例中64例が新型抗凝固療法を受けたが、16カ月の死亡率は8.3%で、79%に完治（mRS 0〜1）がみられ、10.4%に軽〜中等度の障害（mRS 2〜3）、2.2%に重度の障害が残った。これらのデータは、治療前のICHの有無にかかわらず、CVTにおける抗凝固療法を支持している。CVTでは、aPTTで調整した未分画ヘパリンと低分子ヘパリンの効果を示すデータはない。凝溶療法（fibrinolysis）は抗凝固療法によっても臨床的悪化や頭蓋内圧亢進がみられる場合に考慮される。ステロイド薬は血管原性浮腫を軽減させる役目があるが、凝固亢進状態を増悪させる可能性がある。ISCVT研究においては、ステロイドの使用で死亡率と脳幹障害率が高くなる傾向（OR=17.7）が示された。感染症とCVTが疑われる症例の治療には抗生物質による局所または全身性感染症の治療と感染源のドレナージを考えすべきである。

2）急性期の血管内・脳外科治療（表3）：カテーテル血栓溶解術では血栓の機械的な破壊と局所での線溶療法を行う。機械的血栓摘出術・血栓溶解術にはバルーン血栓摘出術と脳動脈血栓症に用いられるMerciリトリバーやPenumbraがあり、局所線溶療法で効果を認められない静脈血栓を除去する。これらの血管内治療の有用性はまだ確立されていないが、もし抗凝固療法中の臨床的悪化、静脈性梗塞やICHによる圧排効果や頭蓋内圧亢進に対して標準的治療が効果がない場合に考慮しても良いだろう。脳外科的に、脳動脈血栓症による著明な頭蓋内圧亢進には頭蓋減圧術が、重度の神経障害を伴う大規模脳腫瘍では腫瘍除去術が必要となる場合がある。

3）早期合併症の管理と予防（表4）：けいれん発作は成人の37%，幼少児の48%，新生児の71%に発症するとされる。発作のない患者への予防的投与は有害な場合はある。頭蓋内圧亢進については、膜脳管からの脳脊髄液の吸収不全による交通性水頭症が6.6%にみられる。閉塞性水頭症は稀であるが、脳室内出血により起こる。治療としては脳室吻合術または、持続する場合には、脳室・腹腔シャント術が必要である。CVT患者の40%が頭蓋内圧亢進による症状で発症するとされる。最適な治療については、無作為試験がなされていない。抗凝固療法や合併症によっては血栓溶解療法による静脈血栓の除去、腰椎穿刺による脳内圧の減圧、アセタゾラミドなどがある。これらの薬物療法は効果がなく、虚血性脳組織に有害である。これにより改善がみられなければ、腰椎穿刺シャントを考慮する必要がある。脳神経外科の介入が必要な場合、視野と乳頭浮腫のモニターが非常に重要であり、稀には視神経開窓術が必要となる。

4）長期の管理と再発予防（表5）：特定の血栓性素因や疾患では再発リスクが高いと考えられるが、抗凝固療法と再発のリスクについての無作為試験がないため、再発予防策はCVTとDVTに関する観察研究に基づいている。ISCVT研究では16カ月間にCVTの再発（2.2%）と他の血栓性イベント（4.3%）を合わせて6.5%にみられ、その41.5%は抗凝固療法を受けていたが詳細は不明である。血栓性素因（thrombophilia）には遺伝性と獲得性があり、獲得性の血栓性素因は再発のリスクに従って軽度と重度に層別される。プロトロンビンG20210A変異のホモ接合体、第5因子欠損Leiden変異のホモ接合体、およびプロテインC、プロテインS、アンチトロンビン欠乏症、複合血栓性素因異常および抗リン脂質抗体症候群は重度に
脳静脈血栓症の診断と管理

37

クラス I 検査や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。

クラス II 検査や治療法の有用性および有効性に関して相反するエビデンスまたは見解の相違が認められる。

クラス IIa 検査や治療法の有用性および有効性を支持するエビデンスまたは見解が多数を占める。

クラス IIb 有用性および有効性を支持するエビデンスや見解は十分ではない。

クラス III 検査や治療法が有用または有効でなく，場合によっては有害となり得ることを示すエビデンスまたは一般的合意がある。

治療の推奨

エビデンスレベル A
複数の無作為試験またはメタ解析により得られたデータがある。

エビデンスレベル B
1つの無作為試験または複数の非無作為試験より得られたデータがある。

エビデンスレベル C
専門家の合意した見解，症例研究，または標準治療法。

診断の推奨

エビデンスレベル A
参照基準を用いてマスクされた評価者により施行された複数の前向きコホート研究のデータがある。

エビデンスレベル B
1つのグループ Aの研究，または1つ以上の症例対照研究のデータ，あるいは参照基準を使ってマスクされていない評価者により施行された研究のデータがある。

エビデンスレベル C
専門家の合意した見解。

小児科領域の脳静脈洞血栓症（表７）

新生児はけいれん発作と傾眠で発症し，幼小児はけいれん発作，意識障害，乳頭浮腫を伴う頭痛，頭蓋内圧亢進などで発症する。危険因子については，新生児は出生時に頭蓋にストレスがかかり，抗凝固蛋白が少なく，母親の周産期合併症，子腫症候群，外傷などが危険因子と考えられる。

危険性血栓性素因以外に，新生児では頭頸部の感染症，膿腺炎，脱水，先天性心疾患などの危険因子とする。診断においては，乳頭浮腫が一過性の視力障害を起こすが，乳頭浮腫が長期間にわたり見られると，乳頭浮腫を含む視神経症を示すことがあり，眼科的精査が必要である。

脳静脈洞血栓症の診断と管理に伴う合併症の管理

CVT 後の頭痛は約 50%の患者にみられ，その多くは CVT と関係のない片頭痛や緊張性頭痛である。持続性または重複の頭痛がある場合には CVT の再発を除外するため適切な検査をすべきである（表１：推奨クラス I，エビデンスレベル C）。

妊娠中の脳静脈洞血栓症（表 6）

妊娠と産褥は凝固亢進状態をもたらす。CVT のリスクが最も高い時期は妊娠第 3 期から出産後までで，73%が産褥期に起こり，帝王切開もリスクを高める。ワルファリンを含むビタミン K 拮抗薬は胎児奇形と胎児・新生児出血を招くため，妊娠中と産褥期の抗凝固療法には，大半の症例で LMWH が用いられる。LMWH には催奇形がなく，胎児出血のリスクも高くなる。抗凝固療法は妊娠期間中と出産後 4 週間まで（全体で最低 6 月）継続することが推奨される。

静脈性血栓塞栓症の既往がある女性の妊娠の転帰は，将来の妊娠中の合併症リスクを低く，88%が正常分娩に至り，その他の妊娠期間は自然流産により中止された。CVT の既往をもつ女性の妊娠中のリスクを考慮すると，将来の妊娠期間中と出産後の LMWH の維持は有益である。

文責：柳原 武彦

表 1 AHA ガイドラインにおける各推奨のクラスとエビデンスレベルの定義

<table>
<thead>
<tr>
<th>クラス</th>
<th>エビデンスレベル</th>
<th>査定や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。</th>
</tr>
</thead>
<tbody>
<tr>
<td>クラス I</td>
<td>エビデンスレベル A</td>
<td>検査や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。</td>
</tr>
<tr>
<td>クラス II</td>
<td>エビデンスレベル B</td>
<td>検査や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。</td>
</tr>
<tr>
<td>クラス III</td>
<td>エビデンスレベル C</td>
<td>検査や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。</td>
</tr>
<tr>
<td>クラス IIa</td>
<td>エビデンスレベル A</td>
<td>検査や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。</td>
</tr>
<tr>
<td>クラス IIb</td>
<td>エビデンスレベル B</td>
<td>検査や治療法の有用性および有効性を示すエビデンスまたは一般的合意がある。</td>
</tr>
</tbody>
</table>

診断の推奨

エビデンスレベル A
参照基準を用いてマスクされた評価者により施行された複数の前向きコホート研究のデータがある。

エビデンスレベル B
1つのグレード Aの研究，または1つ以上の症例对照研究のデータ，あるいは参照基準を使ってマスクされていない評価者により施行された研究のデータがある。

エビデンスレベル C
専門家の合意した見解。
表2 脳静脈洞血栓症の画像診断

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスの分類とレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 単純CTまたはMRIは、CVTが疑われる患者の初期評価に有用であるが、陰性所見が得られたからといってCVTの可能性が除外されるわけではない。単純CTまたはMRIが陰性のCVT疑い例や、単純CTまたはMRIでCVTが示唆された患者のCVTの確定を明らかにするには、静脈造影（CTVまたはMRV）を実施すべきである。</td>
<td>クラスI, エビデンスレベルC</td>
</tr>
<tr>
<td>2. 内科的治療を行っても症状が持続しないあるいは進行するCVT患者や、血栓の伸展を示唆する症状が認められる場合には、CTVまたはMRVにより早期の再検査を実施することが推奨される。</td>
<td>クラスI, エビデンスレベルC</td>
</tr>
<tr>
<td>3. CVTの既往があり、CVTを否定する症状が再発した場合には、CTVまたはMRVによる再検査を実施することが推奨される。</td>
<td>クラスI, エビデンスレベルC</td>
</tr>
<tr>
<td>4. グラディエントエコー法または磁化率強調画像と他のMRI法との併用は、CVTの診断精度の向上に有用な可能性がある。</td>
<td>クラスIIa, エビデンスレベルB</td>
</tr>
<tr>
<td>5. CTVまたはMRVで明らかな結論が得られなかったものの、臨床的にCVTの疑いが高い厚生患者には、カテール脳血管造影が有用な可能性がある。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>6. 病状の安定した患者には、診断から3〜6カ月後にCTVまたはMRVによる再検査を実施し、閉塞した皮質静脈/静脈洞の再開通の評価を行うことが妥当である。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
</tbody>
</table>

CTV：CT静脈造影、CVT：脳静脈洞血栓症、MRV：磁気共鳴静脈造影。

表3 脳静脈洞血栓症急性期の管理と治療

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスの分類とレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 急性期CVT患者の管理と治療はStroke Unitで行うのが妥当である。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>2. 膨脹効果があるCVT患者には、適量の抗凝固療法を投与し、適宜CTVと関連した感染源の外科的ドレナージにより、貯留した血腫を除去すべきである。</td>
<td>クラスI, エビデンスレベルC</td>
</tr>
<tr>
<td>3. ICHの有無にかかわらず、CVT患者には、用量を調整したUFHまたは体重に基づいた十分な抗凝固療法を行う。その後ビタミンK拮抗薬を投与するのが妥当である。</td>
<td>クラスIIa, エビデンスレベルB</td>
</tr>
<tr>
<td>4. 積極的な抗凝固療法を行っても病状が悪化する場合は、血管内治療を検討してもよい。</td>
<td>クラスIIb, エビデンスレベルC</td>
</tr>
</tbody>
</table>

CTV：CT静脈造影、ICH：脳内出血、LMWH：低分子ヘパリン、Stroke Unit：脳卒中集中治療室、UFH：未分画ヘパリン。

表4 脳静脈洞血栓症の早期合併症の管理と予防

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスの分類とレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CVT患者の合併症の治療や予防はStroke Unitで行うのが妥当である。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>2. 発症のいっけん発作を生じた脳実質変化を伴うCVT患者には、さらなるいっけん発作を予防するために、期間を限定して抗てんかん薬を早期に開始することが推奨される。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>3. 発症のいっけん発作を生じた脳実質変化を伴わないCVT患者にも、さらなるいっけん発作を予防するために、期間を限定して抗てんかん薬を早期に開始する適応がある。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>4. いっけん発作がみられない場合、CVT患者に対する抗てんかん薬の日常的な使用は推奨されない。</td>
<td>クラスIII, エビデンスレベルC</td>
</tr>
<tr>
<td>5. 脳内圧亢進を示すCVT患者については、頭蓋内圧の進行の有無を監視することが推奨される。頭蓋内圧の進行が認められる場合には、頭蓋内圧亢進に対する早期的治療が必要である。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>6. 脳内圧亢進を示すCVT患者については、アセタゾラミド投与を開始するのが適切である。視野変化の進行が認められる場合には、他の治療法（頭蓋骨萎縮、頭蓋内圧緩解術、シャント術）が有効な場合もある。</td>
<td>クラスIIa, エビデンスレベルC</td>
</tr>
<tr>
<td>7. 強い抗血栓状態による脳血管の萎縮が頭蓋内出血を引き起こす可能性がある場合には、頭蓋内圧亢進を検討してもよい。</td>
<td>クラスIII, エビデンスレベルB</td>
</tr>
<tr>
<td>8. 前述の全ての治療に必要な場合を除き、CT/MRIで脳実質変化が認められても、CVT患者へのステロイド薬投与は推奨されない。</td>
<td>クラスIII, エビデンスレベルB</td>
</tr>
</tbody>
</table>

CTV：脳静脈洞血栓症、Stroke Unit：脳卒中集中治療室。
脳静脈洞血栓症の診断と管理

表5 脳静脈洞血栓症の長期管理および再発予防

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスの分類とレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CVT患者的管理には、プロテインC、プロテインS、アンチトロンビン欠損症、抗リン脂質抗体症候群、プロトロンビンG20210A変異を含む、凝固亢進状態の検査が有益だろう。一般的には、抗凝固療法終了から2〜4週後に、プロテインC、プロテインS、アンチトロンビン欠損症の検査を実施する。急性期の検査でワルファリン投与例の検査はほとんど有用性がない。</td>
<td>クラスIIa、エビデンスレベルB</td>
</tr>
<tr>
<td>2. 脳梗塞（一過性の脳梗塞を伴う）のCVT患者には、INR目標値を2.0〜3.0として、ビタミンK拮抗薬の3〜6カ月継続を考慮してよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>3. 脳梗塞のCVT患者には、INR目標値を2.0〜3.0として、ビタミンK拮抗薬の6〜12カ月継続を考慮してよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>4. CVT再発例、CVT後のVTE症例、または重度の血栓症が認められるCVT初発例（すなわちプロトロンビンG20210A変異を含む、第V因子Leiden変異を含む）。プロトロンビンC・プロテインS・アンチトロンビン欠損症、複合的な血栓性因異常、抗リン脂質抗体症候群）には、INR目標値を2.0〜3.0として、無期限の抗凝固療法を検討してもよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>5. 血栓症に詳しい医師に相談し、凝固亢進状態の検査やCVT患者のケアについて意見を求めてもよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
</tbody>
</table>

CVT:脳静脈洞血栓症、INR:国際標準化比、VTE:静脈血栓塞栓症。

表6 妊娠中の脳静脈洞血栓症

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスの分類とレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CVTのある妊婦には、妊娠期間中、充分な抗凝固効果を得られる量のLMWHを継続すべきであり、出産後はLMWHまたはINR目標値を2.0〜3.0としてビタミンK拮抗薬を最低限6週間継続投与すべきである（総治療期間は最低限6ヶ月とする）。</td>
<td>クラスI、エビデンスレベルC</td>
</tr>
<tr>
<td>2. 妊娠中の急性CVTには、UFHよりもLMWHの投与が妥当である。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>3. CVTの既往のある女性には、将来の妊娠は禁忌ではないことを助言することが適当である。根拠にある病状について詳しく調べ、血液専門医や母児専門医の診察を受けるのが妥当である。</td>
<td>クラスIIa、エビデンスレベルB</td>
</tr>
<tr>
<td>4. CVTの既往のある女性が妊娠した場合には、妊娠中および出産後にLMWHを予防的に投与する適応があるだろう。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>5. CVT:脳静脈洞血栓症、INR:国際標準化比、LMWH:低分子ヘパリン、UFH:未分画ヘパリン。</td>
<td></td>
</tr>
</tbody>
</table>

表7 小児における脳静脈洞血栓症の管理

<table>
<thead>
<tr>
<th>推奨</th>
<th>エビデンスの分類とレベル</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. CVT患者に血液培養と副鼻腔洞X線検査を行い、根拠に感染症がないかどうかを調べることが考慮されてよい。</td>
<td>クラスIIa、エビデンスレベルB</td>
</tr>
<tr>
<td>2. CVT患者に血液検査に関する検査を行い、根拠に密なる凝固障害を明らかにするのが有益である。障害によっては、その後の再発リスクおよび治療上の意思決定に影響を及ぼす可能性がある。</td>
<td>クラスIIa、エビデンスレベルB</td>
</tr>
<tr>
<td>3. 急性CVTを発症した新生児には、LMWHまたはUFHの投与が考慮してよい。</td>
<td>クラスIIa、エビデンスレベルB</td>
</tr>
<tr>
<td>4. 急性CVTをきたした新生児には、6週間〜3カ月間にわたってLMWHを継続投与することを考慮してもよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>5. 生後28日に到達した急性CVTを診断された小児には、LMWHの投与が考慮してよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>6. 生後28日以降に急性CVTと診断された小児には、LMWHまたは経口ビタミンK拮抗薬を3〜6カ月継続投与するのが妥当である。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>7. 急性CVTをきたしたすべての小児患者において、初期の抗凝固療法が開始された場合は、治療開始後1週間以内に頭部CTまたはMRIを実施し、新たな出血を検討するのが妥当である。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>8. すべての小児患者において、初期の抗凝固療法が行われない場合は、診断後1週間以内に頭部CTまたはMRIを実施し、新たな出血を検討することが推奨される。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>9. CVT患者に対する治療の選択には、適切な水分補給、てんかん発作のコントロール、頭蓋内圧亢進の治療を含めるべきである。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>10. 重度または長期に及び頭蓋内圧亢進患者による視野障害・視野欠損のおそれがあるCVT患児には、視野および視覚検査を定期的に実施すべきであり、頭蓋内圧亢進とその合併症の適切な治療を導入すべきである。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>11. 急性CVTの患児はてんかん発作の発現頻度が高いため、意識消失状態にある患児や機械的呼吸を行っている患児には、持続的脳波モニタリングを考慮してよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
<tr>
<td>12. 小児患者における血管内治療の有用性および安全性は明らかでないため、有効レベルの抗凝固療法による積極的治療にもかかわらず、神経学的徵候が悪化する患者を慎重に選択し、これらの患者に対してのみ血管内治療を検討してもよい。</td>
<td>クラスIIa、エビデンスレベルC</td>
</tr>
</tbody>
</table>

CVT:脳静脈洞血栓症、ICH:脳内出血、LMWH:低分子ヘパリン、UFH:未分画ヘパリン。
脑静脉血栓形成的诊断和处理
一项来自美国心脏协会 / 美国卒中协会针对医疗专业的声明（摘译）

Diagnosis and Management of Cerebral Venous Thrombosis
A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

Gustavo Saposnik, MD, MSc, FAHA, Chair; Fernando Barinagarrementeria, MD, FAHA, FAAN; Robert D. Brown, Jr, MD, MPH, FAHA, FAAN; Cheryl D. Bushnell, MD, MHS, FAHA; Brett Cucchiara, MD, FAHA; Mary Cushman, MD, MSc, FAHA; Gabrielle deVeber, MD; Jose M. Ferro, MD, PhD; Fong Y. Tsai, MD on behalf of the American Heart Association Stroke Council and the Council on Epidemiology and Prevention

背景：此声明旨在提供针对脑静脉窦血栓形成的综述和提供关于其诊断、处理和治疗的推荐意见。面向的读者是负责脑静脉窦血栓形成病人诊断和处理的医师和其它医疗提供者。

方法和结果：专题组成员是由美国心脏协会卒中理事会科学声明监督委员会任命并代表不同专业领域。专题组以 1966 年以来发表的报告为重点, 对相关文献做了回顾, 并使用美国心脏协会证据水平分级方法对证据进行评价和制定建议。声明经专题组批准之后, 再经同行评议并通过美国心脏协会科学顾问和协调委员会的批准。

结论：对脑静脉血栓形成的诊断、处理及复发的预防提供了基于证据的建议。提供了关于妊娠期和儿童人群中脑静脉血栓形成的评价和处理的建议，也总结了关于临床并发症（抽搐发作、脑积水、颅内压增高以及神经系统症状和体征恶化）处理的思考。描述了脑静脉窦血栓形成病人的诊断和处理流程。

关键词：美国心脏协会科学声明; 静脉血栓形成; 硬膜窦血栓形成, 颅内; 脑梗死, 静脉性; 卒中; 疾病处理; 预后; 结局评估; 抗凝剂; 妊娠; 儿童

（Stroke. 2011;42:1158-1192. 北京天坛医院神经内科 曹亦宾 摘译 王拥军 校）

硬脑膜窦和 (或) 脑静脉血栓形成 (CVT) 是一种不常见的卒中类型, 通常好发于年轻人[1]。危险因素具有多样性, 缺乏统一的治疗方法, 临床诊断和处理可能困难。CVT 大约占所有卒中的 0.5%-1%[2]。诱发因素包括先存疾病 (如易栓症、炎症性肠道疾病)、一过性疾病（诸如妊娠、脱水、感染）、某些药物（诸如口服避孕药、毒品滥用）及不可预知的事件（诸如头部外伤）[3-4]。

CVT 的病因和临床表现形式具有多样性，不仅是神经内科和神经外科医生而且也是急诊科、普通内科、肿瘤科、血液科、妇产科、儿科以及家庭医生经常遇到的临床问题。本科学声明旨在回顾 CVT 的相关文献并提供诊断和处理建议。

CVT 的流行病学和危险因素
CVT 是一种少见且经常被误诊的卒中类型，年发病率大约为 5/100 万，占所有卒中的 0.5%-1%[1]。CVT 更常见于青年个体。脑静脉和硬脑膜窦血栓形成国际研究 (ISCVT) 报告的 624 例中有 487 例（78%）病人的年龄小于 50 岁[16]。还没有人群研究报告过
Saposnik et al  Diagnosis and Management of Cerebral Venous Thrombosis

CVT 的患病率。

病因和发病机制：CVT 的潜在危险因素

CVT 的诱因是多方面的。危险因素通常被归类为获得性危险（诸如手术、创伤、妊娠、围产期、抗磷脂抗体综合征、癌症、外源性激素）和遗传性危险（遗传性易栓症）。

表3 总结了促凝因素与 CVT 之间因果关系的证据[10、11]。总结的证据涉及联系强度和一致性、生物学可信度及时间性。其中，最符合这些标准的是抗凝血酶III缺乏、蛋白C和蛋白S缺乏症、凝血因子V(factor V)Leiden阳性、使用口服避孕药及高同型半胱氨酸血症。

血栓前状态

血栓前状态是研究最广泛的 CVT 危险因素之一。ISCVT 研究发现 34% 的 CVT 病人有遗传性或获得性血栓前状态[10]。抗凝血酶III、蛋白C和蛋白S缺乏症两项研究已经对天然抗凝蛋白缺乏症(抗凝血酶III、蛋白C和蛋白S)作为 CVT 危险因素的作用进行了分析。一项研究对 121 例首次患 CVT 的病人和 242 例对照者进行了比较[36]。另一项研究对 51 例 CVT 病人和 120 例健康对照者进行了比较[12]。仅 1 例病人(2%)有抗凝血酶III缺乏。将两项研究合并之后，蛋白C缺乏患者与 CVT 危险的合并比值比(odds ratio, OR)是 11.1(95% CI 1.87-66.05; P=0.009)，而蛋白S缺乏症是 12.5(95% CI 1.45-107.29; P=0.03)。

抗磷脂和抗心磷脂抗体

一项研究发现 CVT 病人中抗磷脂抗体的发生率(9/121)高于对照组 (0/242)[36]。另一项研究中，与正常对照组的3.2%相比，31例 CVT 病人中22.6%被检测出抗磷脂抗体[12]。ISCVT 研究观察到的结果与之相似(5.9%)[10]。

凝血因子V Leiden基因突变和活化蛋白C抵抗

活化蛋白C抵抗主要是由凝血因子V Leiden基因突变所致，而凝血因子V Leiden基因突变是一种常见的遗传性易栓性疾患。

凝血酶原G20210A基因突变

凝血酶原G20210A基因突变大约见于2%的白种人，它可能导致凝血酶原水平的轻度增高[55、56]。一项对9项研究共360例CVT病人和2688例对照受者的meta分析报告[38]，此种基因突变的CVT混合OR值为9.27(95% CI 5.85-14.67)[38]，比它与总的静脉血栓栓塞(VTE)的相关性要强。

高同型半胱氨酸血症

高同型半胱氨酸血症是深静脉血栓形成(DVT)和卒中的一个危险因素，但对其与 CVT 危险性增加的相关性还不清楚。

妊娠和产褥期

妊娠和产褥期是一过性血栓前状态的常见原因[37]。大约2%的妊娠相关性卒中可归咎于 CVT[31]。据估计，产褥期 CVT 的发生率为 12/10 万次分娩，仅略低于产褥期动脉性卒中[38]。

大多数妊娠相关性 CVT 发生在妊娠晚期或产褥期[32]。妊娠可诱发凝血系统发生若干促凝改变，这些改变至少持续至产褥期的早期。分娩后由于血容量丢失和创伤可加重高凝状态。在产褥期，其它危险因素还有感染和器械辅助分娩或剖腹产等。

口服避孕药

应用口服避孕药与 CVT 危险增加有关，大多数患 CVT 的年轻非妊娠妇女是口服避孕药者，而在那些有某种遗传性易栓因素的妇女中口服避孕药者患 CVT 的危险更大。

癌症

据推测，CVT 在癌症特别是血液系统恶性肿瘤病人中或许更常见，但还未见到有对照组的研究。癌症与 CVT 之间联系的潜在机制包括肿瘤直接压迫、肿瘤侵犯脑静脉窦[39-41]或癌症伴随的高凝状态[60]。用于癌症治疗的化疗药物和激素也可能起到一定作用。

其它少见病因

新的神经影像技术近年来提高了发现 CVT 的能力并且也有助于识别出其它潜在的病因，其中包括感染，主要是位于脑膜附近部位(耳、副鼻窦、口腔、面部及颈部)的感染。感染所致的 CVT 在成年人中并不多见，但在儿童中却很常见。

一个病例报道和小规模病例系列研究已将其它疾病与 CVT 联系在一起，包括阵发性睡眠性血红蛋白尿、缺铁性贫血、血小板减少症、肝素诱导性血小板减少症、血栓性血栓减少性紫癜、肾病综合症、炎症性肠道疾病、系统性红斑狼疮、白塞氏病、硬膜外血肿、自发性低颅压以及腰穿。
CTV的临床诊断

主要临床表现

CTV的诊断通常基于临床怀疑和影像检查证实。根据神经系统功能障碍的机制，通常将CTV的临床表现分为两大类：一类与静脉引流受阻所致的颅内压增高有关，另一类与静脉性缺血/梗死或出血所致的局灶性脑损伤有关。头痛是CTV最常见的症状，见于近90%的病人。CTV所致头痛常为弥漫性且常有数天至数周的进行性加重。少数病人可表现为霹雳样头痛或偏头痛型头痛。没有局灶性神经系统表现或视乳头水肿的孤立性头痛可见于高达25%的CTV患者。对于有头痛和视乳头水肿或复视（外展神经麻痹所致）的病人，即使没有其它提示特发性高颅内压的神经系统局灶性体征，CTV也是一个重要的诊断考虑。当因静脉性缺血或出血而发生局灶性脑损害时，经常出现与受累脑组织区域相符的神经系统体征和症状；最常见为偏瘫和失语，但其它皮层体征或感觉症状也可发生。精神异常伴局灶性神经系统体征的情况也有报道。

临床表现还与血栓形成的部位有关。上矢状窦受累最常见，可导致头痛、颅内压增高和视乳头水肿，也可出现运动缺失症状，有时伴有抽搐。在横窦静脉血栓形成，由于皮层受累，有时可以见到偏盲、对侧肢体无力及失语，可以发现与某一原发疾病有关的症状（中耳感染）。

一些临床特征有助于区分CTV和其他发病机制的脑血管病。首先，局灶性或全身性抽搐发作是常见的，大约发生于40%的病人。其次，常有双侧大脑半球受累，这一特征在深部静脉引流系统受累的病例中特别明显，当发生双侧丘脑受累时，可导致意识水平的改变而没有局灶性神经系统症状和体征。由于上矢状窦血栓形成和双侧半球受损，也可出现双侧运动受累体征，包括截瘫。最后，CTV病人经常有缓慢进展的症状。CTV诊断常有延迟，而且令人印象深刻。

其他临床和实验室检查

常规血液检查

对怀疑CTV的患者有必要做全血细胞计数、生化、血沉以及凝血酶原时间及活化的部分凝血活酶时间组成的常规血液检查（I级推荐；C级证据）。2. 推荐在首次临床评估时筛查可诱发CTV的潜在易栓疾患（诸如应用避孕药、潜在炎症性疾病、感染过程）（对检测血栓形成倾向的特殊建议参见本文件的长期处理部分）（I级推荐；C级证据）。

建议

1. 对怀疑CTV的病人，应该做由全血细胞计数、
Saposnik et al      Diagnosis and Management of Cerebral Venous Thrombosis

成像 (I 类推荐；C 级证据)。

孤立性头痛/特发性颅内压增高

将 CVT 与特发性颅内压增高区分开有重要的转归和治疗意义，建议对所有临床上认为特发性颅内压增高者进行脑静脉系统的成像 [67,85]。对于孤立性头痛者，识别 CVT 的合理策略还不十分清楚。头痛是一个相当常见的症状，而且绝大多数单纯头痛的病人都不会有 CVT。常规影像检查的成本-效益比和获益十分不确定。可能提示诊断并因此促使影像评估的因素包括新发的经保守治疗仍在数天至数周之内持续进展的不典型头痛以及霹雳样头痛 [64]。对有某种高凝状态的头痛病人，应高度警惕 CVT。

建议

1. 对临床上认为特发性颅内压增高的病人，推荐做脑静脉系统成像以排除 CVT (I 类推荐；C 级证据)。

2. 对有不典型特征的头痛病人，为排除 CVT 而做脑静脉系统成像是合理的 (IIa 推荐；C 级证据)。

孤立性精神状态改变

偶尔，CVT 病人可表现为嗜睡或意识浑浊而没有明显的局灶性神经功能异常 [96-98]。这类临床表现常见于老年人和有深静脉系统血栓形成者 [89,90]。尽管此种临床表现有许多发病机制，但是一个重要原因是深静脉系统受累所致的双侧丘脑病变。CT 扫描，尤其在病程早期做时，可无特殊改变；MRI 在这类病例通常会显示出异常。

CVT 诊断性影像学检查

在过去 20 年间，诊断性影像学检查在 CVT 的诊断和处理方面所起的作用越来越大 [2,3,5,91-97]。CVT 的诊断性成像可被分为两类：无创检查和有创检查。目的是明确与本病有关的血管和脑实质改变。部分病例仅能靠脑血管数字减影做出诊断 [72,91,94-98]。急性期 CVT 在平扫 CT 上的主要征象是某一皮层静脉或硬脑膜窦呈高密度改变。然而，大约仅有 1/3 的 CVT 被发现有高密度硬脑膜窦的直接征象 [70,94,96]。上矢状窦后部血栓可以看似一个高密度三角，即高密度或实心的 δ(delta) 征。平扫 CT 也可显示缺血性梗死，有时伴有出血成分。横跨常见动脉分界的 (特别是有出血成分的) 或紧邻某一静脉窦的缺血性梗死提示 CVT [99]。蛛网膜下腔出血和 ICH 并不常见 [99]。蛛网膜下腔出血仅见于 0.5%-0.8% 的 CVT 病人 [10,14,99]，而一旦出现，其部位常在大脑凸面，恰与在动脉瘤破裂病人中经常观察到的 Willis 环区域相同。

强化 CT 可以显示静脉窦的硬膜强化伴静脉或静脉窦内的充盈缺损，呈典型的 “空 δ” 征 (empty delta sign) [93]。这种征象在症状起病后数日内可能不会出现但可持续数周。

由于 CVT 的症状可能被疏忽或延迟就诊，使得 CVT 可能只有在亚急性期或慢性期才被发现。与邻近脑组织的密度相比，血栓可以呈等密度、低密度或混杂密度。这种情况下，强化 CT 或 CT 静脉造影 (CTV) 可能有助于影像学诊断 [70-74,94,97,100-105]。

磁共振成像

通常，MRI 对 CVT 的显示在脑静脉血栓形成的每个阶段都比 CT 敏感 [1,70,96,97,101,106,107]。通过在 MRI 上发现某一静脉窦内有血栓可作出 CVT 的诊断 [105,108-113]。孤立性皮质静脉血栓被发现的几率比静脉窦血栓要小得多。静脉血栓的磁共振信号强度随成像时间距血栓形成的时间长短而变化 [6,65,94,101-107]。急性血栓可以是低信号。在第 1 周，由于脱氧血红蛋白含量的增加，静脉血栓通常在 T1 加权像上呈与脑组织相等的信号而坏在 T2 加权像上呈低信号。到第 2 周，血栓含有氧化血红蛋白导致其在 T1 和 T2 加权像上均呈高信号 [2,10,42,76,71,73,74,91-98,100,105,106,108,113-128]。随着血栓的演变，静脉窦内出现脱氧血红蛋白和氧化血红蛋白的顺磁性代谢产物。此期硬膜窦或静脉内血栓在梯度回波和磁敏感加权磁共振成像上呈低信号 [70,119,129]

CVT 在平扫 MRI 上的主要早期征象是硬膜窦内流空影消失和信号强度改变。这一征象是 CT 空 Δ (delta) 征的等位征。急性静脉血栓可呈酷似正常流空影的等信号，为确立诊断可能需要做强化 MRI 和 CTV 或 MR 静脉造影 (MRV)。

MRI 的次要征象与 CT 显示的类型可能相似，包括脑肿胀、水肿和出血等 [91,130-134]。CTV 脑实质病变在 MRI 上比在 CT 上更直观更清晰。点片状或融合成片状出血提示出血性静脉梗死。在一定程度上，与特定静脉窦有关的病变呈区域性分布。额叶、顶叶和枕叶的脑实质改变通常对应上矢状窦血栓形成。颞叶脑实质改变对应侧 (横) 窦和乙状窦血栓形成。深部脑实质异常，包括丘脑出血、水肿或脑室内出血，与 Galen 静脉或直窦血栓形成对应。
CT静脉造影

CTV为显示CVT提供了一种快速和可靠的检查方法，对亚急性期或慢性期CTV的诊断更有帮助。在诊断CTV方面，CTV至少可与MRV媲美[94,97,100,103,106]。

磁共振静脉造影

最常用的MRV技术是时间飞跃(TOF)MRV和造影剂增强磁共振。二维TOF比三维TOF对缓慢血流的敏感性好。静脉窦发育不良在梯度回波或磁敏感加权成像上不会有窦内异常低信号。

对内科药物治疗下仍有持续的或进展性症状的病人，重复影像学检查(包括CTV或MRV)可有助于识别新的或进展的病变，ICH、水肿、血栓扩展及其它脑实质病变的发展[97,110,111,120,128,136-138,140,141]。

深部CVT

深部静脉系统在CT和MRI上容易被显示且很少受到伪差的影响。

有创的诊断性血管造影检查

脑血管造影和直接脑静脉造影

有创的脑血管造影在有MRV和CTV的情况下很少被用来确立CTV的诊断[109,125,133]，只有在MRV或CTV的结果没有定论或考虑行血管内治疗的情况下才做。

脑血管造影

血管造影的结果包括因闭塞所致的静脉窦不显影、静脉淤滞伴扩张的皮层、头皮或面部静脉、侧支引流微小静脉的扩张以及静脉血流逆转。脑血管造影的静脉期显示在形成血栓的脑静脉/窦内有充盈缺损。脑静脉或硬膜窦发育不良或闭锁可以酷似静脉窦血栓形成，有时需无创的影像检查除外CVT是不可能的[2,71,72,95,97,99,108,109,125,142-150,158]。直接脑静脉造影因逆流注射造影剂而可能难以解释，而静脉压又因静脉系统内的相对分隔效应而可能不准确[70]。

建议

1. 尽管平扫CT或MRI有助于疑似CVT病人的最初评估，但是平扫CT或MRI结果阴性并不能排除CTV。对疑似CVT的病人，如果扫描CT或MRI阴性或在扫描CT或MRI提示CTV情况下为确定CTV的范围，应做静脉造影检查(CTV或MRV)(I类推荐;C级证据)。
2. 对内科治疗下仍有持续的或进展的CTV病人，建议早期随访CTV或MRV(I类推荐;C级证据)。
3. 引起为提示CVT复发症状的既往有CVT的病人，建议复查CTV或MRV(I类推荐;C级证据)。
4. 梯度回波T2磁敏感加权成像联合磁共振可能有助于提高CTV诊断的准确性(IIa类推荐;B级证据)。
5. 对CTV或MRV没有定论但临床上仍高度怀疑CVT的病人，导管脑血管造影可能有帮助(Ila类推荐;C级证据)。
6. 对病情稳定的病人，为了评价闭塞皮层静脉/静脉窦的再通情况，在诊断后3-6个月时随访CTV或MRV是合理的（IIa类推荐; C级证据）。

CTV急性期处理和治疗
本文提供了CTV病人诊断和处理的简要程序。

环境
组织化医疗是降低急性卒中后残疾率和死亡率的最有效干预措施之一[166,167]。CTV是一种不常见但又可能危及生命的卒中病因。基于卒中单元的总体疗效，为了优化治疗和减少并发症，在卒中单元内进行CTV的初始处理是合理的。

初始抗凝治疗
CTV抗凝疗法有若干理由：预防血栓增长、促进血管再通以及预防深静脉血栓(DVT)或肺栓塞(PE)。因为在CTV诊断时常存在脑梗死伴出血转化或ICH，这种情况也可使治疗复杂化，因此对抗凝治疗一直有争议。

现有两项随机对照试验，在经造影剂强化成像诊断的CTV病人中对抗凝治疗和安慰剂或开放对照进行了比较。总共纳入79例病人。一项20例病人的试验对采用剂量调节的以使活化的部分凝血活酶时间达治疗前数值的两倍的静脉内普通肝素(UFH)和安慰剂进行了评价[171]。此研究使用肝素的方法为3000单位团注后持续静脉输注。主要结局是3个月时评估头痛、局灶体征、抽搐发作和意识水平的CTV严重程度量表。次要结局是ICH。此试验因有治疗获益而在纳入预期60例病人中的20例时被提前终止。在3个月时，肝素组10例病人中，8例完全恢复，2例有轻度神经功能缺失。安慰剂组10例病人中，3个月时1例完全恢复，6例有轻度神经功能缺失，3例死亡。发生ICH者见于2例安慰剂治疗的病人而未见于肝素治疗的病人。安慰剂组中1例病人有未经证实的肺栓塞。

另一项59例病人的试验对剂量基于体重(180抗Xa因子单位/天/公斤体重，分两次剂量)的皮下注射低分子肝素(nadroparin)和安慰剂进行了比较。疗程为3周，随后被随机化到低分子肝素组的病人接受3个月的口服抗凝治疗（没有安慰剂对照）[172]。此研究在前3周为盲法而随后为开放标签。主要结局是日常生活活动量表、牛津卒中残疾量表及死亡。次要终点是症状性ICH。发生ICH者见于2例安慰剂治疗的病人而未见于肝素治疗的病人。安慰剂组中1例病人有未经证实的肺栓塞。

在就诊时CTV合并脑出血的特殊情况下，即使不用抗凝治疗，出血也与不良预后有关。研究提示CTV抗凝治疗脑出血的发生率低[171,175]。在病人有抗凝治疗主要禁忌证（如近期严重出血）的特殊情况下，临床医生必须依据临床情况权衡抗凝治疗的风险和益处。在这种情况下，就像对待一般静脉血栓一样，请一位抗凝治疗方面的专家会诊可能是适当的，如果有可能，可以考虑低剂量强度抗凝治疗。

来自观察性研究的资料
现有许多观察性研究，既有前瞻性的，也有回顾性的，但大多数来自单中心[10,136,175-178]。因为大多数研究中绝大多数病人在诊断时是用静脉UFH或低分子肝素(LMWH)治疗的，最终应用维生素K拮抗剂，因此，并非所有的研究都专门报告抗凝治疗的结局。死亡率低，通常<10%，常死于基础病（如，癌症）而不是CTV，而且死于ICH罕见。绝大多数病人神经系统功能完全恢复，少数变成残疾。

目前为止最大规模研究为ISCVT，纳入来自21个国家89个中心的624例病人。几乎所有病人初始治疗为抗凝，16个月死亡率8.3%，79%完全恢复(改良Rankin评分[mRS]评分0-1)。6.4%轻-中度残疾(mRS评分2-3)。2.2%仍有重度残疾(mRS评分4-5)[10]。几乎没有研究有足够的未接受抗凝治疗的病人例数来合理推断抗凝治疗的疗效。

总之，来自有限的关于抗凝治疗的预后和出血并发症的随机对照试验的资料和观察性资料支持抗凝在CTV治疗中起到一定作用，无论是否存在治疗前ICH。写作组一致支持在CTV病人处理中采用抗凝治疗。如果给予抗凝治疗，没有支持在CTV病人中采用以调整的剂量UFH的应用或LMWH在预后方面的差异的资料。

其它治疗
纤维蛋白溶解疗法

尽管CTV病人接受抗凝治疗可以恢复，但是在抗

ICH(低分子肝素组有1例非致命性出血，安慰剂组有1例致命的未被证实的肺栓塞)。6例积极治疗的病人(12%)和8例对照病人(28%)3个月时完全恢复。对这2项试验的Meta分析[161]显示，抗凝治疗的死亡或生活不能自理的相对危险度(relative risk 0.46, 95% CI 0.16-1.31)没有统计学显著性，对抗凝治疗有利的危险性差异–13% (95% CI –30%-3%)。死亡的相对危险度是0.33 (95% CI 0.08-1.21), 危险性差异是–13% (95% CI –27%-1%)。
凝治疗下仍有9%-13%的病人预后不良。单纯抗凝治疗或许不能使一个大的或广泛的血栓溶解，而临床情况即使在肝素治疗期间也会恶化。不完全再通或持续性血栓形成可以解释这一现象。单纯抗凝治疗下CVT部分或完全再通率为47%-100%。[110,178,192,193]

不幸的是，大多数报告3-6个月时部分或完全再通的研究为小样本研究。将共包括114例病人的4项研究合并后，发现94例(82.5%)在3-6个月时有部分或完全再通[110,178,192,193]。接受溶栓治疗的病人再通率可能更高[14]。通常，如果在抗凝治疗下仍有临床恶化或如果某一病人在其他处理方法下仍有进行性颅内压增高，则采用溶栓治疗。

血管内介入治疗还没有得到来自与抗凝治疗相比较或相互之间相比较的随机对照试验的支持。大多数证据基于小规模病例系列或经验性病例报告。

直接导管溶栓

在直接导管溶栓时，血栓经导丝的机械性操作之后可增加可能受到溶栓药物作用的血栓凝块的量，可减少溶栓药物的用量[161,113,131,130,170,188,192,195-205]。

美国的一项回顾性多中心CVT研究中，182例病人中的27例(15%)接受了血管内溶栓治疗。10例病人正在接受同期抗凝治疗。26例(96%)获得血管再通，4例发生颅内出血，1例(4%)病人死亡。

一项对包括169例局部溶栓治疗的CVT病人的系统性回顾显示严重CVT病人可能从治疗中获益，提示局部溶栓治疗能降低危重CVT病人的病死率。溶栓后17%的病人发生ICH，与5%的病人病情恶化有关[206]。

机械性取栓/溶栓

球囊辅助的取栓和溶栓

尽管使用全身性溶栓或对血凝块行机械性破碎和直接注射溶栓药物，但是静脉窦血栓可能仍持续存在。因为球囊充盈后可以减少溶栓药物的流失而潜在地减少所需的溶栓药物剂量、降低出血的发生率[74,207,208]以及缩短操作时间，所以球囊辅助的溶栓或许更有效。在溶栓前可以用球囊做部分性血栓去除术[112,209]。

导管血栓去除术

对局部应用溶栓药后仍持续存在的广泛血栓病人，可以考虑采用流变(rheolytic)导管血栓去除术。AngioJet(MEDRAD, Inc, Warrendale, PA)就是一种这样的装置，它采用通过高速生理盐水喷头的文丘里效应(Venturi effect)而发生在导管头端的流体动力学溶栓作用。

Merci取栓装置(Concentric Medical, Mountain View, CA)也已经被用于去除脑静脉系统的血栓。此技术也需要将导管直接送到静脉窦。将小螺旋形装置送出导管头端并被推送进血栓内，然后缓慢地与附着的血栓一起被拉回到导管内。为了避免损伤静脉窦壁或窦内小梁，可以先用此装置行部分再通，随后再进行溶栓[195]。现有证据目前尚处在经验阶段。

Penumbra系统(Penumbra, Inc, Alameda, CA)是新一代神经系统血栓去除装置，能起到去除和抽吸急性血栓凝块的作用。它采用一个内有能破碎血凝块和有助于抽吸的一个基于导丝的分离器的能抽吸血栓的再灌注导管。关于其治疗效果目前仅有经验性的证据[212]。

手术方面的考虑

由于静脉血栓形成血管内治疗方法的进展，外科手术所起的作用已经越来越局限。需要外科手术血栓切除术者不常见，但如果在最佳内科治疗下严重的神经系统或视力恶化发生可以被考虑[213,214]。如果大的静脉性梗死导致明显的颅内压增高时，则需开颅减压术作为挽救生命的措施。同样，大的血肿如果伴进行性或严重的神经系统功能缺失可能需要被考虑做手术清除术。

总结

这些直接窦内溶栓技术和机械性治疗方法的应用仅受到个案报告和小规模病例系列的支持。如果在应用抗凝治疗的情况下仍有临床恶化，或病人出现导致常规治疗方法抵抗的颅内压增高来自静脉血栓死或ICH的占位效应，那么可以考虑这些介入治疗技术。

阿司匹林

没有直接评价阿司匹林在CVT处理中作用的对照试验。

激素

激素通过减轻血管源性水肿而可能在CVT中起到一定作用，但激素可以增加高凝状态。在ISCVT的624例病人中一项匹配的病例-对照研究中[216]，将150例由经治医生决定采用激素治疗的病人与150例未采用激素的病人进行比较，并与基于CVT结局不良的预后因素治疗的病人匹配。采用激素治疗的病人与对照病人的特征相似，除了更容易有血管炎。在6个月，治疗有死亡或不能独立的危险较大的趋势(OR 1.7, 95% CI 0.9-3.3)，而在排除血管炎、恶
Saposnik et al      Diagnosis and Management of Cerebral Venous Thrombosis

性病、炎性疾病及感染后，这一趋势没有差别。在 CT/MRI 上有脑实质病变的病人中，结果令人震惊，激素治疗的死亡或依赖的风险比增加 4.8 倍（95% CI 1.2–19.8）。

抗生素
局部（如，中耳炎、中耳乳突炎）和全身性（脑膜炎、败血症）感染可以合并附近或远隔静脉窦血栓形成。怀疑感染和 CVT 病人的处理应包括应用适当的抗生素和感染灶（如，硬膜下积脓或副鼻窦化脓性积液）的手术引流。

早期并发症
脑积水、颅内压增高和抽搐发作的处理和预防
抽搐发作
抽搐发作见于 37% 的成年人，48% 的儿童和 71% 的新生儿 CVT 病人[102,183]。尚无临床试验对抗癫痫治疗在 CVT 中应用的最佳时机或药物选择进行研究。是否对所有 CVT 病例都开始抗癫痫治疗或等到有抽搐发作才开始抗癫痫治疗仍有争议。因为抽搐发作可加重缺氧性脑损害，所以即使一次抽搐发作之后就应用抗癫痫治疗也是合理的[217]。在没有抽搐发作的情况下，预防性应用抗癫痫药物可能有害（引起副作用的风险可能超过其治疗益处）[196,197,209]。

几项研究报告了 CVT 病人抽搐发作的发生率和特征。一项研究报道[218]，在 91 例病人中，32% 以抽搐发作就诊，2% 在住院期间出现抽搐发作，仅 9.5% 出现晚期抽搐发作。早期抽搐发作在有 CT/MRI 上脑实质病变的病人中发生的可能性高达 3.7 倍（95% CI 1.4–9.4）而有感觉缺失的病人中的可能性增加 7.8 倍（95% CI 0.8–74.8）。来自 ISCVT 的一项更近的报告[197]显示，624 例病人中的 245 例（39%）以抽搐发作就诊，而 43 例（6.9%）在诊断后 2 周内出现早期抽搐发作。除了诊断时抽搐发作，仅诊断时 CT/MRI 上有幕上脑实质病变（见于 58%）与早期抽搐发作的发生有关（OR 3.1, 95% CI 1.6–9.6）。此外，在有幕上病变而起病时没有抽搐发作的病人中，应用抗癫痫药物可使 2 周内抽搐发作的风险降低 70%，尽管这并没有统计学上的显著性（OR 0.3, 95% CI 0.04–2.6）。

在这些结果的基础上，作者建议对表现为抽搐发作的有幕上病变的急性 CVT 病人使用抗癫痫药物[197]。

脑积水
上矢状窦和横窦是通过横跨静脉窦壁突入到蛛网膜下腔并引流到静脉系统的高度血管化结构的蛛网膜颗粒进行脑脊液 (CSF) 吸收的主要部位。在 CVT，蛛网膜颗粒的功能可能受到障碍，潜在地导致 CSF 吸收的衰竭和交通性脑积水（6.6%）[14,198]。梗阻性脑积水是 CVT 的一个少见的并发症，可由出血破裂入脑室系统所致。通常与累及大脑静脉的血栓有关，还可以与丘脑出血有关。此综合征在新生儿已有很好的描述但可以发生在所有年龄组[201,202]。

颅内压增高
高达 40% 的 CVT 病人表现为单纯颅内压增高[183]。以弥漫性脑水肿为特征，有时在 CT 上类似裂隙状脑室。临床特征包括进行性头痛、视乳头水肿以及第 III 或第 VI 对颅神经麻痹。导致颅内压增高的主要原因是静脉流出受阻和因 CSF 吸收障碍而加剧的脑组织淤血。

尚无任何随机试验证实最佳治疗；然而，对颅内压增高的合理处理应是采用多种治疗方法相结合。首先，减轻静脉流出血栓性阻塞的措施，诸如抗凝和溶栓治疗，可缓解颅内压增高。其次，通过腰穿放 CSF 至末压达到正常可即刻减轻颅内压增高。不幸的是，腰穿需要临时中断抗凝治疗，有血栓扩大的危险。尽管缺乏随机临床试验，醋氮酰胺是治疗 CVT 所致颅内压增高的一种常用的治疗选择[139]。它在 CVT 病人的颅内压增高的急性处理中起到有限的作用。醋氮酰胺是一种碳酸酐酶抑制剂，是一种弱的利尿剂且能减少 CSF 的产生。尽管偶尔被使用，但是皮质激素类并没有效果[216]且能带来相关的对缺血脑组织有害的高血糖和高乳酸的危险。如果有持续的颅内压增高，可能需要多次腰穿。对顽固性颅内压增高的病例，可能需要做腰大池腹膜腔分流术[199]。因为视神经长期受压可以导致永久性失明，所以在病人有颅内压增高期间密切监测视野和视乳头水肿的严重程度至关重要。眼科会诊对这一情况有帮助。尽管很少需要，但是视神经开窗术是阻止进行性视力丧失的一个治疗方法。

现有关于去骨瓣减压术在 CVT 合并脑水肿、静脉性梗死、神经系统功能恶化或濒临脑疝中的治疗作用的证据有限[200,202,203]。阻止术后近期的抗凝治疗是开颅手术的一个缺点。

建议
1. 怀疑有细菌性感染的 CVT 病人应接受合理
的抗生素治疗且应在适当时机接受 CVT 相关性感染灶的化脓性积液的引流手术 (I 类推荐; C 级证据)。
2. 对 CVT 合并颅内压增高的病人，建议监测有无进行性视力丧失，而这一情况一旦被观察到，则应紧急治疗颅内压增高 (I 类推荐; C 级证据)。
3. 对有脑实质病变的 CVT 合并与单次抽搐发作的病人，建议早期开始规范疗程的抗癫痫药物以预防进一步的抽搐发作 (I 类推荐; B 级证据)。
4. 对没有脑实质病变的 CVT 合并与单次抽搐发作的病人，勉强地建议早期开始规定疗程的抗癫痫药物以预防进一步的抽搐发作 (IIa 类推荐; C 级证据)。
5. 在没有抽搐发作的情况下，不建议对 CVT 病人常规应用抗癫痫药物 (III 类推荐; C 级证据)。
6. 对 CVT 病人，无论是否存在 ICH，采用按剂重调节的 UFH 或基于体重的充足抗凝剂量的 LMWH 开始抗凝治疗是合理的，后续应用维生素 K 拮抗剂 (IIa 类推荐; B 级证据)。（为了解详细情况，参见“CVT 的急性期处理和治疗：初始抗凝治疗。”）
7. 为治疗和预防 CVT 病人的临床并发症，将病人收住到卒中单元是合理的 (IIa 类推荐; C 级证据)。
8. 对 CVT 合并与颅内压增高的病人，开始醋氮酰胺治疗是合理的。如果有进行性视力丧失，其他治疗 (腰穿、视神经减压术，或脑脊液分流术) 可能是有效的 (IIa 类推荐; C 级证据)。
9. 如果在强化抗凝治疗后发生病情恶化，则可以考虑血管内介入治疗 (IIa 类推荐; C 级证据)。
10. 对因可引起难治性颅内压增高的严重占位效应或颅内出血而出现神经系统症状和体征恶化的病人，可以考虑去骨瓣减压术 (IIb 类推荐; C 级证据)。
11. 对 CVT 病人，即使在 CT/MRI 上存在脑实质病变，不推崇激素类药物治疗，除非因其他基础疾病所需 (III 类推荐; B 级证据)。

CVT 的长期处理和复发

预防策略集中在对那些 CVT 或其它 VTE 复发高危 CVT 病人的预防上。有某些易栓状态或疾病 (如，癌症) 的病人可被认为高危病人。还没有关于首次或复发 CVT 长期预防的随机临床试验。总体上，任何类型复发性血栓形成的年复发危险大约是 6.5%[10,117]。

因为还没有关于成年 CVT 病人抗凝治疗的二级预防试验，因此仅能用评估正在用或不用抗凝治疗的 CVT 或 VTE 复发风险的观察性研究来作为预防策略的评价。在一组于 1978 年至 2001 年间 Mayo Clinic 治疗的 154 例病人队列中，56 例初始接受肝素和华法林两种治疗，12 例仅肝素治疗，21 例仅华法林治疗 [61]。77 例 (50%) 用华法林治疗平均 9 个月，25 例为终身服用华法林 [61]。在 36 个月随访 (464 个病人年) 期间，有 20 例病人 (13%) 共 23 次 VTE 复发，大多数发生在第 1 年内。10 例病人有 CVT 复发 (2.2/100 个病人年)，11 例有 DVT 或 PE (2.8/100 个病人年)。9 次复发事件发生在病人正在服用华法林期间。随访 8 年之后，华法林对存活或无复发存活没有影响 [61]。

一组比利时一大学医院连续治疗的 54 例 CVT 病人队列中，平均随访 2.5 年，8 例 (14.8%) 有 VTE 复发 (7 例为 DVT 或 PE, 1 例为 CVT 和肠系膜静脉血栓) (4.5/100 病人年)。复发的平均时间是 2.5 个月 (范围从 2 周至 4 年)。这 8 例病人中仅 2 例在复发时正在服用抗凝药，1 例的国际标准化比率 (INR) 为 1.6，另 1 例 INR 为 2.1，6 例没有正在服用抗凝药的复发 VTE 病人中，复发发生在先证事件后 2 周至 10 个月之间。有某种易栓疾患、有 VTE 病史及没有接受口服抗凝药容易复发 [176]。

在 ISCVT 研究中，平均随访 16 个月期间，624 例 CVT 病人中有 14 例 (2.2%) 复发 CVT 和 27 例 (4.3%) 其他血栓事件 (16 例 DVT, 3 例 PE, 2 例缺血性卒中，2 例短暂性脑缺血发作及 4 例急性肢体缺血) [176]。这 41 例复发或其它血栓性事件的病人中有 17 例 (41.5%) 正在服用抗凝药，但这些正在接受治疗剂量的抗凝药患者的复发 VTE 病人中，复发发生在先证事件后 2 周至 10 个月之间。有某种易栓疾患、有 DVT 病史及没有接受口服抗凝药容易复发 [176]。

CVT 后任何血栓事件 (CVT 或系统性) 的总复发危险大约为 6.5%。基于对本病最大规模的研究 [10]，CVT 之后其它 VTE 表现的危险是 3.4% [209] 至 4.3% [110]。

有严重易栓症的病人 VTE 危险增加。

CVT 和其它 VTE 事件的二级预防

DVT/PE 和 CVT 有一些相同之处。两者的慢性或一过性危险因素是相似的。在 ISCVT 病例队列中，CVT 或其它 VTE 复发的总发生率是 4.1/100 人年，男性和红细胞增多 / 血小板增多是被发现的唯一独立的预测因子 [219]。同一研究报告了血栓性复发事件的累积危险的稳定增加不受抗凝治疗时间的影响，提示需要开展一个临床试验评价短期与长期抗凝治
Saposnik et al Diagnosis and Management of Cerebral Venous Thrombosis

Therapy's efficacy and safety [219]. Despite CVT's higher systemic VTE risk, only a few studies have systematically evaluated the risk of these complications. Therefore, the effectiveness of any proposed anticoagulant regimen must be weighed against these risks. It is important to note that CVT is associated with a higher risk of VTE recurrence compared to CVST, and that anticoagulant therapy should be considered in patients with severe CVT recurrence [219,220].

However, it is important to consider the individual risk of each patient and their risk profile, including the risk of future VTE recurrence, risk of bleeding, and risk of thrombus formation in the absence of anticoagulation [220].

易栓症和长期处理的危险分层

易栓症可能是遗传性或获得性的, 基于在家族病例队列中观察到的血栓复发危险, 遗传性易栓症被分层为轻度或重度 [221]. 在 VTE 病人中, 未正在接受抗凝治疗情况下 VTE 的累积复发危险最大的易栓症是抗凝血酶和蛋白 C 和蛋白 S 缺乏症, 2 年复发率 19%, 5 年复发率 40%, 10 年复发率 55%. 纯合子凝血酶原 G20210A、纯合子因子 V Leiden、蛋白 C、蛋白 S 或抗凝血酶缺乏症、易栓性联合缺陷以及抗磷脂抗体综合征被分类为重度.

抗磷脂抗体综合征是一种获得性易栓症, 伴有特殊的实验室标准 (狼疮抗凝物、抗心磷脂抗体及抗 β2 糖蛋白 I) 和静脉性或动脉性血栓事件或流产病史 [224]. 尽管没有报道针对 CVT 复发率的前瞻性研究, 但是与这些疾病相关的复发性 VTE 风险增加符合严重易栓症的定义。目前对于 VTE 病人的建议要求对有抗磷脂抗体综合征的病人无限期抗凝治疗 (调整剂量的华法林 INR 2.0-3.0 或肝素) [220].

其它能确定 CVT 后复发性 CVT 或 VTE 危险的实验室测定

在 DVT 或 PE 病人中, 越来越多的证据提示临床上可用 D-二聚体测定检测复发性 VTE 的风险 [224,229,230]. 尽管 D-二聚体应用于长期抗凝治疗病人 VTE 二级预防看似有效, 但是标准化的 D-二聚体测定法的缺乏可能限制其在临床上的适用性和可信性 [232].

建议

1. 检测血栓前状态, 包括蛋白 C、蛋白 S、抗凝血酶缺乏症、抗磷脂抗体综合征、凝血酶原 G20210A 基因突变以及因子 V Leiden, 可有益于 CVT 病人的处理。蛋白 C、蛋白 S 和抗凝血酶缺乏症的患者在完成抗凝治疗后 2 至 4 周。急性期或服用华法林病人的检测结果的价值非常有限 (IIa 类推荐; B 级证据)。

2. 对应激性 CVT (与某种一过性危险因素相关的) 病人, 维生素 K 抗凝剂可以持续 3 至 6 个月, INR 目标值 2.0-3.0 (IIb 类推荐; C 级证据)。

3. 对非应激性 CVT 病人, 维生素 K 抗凝剂可以持续 6 至 12 个月, INR 目标值 2.0-3.0 (IIb 类推荐; C 级证据)。
Stroke  April 2011

是 CVT 的潜在病因。因为没有进行长期血管造影检查的队列研究，因此尚不清楚 CVT 之后硬脑膜静静脉瘘的确切发生率。在没有系统性血管造影随访的队列研究中，硬脑膜静静脉瘘的发生率 (1%-3%) [35, 94, 201, 205, 237]. 脑血管造影可有助于确定硬脑膜静静脉瘘的存在。

建议

1. 对有 CVT 病史主诉为新的、持续的或严重的头痛病人，应考虑对 CVT 复发和颅内压增高进行评估 (I 类推荐；C 级证据)。

特殊人群的 CVT

妊娠期 CVT

妊娠诱发凝血系统的改变，这些改变可持续到产褥期且可导致高凝状态从而增加患 CVT 的危险。据估计，在西方国家妊娠期和产褥期 CVT 的发病率的变化范围在 1/2500 至 1/10000 次分娩之间，而 OR 变化范围从 1.3 至 13 [238-240]. CVT 危险最大的阶段是妊娠晚期和产后最初 4 周 [240]. 在妇女中高达 73% 的 CVT 发生在产褥期 [240]. 剖腹产似乎与致畸性胚胎病和胎儿及新生儿出血有关，因此通常被认为是禁用于妊娠期。因此，大多数妇女妊娠期和早期产褥期 CVT 的抗凝治疗为 LMWH [220].

与 UFH 不同，LMWH 与致畸性胚胎病和胎儿及其新生儿出血无关，因此通常被认为是禁用于妊娠期。因此，大多数妇女妊娠期和早期产褥期 CVT 的抗凝治疗为 LMWH [220].

危险因素

儿童 CVT 的危险因素与年龄有关。新生儿占儿童 CVT 病人的 43% [91]. 新生儿患病危险性增加的可能原因有几种。首先，出生过程中婴儿头部受到明显的机械性力的作用而导致颅骨沿颅缝线塑形，这将引起其下的硬脑膜静脉窦发生机械性变形和损伤以及血栓形成。新生儿也有血栓倾向增大 [250]. 第二，循环性母亲的抗磷脂抗体经过胎盘转运到胎儿，这种情况可持续到新生儿期 [251]. 第三，新生儿循环性抗凝蛋白 (包括蛋白 C、蛋白 S 及抗凝血酶) 水平下降，而相对于成年人的血球压积较高。此外，随着正常体液丢失和出生后生活第一周内相对性新生儿脱水而发生血液浓缩。半数以上的新生儿 CVT 有多种危险因素 [252]. 母亲怀孕和分娩时并发症可增加新生儿 CVT 的危险。新生儿先兆子痫 / 子痫是新生儿 CVT 的一个危险因素 [253]. 母亲先兆子病 / 子病是新生儿 CVT 的一个危险因素 [253].

在未来妊娠和复发

与健康个体相比，有既往 VTE 的病人再次发生静脉血栓事件的危险增加 [244,245]. 同样，有 VTE 病史的妇女在未来妊娠时似乎也有血栓事件 (即，DVT、PE) 危险的增加 [97]. 妊娠，特别是产褥期，是已知的 CVT 危险因素。现有数据显示，CVT 并不是再次妊娠的禁忌证。鉴于妊娠给有 CVT 史的妇女带来的额外危险，再次妊娠期和产后期预防性 LMWH 可能有益处。

儿童人群中的 CVT

儿童 CVT 的发病率是 0.67/100 000 儿童 / 年 [91]. 当排除新生儿时，报告的发病率是 0.34/100 000 儿童 / 年 [249]. 新生儿表现为抽搐发作或昏睡，而年长婴儿和儿童 (与成年人相似) 常常表现为抽搐发作、意识水平改变、进行性头痛伴视乳头水肿、孤立性颅内压增高或局灶性神经功能缺失。
Saposnik et al  Diagnosis and Management of Cerebral Venous Thrombosis

Cerebral Venous Thrombosis (CVT) is a complex condition with various causes. Iron-deficiency anemia is a determined CVT risk factor. Thrombophilic disorders are common in neonates and children, occurring in 33% to 66% of cases, frequently with other CVT risk factors. Radiological diagnosis is similar to adults, requiring high suspicion and specialized venous imaging. Neonates, especially, lack specific clinical presentations; most cases present with seizures. Children’s CVT neuroimaging results resemble those of adults. In neonates, two-dimensional TOF MRV has several disadvantages, including枕骨挤压上矢状窦后部局部区域无血流，常见于14%没有CVT的新生儿 [255,256]。因此，常需要CTV明确是否存在MRV提示的CVT。在新生儿，经囟门多普勒超声可通过显示闭塞性血栓所致的血流缺失而提示CVT，尤其是闭塞性血栓，这种技术不是太可靠 [257]。

脑实质病变在新生儿比在儿童更容易是出血性的。新生儿颅内出血常包括幕上硬膜下出血。有脑室出血的足月新生儿的病因为CVT者占34%的病例，经常伴有丘脑出血 [205]。预后新生儿、年长婴儿和儿童CVT有显著不良预后率的发生。对新生儿，需要长期随访确定预后，因为神经缺失症状会随着历时数年的脑发育成熟才会变得明显。在CVT新生儿中，289%-83% [102,245,253,259]可以观察到神经功能缺失。

一项研究显示长期随访中18%的儿童CVT有后遗视力障碍。其它研究报道儿童和成人CVT的结果相似 [237,235,262]。

儿童人群中的CVT的处理

考虑新生儿和儿童CVT的血管内治疗受到不良预后发生率的驱动。还没有对儿童CVT进行过随机临床试验。因此，治疗实践主要是来自成年人研究结果的外推。对儿童，且越来越多地对新生儿，CVT治疗的主流是抗凝治疗，包括LMWH、UFH及华法林。个体和地区性医疗在儿童CVT且特别是在新生儿CVT方面的差异非常大。抽搐发作在超过50%的儿童人群CVT中观察到 [102]。鉴于癫痫性抽搐发作在儿童病人中发生率较高，可以考虑对无意识或机械性通气的儿童行连续的脑电图监测。

主要证据

尽管没有随机化试验，但是越来越多的来自病例系列和大规模观察性研究的支持证据支持抗凝在儿童或新生儿CVT中的疗效 [72,179,201,236,263]。近期发表的一项来自荷兰的病例系列研究了抗凝在CVT、脑室出血或丘脑出血的新生儿中的应用 [201]。10例新生儿中，1例婴儿在治疗开始前死亡，2例在常规应用LMWH治疗之前出生，其余7例新生儿接受3个月的LMWH (dalteparin)，以抗Xa水平0.5-1.0 U/mL为目标值。治疗期间没有出血增加或新出血。另一项纳入42例儿童CVT的研究报告，即使在存在ICH情况下，抗凝治疗也是安全的且能改善预后 [187]。最后，在一项基于方案的抗凝治疗的前瞻性单中心研究中，共纳入162例儿童病人，大约半数在诊断时接受抗凝治疗，包括35%的新生儿和71%的儿童。出血性并发症罕见(6%)，均为非致命性且大多数临床预后良好。未经抗凝治疗的病人中超过1/4的新生儿和超过1/3的儿童被观察到有CVT扩大 [264]。进一步关于以诊断时脑出血分层的最佳抗凝剂量正通过国际儿童卒中研究而处在计划阶段 [265,266]。

已发表的儿童卒中指南

在过去5年间，3套针对儿童CVT治疗的指南被发表 [267-269]。所有这3套指南都建议对非新生儿期的儿童采用LMWH、UFH和(或)华法林治疗3-6个月，即使在脑出血存在的情况下。

与之不同的是，关于对新生儿CVT的抗凝治疗没有一致的建议。3个已发表的指南中，1个没有提及新生儿CVT [268]，1个建议急性期抗凝 [269]，另1个建议不进行急性期抗凝 [251]。特别是，美国胸科医师学院建议初始抗凝，除非存在明显出血的情况下，而提议在这种情况下进行病例监测CVT是否扩大，如果发生扩大则开始抗凝治疗。建议抗凝治疗至少6周且不超过3个月。提议在6周时应该做静脉成像检查，如未见完全再通，则可以停用抗凝。AHA指南对初始抗凝未做出推荐意见。对于有血栓扩大或易栓症(其在急性疾病期间不会总能被诊断出来)的新生儿抗凝被认为是合理的。不情愿用抗凝治疗新生儿CVT基于若干担忧。首先，缺乏对新生儿安全性的研究资料；其次，担心会增加新生儿脑对出血的敏感性。在当前预后文献发表之前，不治疗新生儿的另一个原因是新生儿CVT的预后良好因此治疗是不必要的这一错觉。如之前章节所指出的那样，这些假设已经部分地被在过去几年发表的研究所推翻。然而，在缺乏临床试验数据的情况下，医疗实践的变异是可理解的 [251]。

建议

1. 对儿童CVT的支持性措施应包括适当补液、
1. 判断癫痫性抽搐发作以及颅内压增高的治疗（I 类推荐；C 级证据）。
2. 既然 CVT 儿童有因严重或长期颅内压增高而发生视力丧失的可能性，那么应做视野和视敏度的定期评估并应采取适当措施控制颅内压增高和其并发症（I 类推荐；C 级证据）。
3. 对所有儿童病人，如果撤除初始抗凝，建议在诊断后的第 1 周重复包括静脉成像在内的神经影像以监测早期血栓扩大或新的梗死或出血（I 类推荐；C 级证据）。
4. 对超过出生后 28 天诊断的急性 CVT 儿童，即使存在颅内出血，用全剂量 LMWH 治疗是合理的（IIa 类推荐；C 级证据）。
5. 对超过出生后 28 天诊断的急性 CVT 儿童，继续 LMWH 或口服维生素 K 拮抗剂 3-6 个月是合理的（IIa 类推荐；C 级证据）。
6. 对所有急性 CVT 儿童病人，如果开始初始抗凝治疗，治疗后在最初 1 周做头部 CT 或 MRI 以监测其它出血是合理的（IIa 类推荐；C 级证据）。
7. CVT 儿童可从为识别潜在凝血缺陷而做的易栓症测定中获益，一些易栓症可影响随后再血栓的危险性并影响治疗决策（IIb 类推荐；B 级证据）。
8. CVT 儿童可从利用血培养和副鼻窦放射检查调查潜在感染中获益（IIb 类推荐；B 级证据）。
9. 对急性 CVT 新生儿，可以考虑用 LMWH 或 UFH 治疗（IIb 类推荐；B 级证据）。
10. 对急性 CVT 新生儿，可以考虑持续 LMWH 治疗 6 周至 3 个月（IIb 类推荐；C 级证据）。
11. 血管内介入治疗在儿童病人中的用途和安全性不确定，仅可考虑将其用于仔细选择的在强化或治疗水平抗凝治疗下有进行性神经系统的恶化病人（IIb 类推荐；C 级证据）。

临床结局：预后
神经系统功能恶化可以发生在 23% 的病人，甚至在诊断后数天。神经系统功能恶化以意识水平下降、精神状态紊乱、新的抽搐发作、局灶体征恶化或新的局灶体征、头痛强度增加或视力丧失。当重复神经影像检查时大约三分之一有神经系统功能恶化的病人有新的脑实质病变。入院时有意识水平下降的病人更容易恶化 [1,278]。

早期死亡
大约 3%-15% 的病人死于本病的急性期 [28]。大多数早期死亡是 CVT 的结果。CVT 急性期死亡的主要原因是继发于大的出血性病变的经天幕脑疝 [5]，其次是多发病变或弥漫性脑水肿所致的脑疝。早期死亡的其它原因包括癫痫持续状态、内科并发症和 PE [136,279]。

晚期死亡
急性期后死亡主要与基础疾病有关，特别是与恶性疾病有关 [10,14]。

长期结局
在 ISCVT 研究中 [55]，最后一次随访（平均 16 个月）时在 79% 的病人中观察到完全恢复；然而，随访结束时总死亡率是 8.3%，而生活不能自理率为 5.1%（mRS 评分≥ 3）。在一项包括回顾性和前瞻性的系统回顾中，总的死亡率是 9.4%，而生活不能自理 （mRS 评分≥ 3 或 Glasgow 预后量表评分 ≥ 3）的比例是 9.7% [28]。7 项队列研究（包括资料可被分别分析的回顾性/前瞻性研究的前瞻性部分）中，总的死亡和生活不能独立的发生率是 15%（95% CI 13%-18%）[10]。

神经心理和神经精神后遗症
关于 CVT 存活者长期神经心理和神经精神预后的资料很少 [260,272]。尽管大多数 CVT 健康人有明显的面良好恢复，但是大约一半存活者感到抑郁或紧张，而且轻微的智能或语言缺陷妨碍重返工作 [260,272]。意志力丧失、执行力缺失以及健忘可由深静脉系统血栓伴双侧丘脑广泛梗死所致。记忆缺失、行为问题或执行力缺失可以持续存在 [260,280]。失语，通常为流畅型，可由左侧横窦血栓伴颞叶梗死或出血引起。通常恢复良好，但轻度自发表语言和命名障碍可以持续。

长期预后不良的危险因素
在 ISCVT 队列中长期预后不良的危险因素是中
危险评分模型

尽管总体预后良好，但是大约 15% 的 CVT 病人死亡或因 CVT 变得不能自理。危险分层评分可以提高我们告知 CVT 病人其个体预后和选择可从加强监护和有创性治疗强化中获益的能力。一项研究创建并验证了一个预测不良预后的危险评分模型。此危险评分模型的分值范围从 0（最低危险）至 9 分（最高危险），而界限 (cutoff) 值≥ 3 提示 6 个月时的死亡或不能自理。存在恶性病、昏迷或深静脉系统血栓为 2 分，而男性，存在意识水平下降或 ICH 为 1 分。在验证样本中推导队列预测能力 (c 统计量) 为 85.4%、84.4% 和 90.1%。在合并样本中的敏感性和特异性分别是 96.1% 和 13.6%。

另一研究 [284] 将年龄大于 37 岁和中枢神经系统感染合并到此模型中，并给每一个指标指定一个加权指数。此研究验证了 90 例 CVT 病人的评分并得出了 0.81 的的受试者工作特征曲线下面积预测死亡率。界限评分≥ 14，敏感性是 88% 而特异性为 70%。良好预后（被定义为 mRS 评分 <2）的预示值为 95%，而不良预后的预示值为 30%。

血管再通

一项包括五项小规模研究的系统回顾 [28] 中，CVT 血管再通率在随访 3 个月时和 1 年时分别为 84% 和 85%。观察到脑深部静脉和海绵窦血栓的再通率最高，而横窦血栓的再通率最低 [193]。在成年人中，闭塞静脉窦的再通与 CVT 的预后无关 [41,194]。

总结/进一步思考

本声明提供了一个对 CVT 的诊断和处理及其最常见的并发症相关文献广泛的和评论性的综述。

硬脑膜窦或脑静脉窦血栓形成 (CVT) 占所有卒中中的 0.5% - 1%，最常累及于年轻病人 [1,4,6]。CVT 病人通常表现为头痛，尽管一些病人有局灶性神经功能缺失、意识水平下降和抽搐发作，或者有局灶性神经系统的体征。静脉窦血栓的颅内压增高 [1,4,6]。少见情况下，隐袭性起病可以给诊断带来挑战。大约三分之二的静脉窦血栓病人有一种促凝血因子或一个直接的病因。通常靠 CT(CVT) 或 MRI(MRV) 静脉造影检查显示由血栓所致的静脉窦或脑静脉的阻塞做出诊断 [70,96]。CVT 的处理包括对基础疾病的治疗、对症治疗、对颅内压增高、ICH 或静脉梗死并发症的预防和治疗，特别是抗凝治疗。

卒中的诊断和治疗技术正处在不断演变之中。在对脑静脉窦血栓形成的病理生理的认识上已经取得了重要进展。然而，有前途的技术（血管内操作、用于处理有占位效应或 ICH 的难治性颅内压增高的偏侧开颅术等）在被广泛使用之前还需要经过严谨的评价。

尽管近年对 CVT 的研究取得了实质性的进展，但是大多数文献仍然是描述性的。CVT 写作组为强调需要进一步研究的领域（如，更大规模随机临床试验以明确治疗性干预的益处）做出了努力并提供了反映当前标准临床实践的建议。一项旨在比较抗凝治疗和血管内溶栓的益处的随机临床试验 (Thrombolysis Or Anticoagulation for Cerebral Venous Thrombosis, TO-ACT Trial) 正在进行之中。TO-ACT 的结果可能有助于改进 CVT 病人的急性期处理。

CVT 的处理面对的困境可能是复杂的。鉴于文献中没有强有力的证据指导其中一些具有挑战性的临床决策，因此处理这类病人的医疗专业人员可能需要相关亚专业医师的协助。本声明不太可能终结关于 CVT 处理的争议。更确切地讲，本声明的内容应被视作对当前现有最佳证据的汇集。通过一个创新的研究和系统性评价的过程，诊断、处理和治疗方法将不断演变并因此而给 CVT 病人带来更好的预后。